AMERICAN SOCIETY OF GENE & CELL THERAPY

23rd Annual Meeting

FINAL PROGRAM GUIDE

VIRTUAL MEETING FORMAT

MAY 12-15, 2020
We’re bringing cutting-edge cures from bench to bedside to help patients like Kruz and Paizlee.

Our open or soon-to-open trials include:

• αβ T-cell depleted haploidentical stem cell transplantation and solid organ transplantation for Schimke immuno-osseous dysplasia (SIOD), cystinosis, and focal segmental glomerulosclerosis (FSGS)

• Gene editing to treat sickle cell disease

• CD19/22 CAR-T cell therapy for acute lymphoid leukemia (ALL)

• Immunotherapy for GD2 diffuse intrinsic pontine glioma (DIPG)

• Gene therapy for Fanconi anemia and cerebral adrenoleukodystrophy

• Antibody-based conditioning to replace chemotherapy in stem cell transplantation

• Tr1 cells to suppress allogenic responses in stem cell transplantation

To learn more, call (650) 497-8953 or visit basscenter.stanfordchildrens.org.
# TABLE OF CONTENTS

A Welcome from Guangping Gao, PhD .................................................................2  
Mobile App & Virtual Meeting Instructions .......................................................3  
General Meeting Information .............................................................................4  
Annual Meeting Supporters ...............................................................................6  
Program Committee & Abstract Planning Committee .........................................9  
Abstract Reviewers ............................................................................................13  
Faculty List ........................................................................................................24  
ASGCT Award Recipients ..................................................................................33  
Schedule at a Glance ..........................................................................................35  
Program Schedule • Tuesday, May 12 ..............................................................37  
Program Schedule • Wednesday, May 13 ..........................................................72  
Program Schedule • Thursday, May 14 .............................................................92  
Program Schedule • Friday, May 15 .................................................................111  
Annual Meeting Exhibitors ...............................................................................129
A WELCOME FROM
GUANGPING GAO, PHD

Dear Colleagues,

On behalf of the American Society of Gene & Cell Therapy (ASGCT), it is my pleasure to welcome you to the our first-ever virtual ASGCT Annual Meeting. I am honored to join thousands of our colleagues from around the globe who believe in our Society’s mission of advancing knowledge, awareness, and education to expand the discovery and clinical application of gene and cell therapies for alleviation of human disease.

I’m especially grateful this year that we’re able to come together (separately) to share valuable research in our field and learn from each other in this virtual environment. All of the material this week will be available to view online and I hope you enjoy all that we have to offer.

I would like to extend a warm welcome to Carl June, M.D. and Feng Zhang, Ph.D., who will present the George Stamatoyannopoulos Memorial Lecture on Wednesday and the Presidential Symposium on Thursday, respectively. I would also like to take this opportunity to congratulate Drs. Mavis Agbandje-McKenna, Daniel Bauer, James Dahlman, Viviana Gradinaru, Shengdar Tsai, and Peter Marks on the awards they will so deservedly receive.

This scientific and educational program reflects the wonderful advancements that have occurred in gene and cell therapy over the past year, and I remain humbled by enthusiasm of our invited speakers in delivering their expertise in this unprecedented environment.

In addition, we are thrilled to share more new abstracts than we ever have before. This incredible level of work demonstrates the advances across the breadth of our field that will be presented virtually as oral presentations or poster sessions.

Be sure to visit our virtual Exhibit Hall to find out about the products and services offered by our partner companies, via conversations at their virtual booths and more formal presentations in the Tools & Technologies Forum.

Finally, I would like to thank everyone involved in the planning and execution of our Annual Meeting, especially the Program Committee, Scientific and Education Committees, abstract reviewers, staff, and all of our volunteers. Their sustained support, dedication, and hard work throughout the year now comes to fruition in what is sure to be a spectacular meeting.

Sincerely,

Guangping Gao, Ph.D. President, ASGCT
ATTEND THE 23RD ANNUAL VIRTUAL MEETING

- Live-stream event coverage
- Attend the virtual career fair
- Visit the virtual exhibit hall

Sponsored by:

DOWNLOAD THE #ASGCT20 MOBILE APP

SEARCH "ASGCT" ON GOOGLE PLAY OR APPLE APP STORE

- Build your schedule and find exhibitors
- Read all #ASGCT20 abstracts
- Receive up-to-the-minute updates, including room and schedule changes
- Create a MyProfile to connect with other attendees

Sponsored by:

App support: info@tripbuildermedia.com
support@tripbuildermedia.com
American Society of Gene & Cell Therapy

MISSION AND VISION
The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease.

ASGCT’s strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

ABSTRACT VOLUME - MOLECULAR THERAPY
All abstracts accepted for presentation at the ASGCT 23rd Annual Meeting have been published in the May supplement of Molecular Therapy. Attendees are able to access a copy of the supplement online at the Molecular Therapy website, or have access to the abstracts through the Mobile App.

CONTINUING MEDICAL EDUCATION
The ASGCT Board of Directors decided that the Society will not offer CME credit for the 23rd Annual Meeting.

DISCLOSURE
In keeping with good practices, ASGCT requires faculty to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in this educational activity.

EDUCATIONAL METHODS AND MATERIALS
Lectures, Case Presentations, Panel Discussions, Question and Answer Sessions, Audio/Video Presentations, Abstracts, Posters.

EDUCATIONAL OBJECTIVES
At the conclusion of the activity, the participant should be able to:
• Provide advice to patients who inquire about the potential of gene and cell therapy or the availability of open clinical trials, based on their exposure to the current clinical trials in gene and cell therapies.
• Better instruct their students in medical school and other health venues using the state-of-the-art basic science and clinical trials data presented at the meeting.
• Use the latest advances in gene and cell therapy to enhance their research mission, as physician scientists conducting basic and clinical research.
• Demonstrate improved regulatory compliance in conducting gene and cell therapy clinical trials, through exposure to NIH and FDA faculty during the educational program.
GENERAL MEETING INFORMATION

EVALUATION METHOD
Evaluation by questionnaire will address program content, presentation, and possible bias.

NEEDS
Clinical gene transfer has become increasingly complex due to ongoing developments in the fields of gene and cell therapy, together with bioethics, research integrity, and financial conflicts, as well as federal mandates, regulations and guidelines. Oligonucleotide Therapies, Novel Vector Development, Host-Vector Interactions and Vaccine Therapies will be discussed as well as many other scientific topics. This meeting will provide an educational forum for scientists and clinicians to expand their knowledge about the broad developments in these fields.

TARGET AUDIENCE
The target audience includes basic science and translational researchers, clinical investigators, physicians, postdoctoral fellows, graduate students, employees of federal government and regulatory agencies, and other healthcare professionals with an interest in the latest advancements in the fields of gene and cell therapy.

DATES
The ASGCT 23rd Annual Meeting will begin on the morning of Tuesday, May 12, 2020 and continue through 12 pm on Friday, May 15, 2020. Exhibits will be open 24/7, Monday, May 11 through Friday, May 15.

MOBILE APP
The full ASGCT 23rd Annual Meeting program, including session schedules, faculty, exhibits, sponsors and abstracts, is available through the ASGCT Mobile App which can be accessed by searching “ASGCT” on the Apple App Store or Google Play Store to download.
THANK YOU TO OUR 23RD ANNUAL MEETING SPONSORS!

DIAMOND

University of Massachusetts Medical School

PLATINUM

cytiva

PTC Therapeutics

Sangamo Therapeutics

SAREPTA Therapeutics

GOLD

aldevron

dyno therapeutics

editas MEDICINE

iveric bio

PALL Biotech

reGenX BIO

sanofi

spark therapeutics

SILVER

audentes

bluebirdbio

Burroughs Wellcome Fund

Fujifilm Diosynth Biotechnologies

Genentech

GenScript

halo labs

nih National Center for Advancing Translational Sciences

Oxford Biomedical

rocket pharma

TERUMO BCT

vertex

voyager therapeutics

BRONZE

ADVERUM BIOTECHNOLOGIES

agtc

akouos

AstraZeneca

avrobio

beam therapeutics

Biogen

Charles river

Homology Medicine, Inc.

Legend Biotech

MeiraGTx

orchard therapeutics

Pfizer

Prevail Therapeutics

Selecta Biosciences

Uniqure

Viralgen

Yposkesi
Gaining momentum in gene therapy

At Adverum, we are advancing novel gene therapies for patients with serious rare and ocular diseases. By leveraging our core capabilities, which include clinical development and in-house manufacturing expertise, we are moving product candidates into the clinic that are designed to provide durable efficacy with the potential to greatly improve the quality of life for patients.

To learn more, visit www.adverum.com
Healthy hearing available to all

Millions of children are directly affected by genetic hearing loss\(^1\)

We are a precision genetic medicine company dedicated to the development of gene therapies with the potential to restore, improve, and preserve hearing

FOR MORE INFORMATION VISIT: www.akouos.com
PROGRAM COMMITTEE & ABSTRACT PLANNING COMMITTEE

2020 ASGCT Program Committee

Thank you to the following individuals for serving on the ASGCT Program Committee and helping with the overall development of the ASGCT 23rd Annual Meeting.

CHAIR
Guangping Gao, PhD – University of Massachusetts Medical School

MEMBERS
Jennifer E. Adair, PhD – Fred Hutchinson Cancer Research Center
Aravind Asokan, PhD – Duke University School of Medicine
Paula M. Cannon, PhD – University of Southern California
Terence R. Flotte, MD – University of Massachusetts Medical School

2020 Abstract Planning Committee

Thank you to the following individuals for reviewing and selecting abstracts for presentation in the Presidential Symposium and Clinical Trials Symposium!

PRESIDENT
Guangping Gao, PhD – University of Massachusetts Medical School

ASGCT PRESIDENT-ELECT
Stephen J. Russell, MD, PhD – Mayo Clinic

ASGCT SECRETARY AND ABSTRACT CHAIR
Terence R. Flotte, MD – University of Massachusetts Medical School

ASGCT PROGRAM COMMITTEE MEMBERS
Aravind Asokan, PhD – Duke University School of Medicine
Paula M. Cannon, PhD – University of Southern California
Do you love to solve complex problems?
Energized by a fast-paced environment where people care about the work and each other?

At AVROBIO, we work together toward our ambitious goal to halt or reverse genetic disease with a single dose of gene therapy.

We embrace a pioneering spirit and share a passion for developing gene therapies with the potential to transform the lives of patients and families living with genetic disorders.

We’re all about getting the job done — together.

Learn more about joining the AVROBIO team at www.avrobio.com/work-with-us

Please join us at our scientific oral presentations:

“Gb3 substrate in endothelial cells of renal peritubular capillaries was reduced in a previously untreated classic Fabry male patient treated with AVR-RD-01 investigational lentiviral gene therapy”

AVROBIO-sponsored Phase 2 trial of AVR-RD-01

Birgitte Volck, M.D., Ph.D., president of Research & Development, AVROBIO

Wednesday, May 13, 2020, 5 – 5:15 p.m. ET

“Hematopoietic stem cell gene therapy for cystinosis: Initial results from a Phase I/II clinical trial”

Collaborator-sponsored Phase 1/2 trial of AVR-RD-04*

Stephanie Cherqui, Ph.D., associate professor, University of California, San Diego

Wednesday, May 13, 2020, 4:30 – 4:45 p.m. ET

*The Phase 1/2 clinical trial is funded by grants to UCSD from the California Institute for Regenerative Medicine (CIRM) and the Cystinosis Research Foundation (CRF).

“Hematopoietic stem cell gene therapy corrects neuromuscular manifestations in preclinical study of Pompe mice”

AVROBIO-sponsored Phase 1/2 trial of AVR-RD-03

Niek van Til, Ph.D., senior director, AVROBIO

Thursday, May 14, 2020, 4:30 – 4:45 p.m. ET
BMI technology with Fluorescence ID detects, counts, and sizes subvisible particles — and tells you whether they are proteinaceous or not. Find out more! Visit us at Booth 445.

Are you seeing the whole picture with your AAV analytics?

Subvisible particles (SVPs) may be hiding in your formulation, even if smaller aggregates are not detected by DLS or SEC. The Horizon® System from Halo Labs lets you quickly count and characterize SVPs with only 25 μL per sample — and get a more complete picture of your viral vector stability.

CLICK TO VISIT OUR VIRTUAL BOOTH!
PTC Therapeutics Symposium at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Join our expert Faculty for an interactive discussion on hot topics and key challenges associated with the constantly evolving field of gene therapy. In a peer-to-peer setting, we will share key insights gathered through our experience in this space while illustrating our commitment to finding innovative treatment options for patients with rare diseases.

We look forward to connecting with you.

Led by:

Mark Pykett  
Chief Scientific Officer  
PTC Therapeutics

Timothy Feyma  
Co-Director, Complex Movement Disorder Clinic  
Gillette Children’s Specialty Healthcare  
St Paul, Minnesota

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00–12:05</td>
<td>Welcome and Introduction</td>
<td>Mark Pykett, Chair</td>
</tr>
<tr>
<td>12:05–12:40</td>
<td>Overview of PTC Therapeutics’ Gene Therapy Programs</td>
<td>Mark Pykett</td>
</tr>
<tr>
<td>12:40–13:10</td>
<td>Gene Therapy for Neurological Disease: Clinical Outcomes in AADC Deficiency</td>
<td>Timothy Feyma</td>
</tr>
<tr>
<td>13:10–13:25</td>
<td>Interactive Q&amp;A</td>
<td>All (Moderated by Chair)</td>
</tr>
<tr>
<td>13:25–13:30</td>
<td>Adjourn</td>
<td>Mark Pykett</td>
</tr>
</tbody>
</table>

Thursday, May 14 2020  
12:00–1:30pm EDT

Please find our symposium webinar by following this link: asgct.org/2020
ABSTRACT REVIEWERS

Thank you to our 2020 abstract reviewers for their time and expertise!

RNA VIRUS VECTORS

Brian W. Bigger, PhD – University of Manchester
Bobby Gaspar, MD, PhD – UCL Great Ormond Street Institute of Child Health
Carol H. Miao, PhD – University of Washington
Axel Schambach, MD, PhD – Hannover Medical School
Kshitiz Singh, MBBS, MMST – Children’s Hospital of Philadelphia
Andrew C. Wilber, PhD – SIU School of Medicine

AAV VECTORS - VIROLOGY AND VECTOROLOGY

Aravind Asokan, PhD – Duke University School of Medicine
John A. Chiorini, PhD – NIDCR/National Institutes of Health
Beverly L. Davidson, PhD – Children’s Hospital of Philadelphia
Federico Mingozzi, PhD – Spark Therapeutics
Jun Xie, PhD – University of Massachusetts Medical School

AAV VECTORS - PRECLINICAL AND PROOF-OF-CONCEPT STUDIES

Shannon E. Boye, PhD – University of Florida
Allison M. Bradbury, PhD – Nationwide Children’s Hospital
Vania Broccoli, PhD – Ospedale San Raffaele
Miguel Sena-Esteves, PhD – University of Massachusetts Medical School
Phillip WL Tai, PhD – University of Massachusetts, Medical School
Jagdeep S. Walia, MBBS, FRCPC, FCCMG – Queen’s University

AAV VECTORS - CLINICAL STUDIES

Carsten G. Bonnemann, MD – NINDS/NIH
Florian Eichler, MD – Massachusetts General Hospital
Steven J. Gray, PhD – University of Texas Southwestern
Daniel M. Lipinski, MSc, DPhil – Medical College of Wisconsin
Jerry R. Mendell, MD – Gene Therapy Center Nationwide
Amit Nathwani, MD, PhD – Freeline Therapeutics

GENE TARGETING AND GENE CORRECTION

Paula M. Cannon, PhD – University of Southern California
Benjamin P. Kleinstiver, PhD – Massachusetts General Hospital and Harvard Medical School
Punam Malik, MD – Cincinnati Children’s Hospital Medical Center
Shondra M. Miller, PhD – St. Jude Children’s Research Hospital
David J. Segal, PhD – UC Davis Genome Center
Scot A. Wolfe, PhD – University of Massachusetts Medical School
proven past. new beginning.

GE Healthcare Life Sciences is now Cytiva.

Our trusted legacy of proven products relies on the talent of our people. A team of people focused on helping you advance and accelerate the development, manufacture, and delivery of transformative medicines for patients.

Find us at cytiva.com

Learn about advances in AAV production at our industry symposium 13 May 2020 at 12:00 pm.

Catarina Flyborg
Vice President
Cell & Gene Therapy, Cytiva
ABSTRACT REVIEWERS

OLIGONUCLEOTIDE THERAPEUTICS
Annemieke M. Aartsma-Rus, PhD – Leiden University Medical Center
Mark A. Behlke, MD, PhD – Integrated DNA Technologies
Si-ping Han, PhD – Beckman Research Institute, City of Hope
Mark A. Kay, MD, PhD – Stanford University School of Medicine
Anastasia Khvorova, PhD – University of Massachusetts Medical School
Xuehai Liang, PhD – Ionis Pharmaceuticals, Inc.

SYNTHETIC/MOLECULAR CONJUGATES AND PHYSICAL METHODS FOR DELIVERY OF GENE THERAPEUTICS
David A. Dean, PhD – University of Rochester
Dexi Liu, PhD – University of Georgia College of Pharmacy
Angela K. Pannier, PhD – University of Nebraska-Lincoln
Kevin G. Rice, PhD – University of Iowa College of Pharmacy
Daniel Siegwart, PhD – UT Southwestern Medical Center
Matthew H. Wilson, MD, PhD – Vanderbilt University
Assem G. Ziady, PhD – Cincinnati Children’s Hospital Medical Center

NORD was founded over 35 years ago by a group of parents advocating for their children struggling with rare diseases. We fight to improve the lives of over 25 million Americans impacted by rare diseases.

Alone we are rare. Together we are strong.

We support patients and families at every step of their rare journey.
Find robust information on rare diseases on our Rare Disease Database.
Build your knowledge about rare through our CME program and events.

Visit rarediseases.org to learn more about NORD’s webinars, conferences and other resources to help you and your patients.
ABSTRACT REVIEWERS

METABOLIC, STORAGE, ENDOCRINE, LIVER AND GASTROINTESTINAL DISEASES
Nicola Brunetti-Pierri, MD – Telethon Institute of Genetics & Medicine
Cary O. Harding, MD – Oregon Health & Sciences University
Dwight Koeberl, MD, PhD – Duke University Medical Center
Gerald S. Lipshutz, MD – David Geffen School of Medicine at UCLA
Pasquale Piccolo, PhD – Telethon Institute of Genetics and Medicine
Charles P. Venditti, MD, PhD – National Human Genome Research Institute

CARDIOVASCULAR AND PULMONARY DISEASES
Uta Griesenbach, PhD – Imperial College Faculty of Medicine
Costanza Emanueli, PhD, FAHA – Imperial College of London National Heart & Lung Institute
Judith S. Greengard, PhD – Adverum Biotechnologies
Xiao Xiao, PhD – University of North Carolina at Chapel Hill
David W. Parsons, PhD – Women’s & Children’s Hospital
Patrick L. Sinn, PhD – University of Iowa

the science to prevail.

We are developing disease-modifying gene therapies for patients with Parkinson’s disease and other neurodegenerative disorders.

www.prevailtherapeutics.com
RON
Hemophilia B patient in AMT-061 gene therapy trial

PIONEERS IN
THE FIELD OF
GENE THERAPY

www.uniQure.com
Vertex creates new possibilities in medicine so people with serious diseases can lead better lives.

We invest in science and innovation to strike at the core of serious diseases. Our scientists don’t see the impossible as an obstacle — they see it as a good place to start.
ABSTRACT REVIEWERS

NEUROLOGIC DISEASES
Rebecca Ahrens-Nicklas, MD, PhD – Children’s Hospital of Philadelphia
Rita Batista, PhD – University of Massachusetts Medical School
Paul D. Gamlin, PhD – University of Alabama at Birmingham
Gwladys Gernoux, PhD – University of Nantes
Heather L. Gray-Edwards, DVM, PhD – University of Massachusetts Medical School
Dan Wang, PhD – University of Massachusetts Medical School

MUSCULO-SKELETAL DISEASES
Jeffrey S. Chamberlain, PhD – University of Washington School of Medicine
Dongsheng Duan, PhD – University of Missouri School of Medicine
Paul Gregorevic, PhD – The University of Melbourne
Scott Q. Harper, PhD – Ohio State University & Nationwide Children’s Hospital
Rita Perlingeiro, PhD – University of Minnesota
Kathryn R. Wagner, MD, PhD – The Johns Hopkins School of Medicine
ABSTRACT REVIEWERS

CANCER - IMMUNOTHERAPY, CANCER VACCINES
Chiara Bonini, MD – Università Vita Salute San Raffaele
Maria G. Castro, PhD – University of Michigan Medical School
Monica Casucci, MSc – San Raffaele Scientific Institute
Conrad Russell Y. Cruz, MD, PhD – Children’s National Hospital
Paola Grandi, PhD – University of Pittsburgh

CANCER - ONCOLYTIC VIRUSES
Evanthia Galanis, MD, DSc – Mayo Clinic
Karin Jooss, PhD – Gritstone Oncology, Inc.
David H. Kirn, MD – 4D Molecular Therapeutics
Melissa A. Kotterman, PhD – 4D Molecular Therapeutics
Liliana Maruri Avidal, PhD – Ignite Immunotherapy
Stephen J. Russell, MD, PhD – Mayo Clinic

ORAL PRESENTATIONS

A Highly-Evolved Novel AAV Gene Therapy Directly Addresses Fabry Disease Pathology In Vivo by Cell Autonomous Expression in the Heart and Other Target Organs
*Date & Time:* Tuesday May 12, 2020 5:15 PM - 5:30 PM ET

Directed Evolution of AAV Targeting Lung Epithelia Using Aerosol Delivery Identifies 4D-A101, a Variant Demonstrating Robust Gene Delivery in Non-Human Primates
*Date & Time:* Friday May 15, 2020 11:00 AM – 11:15 AM ET

4DMT PRECISION-GUIDED GENE THERAPY

Robust transgene payload expression in heart tissue from NHP and Fabry knockout mice

4D-A101 payload expression in primate upper airway and alveoli after aerosol delivery
ABSTRACT REVIEWERS

CANCER - TARGETED GENE AND CELL THERAPY
Prasad S. Adusumilli, MD – Memorial Sloan Kettering Cancer Center
Catherine M. Bollard, MD – Children’s National Medical Center
Marco L. Davila, MD, PhD – H. Lee Moffitt Cancer Center and Research Institute
Saad Kenderian, MD – Mayo Clinic
Michael C. Milone, MD PhD – Hospital of the University of Pennsylvania
Yiping Yang, MD, PhD – Ohio State University

HEMATOLOGIC AND IMMUNOLOGIC DISEASES
Daniel E. Bauer, MD, PhD – Boston Children’s Hospital/Harvard Medical School
Cynthia Dunbar, MD – NIH/NHLBI Translational Stem Cell Biology Branch
Lindsey A. George, MD – The Children’s Hospital of Philadelphia
Megan D. Hoban, PhD – bluebird bio
Jean-Yves Metais, PhD – St. Jude Children’s Research Hospital
Emmanuelle Six, PhD – Imagine Institute

Imagine a world where we can reset a patient’s immune system through stem cell transplant to cure autoimmune diseases, blood cancers and genetic diseases.

RESET THE IMMUNE SYSTEM TO MAKE NEW CURES POSSIBLE
We’re developing medicines to improve all aspects of the transplant journey, including patient preparation, stem cell collection, cell dose and safe immune regeneration.

magentatx.com | @magentatx
ABSTRACT REVIEWERS

IMMUNOLOGICAL ASPECTS OF GENE THERAPY AND VACCINES

Andrea Annoni, PhD – San Raffaele Telethon Inst. for Gene Therapy
Roberto Calcedo, PhD – Affinia Therapeutics
Ying Kai Chan, PhD – Harvard
Roland W. Herzog, PhD – Indiana University
Allison M. Keeler-Klunk, PhD – University of Massachusetts Medical School
Masataka Suzuki, PhD – Baylor College of Medicine

CELL THERAPIES

Jennifer E. Adair, PhD – Fred Hutchinson Cancer Research Center
M Graça D. Almeida-Porada, MD, PhD – Wake Forest School of Medicine
Paul Gadue, PhD – Children’s Hospital of Philadelphia
Donald B. Kohn, MD – University of California, Los Angeles
Eirini P. Papapetrou, MD, PhD – Icahn School of Medicine at Mount Sinai
Alice F. Tarantal, PhD – University of California, Davis

VECTOR AND CELL ENGINEERING, PRODUCTION OR MANUFACTURING

Matthias Hebben, PhD – LogicBio Therapeutics
Robert M. Kotin, PhD – University of Massachusetts Medical School
Maritza C. McIntyre, PhD – Advanced Therapies Partners, LLC
Isabelle Riviere, PhD – Memorial Sloan Kettering Cancer Center
Johannes C.M. van Der Loo, PhD – Children’s Hospital of Philadelphia
J. Fraser Wright, PhD – Stanford School of Medicine

PHARMACOLOGY/TOXICOLOGY STUDIES OR ASSAY DEVELOPMENT

Eva Andres-Mateos, PhD – Akouos, Inc.
Linda B. Couto, PhD – Akouos, Inc.
David J. Dismuke, PhD – StrideBio
Virginia A. Haurigot, PhD – Spark Therapeutics
Jakob Reiser, PhD – Food and Drug Administration
Abraham Scaria, PhD – Iveric Bio
Join the ESGCT e-School...

...live and online every Wednesday at 14:00 CEST.
This weekly programme of FREE 30 minute virtual lectures is designed especially for students and Early Career Researchers. The e-School has been created in lieu of the 2020 ESGCT Spring School in Athens, which has now been postponed to March 2021.

Cutting-edge updates on SARS CoV2
The ESGCT e-Seminars series is a programme of FREE online specialist lectures. This topical series focuses and provides cutting-edge updates on SARS CoV2. Five talks are currently confirmed, and this weekly series begins on Wednesday 20 May 2020 at 15:00 CEST.

Athens Spring School 2021
New dates: 17-19 March 2021

28th Congress
in collaboration with BSGCT:
New dates coming shortly.
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annemieke Aartsma-Rus, PhD</td>
<td>Leiden University Medical Center</td>
<td>Leiden, Netherlands</td>
</tr>
<tr>
<td>Jennifer Adair, PhD</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>Seattle, WA</td>
</tr>
<tr>
<td>Blake Aftab, PhD</td>
<td>Atara Biotherapeutics, Inc.</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Nadav Ahituv, PhD</td>
<td>University of California, San Francisco</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Nabil Ahmed, MD</td>
<td>Baylor College of Medicine</td>
<td>Houston, TX</td>
</tr>
<tr>
<td>Alessandro Aiuti, MD, PhD</td>
<td>IRCCS San Raffaele Scientific Institute;</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>Carlo Anciello, MD, PhD</td>
<td>San Raffaele Telethon Institute for Gene</td>
<td></td>
</tr>
<tr>
<td>John Bell, PhD</td>
<td>Ottawa Hospital Research Institute</td>
<td>Ottawa, ON</td>
</tr>
<tr>
<td>Jean Bennett, MD, PhD</td>
<td>University of Pennsylvania Perelman School</td>
<td>Philadelphia, PA</td>
</tr>
<tr>
<td>Maria Bernardo, MD, PhD</td>
<td>San Raffaele Telethon Institute</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>Antonio Bertoletti, MD</td>
<td>Duke-Nus Medical School</td>
<td>Singapore</td>
</tr>
<tr>
<td>Michael R. Betts, PhD</td>
<td>University of Pennsylvania Perelman School</td>
<td>Philadelphia, PA</td>
</tr>
<tr>
<td>Kapil Bharti, PhD</td>
<td>NEI/NIH</td>
<td>Bethesda, MD</td>
</tr>
<tr>
<td>Diana Bharucha-Goebel, MD</td>
<td>NIH &amp; Children’s National Health System</td>
<td>Bethesda, MD</td>
</tr>
<tr>
<td>Catherine Bollard, MD</td>
<td>The George Washington University</td>
<td>Bethesda, MD</td>
</tr>
<tr>
<td>Carsten Bonnemann, MD</td>
<td>NINDS/NIH</td>
<td>Bethesda, MD</td>
</tr>
<tr>
<td>Ryan Boudreau, PhD</td>
<td>University of Iowa</td>
<td>Iowa City, IA</td>
</tr>
<tr>
<td>Allison M. Bradbury, PhD</td>
<td>Abigail Wexner Research Institute</td>
<td>Columbus, OH</td>
</tr>
<tr>
<td>Xandra Breakefield, PhD</td>
<td>Massachusetts General Hospital / HMS</td>
<td>Charlestown, MA</td>
</tr>
<tr>
<td>Michael Brehm, PhD</td>
<td>University of Massachusetts Medical School</td>
<td>Worcester, MA</td>
</tr>
<tr>
<td>Malcolm Brenner, PhD</td>
<td>Baylor College of Medicine</td>
<td>Houston, TX</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliation</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Vania Broccoli, PhD</td>
<td>San Raffaele Scientific Institute</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Milano, Italy</td>
<td></td>
</tr>
<tr>
<td>PJ Brooks, PhD</td>
<td>National Center for Advancing Translational Sciences, NIH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bethesda, MD</td>
<td></td>
</tr>
<tr>
<td>Christine Brown, PhD</td>
<td>City of Hope National Medical Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Duarte, CA</td>
<td></td>
</tr>
<tr>
<td>Christian Buchholz, PhD</td>
<td>Paul-Ehrlich-Institut</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Langen, Germany</td>
<td></td>
</tr>
<tr>
<td>Hildegard Büning, PhD</td>
<td>Hannover Medical School</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hanover, Germany</td>
<td></td>
</tr>
<tr>
<td>Barry J. Byrne, MD, PhD</td>
<td>University of Florida College of Medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gainesville, FL</td>
<td></td>
</tr>
<tr>
<td>Roberto Calcedo, PhD</td>
<td>University of Pennsylvania</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Philadelphia, PA</td>
<td></td>
</tr>
<tr>
<td>Jose Cancelas, PhD</td>
<td>University of Cincinnati Hoxworth Blood Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cincinnati, OH</td>
<td></td>
</tr>
<tr>
<td>Nathalie Cartier-Lacave, PhD</td>
<td>INSERM</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paris, France</td>
<td></td>
</tr>
<tr>
<td>Toni Cathomen, PhD</td>
<td>Medical Center - University of Freiburg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Freiburg, Germany</td>
<td></td>
</tr>
<tr>
<td>Marina Cavazzana, MD, PhD</td>
<td>Assistance Publique-Hôpitaux de Paris</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paris, France</td>
<td></td>
</tr>
<tr>
<td>Jeffrey Chamberlain, PhD</td>
<td>University of Washington School of Medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>Ying Chan, PhD</td>
<td>Harvard</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boston, MA</td>
<td></td>
</tr>
<tr>
<td>Joanne Clark, DPhil</td>
<td>BIDMC/HMS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boston, MA</td>
<td></td>
</tr>
<tr>
<td>Richard A. Colvin, MD, PhD</td>
<td>bluebird bio</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cambridge, MA</td>
<td></td>
</tr>
<tr>
<td>Kenneth Cornetta, MD</td>
<td>Indiana University</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Indianapolis, IN</td>
<td></td>
</tr>
<tr>
<td>Thomas J. Cradick, PhD</td>
<td>CRISPR Therapeutics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Belmont, MA</td>
<td></td>
</tr>
<tr>
<td>Gay M. Crooks, MD</td>
<td>University of California Los Angeles</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>Conrad Russell Cruz, MD, PhD</td>
<td>Children's National Medical Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Washington, DC</td>
<td></td>
</tr>
<tr>
<td>Agnieszka Czechowicz, MD, PhD</td>
<td>Stanford Medical School</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Palo Alto, CA</td>
<td></td>
</tr>
<tr>
<td>Sandra P. D’Angelo, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>New York, NY</td>
<td></td>
</tr>
<tr>
<td>Ronald C. Desrosiers, MD, PhD</td>
<td>University of Miami Miller School of Medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Miami, FL</td>
<td></td>
</tr>
<tr>
<td>Ben E. Deverman, PhD</td>
<td>Broad Institute of MIT and Harvard</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cambridge, MA</td>
<td></td>
</tr>
</tbody>
</table>
FACULTY LIST

Kevin Donahue, MD  
University of Massachusetts School of Medicine  
Worcester, MA

John Doyle, PhD  
Pfizer  
New York, NY

Victor J. Dzau, MD  
National Academy of Medicine  
Washington, DC

Lauriel Earley, PhD  
Spark Therapeutics  
Seattle, WA

Anne-Virginie Eggimann, MSc  
bluebird bio, Inc.  
Cambridge, MA

Costanza Emanueli, FAHA  
Imperial College London National Heart & Lung Institute  
London, United Kingdom

Hildegund CJ Ertl, MD  
Wistar Institute, University of Pennsylvania  
Philadelphia, PA

Katherine Excoffon, PhD  
Wright State University  
Dayton, OH

Muller Fabbri, MD, PhD  
University of Hawaii  
Honolulu, HI

Graeme Fielder, PhD  
Audentes Therapeutics  
San Francisco, CA

Terence Flotte, MD  
University of Massachusetts Medical School  
Worcester, MA

Susanne Gabrielsson, PhD  
Karolinska Institute - Sweden  
Stockholm, Sweden

Anne Galy, PhD  
Genethon  
Evry, France

Paul Gamlin, PhD  
University of Alabama at Birmingham  
Birmingham, AL

David Gamm, MD, PhD  
University of Wisconsin School of Medicine and Public Health  
Madison, WI

Nicole Gaudelli, PhD  
Beam Therapeutics  
Cambridge, MA

Paloma Giangrande, PhD  
Moderna Therapeutics  
Cambridge, MA

Andrew Giessel, PhD  
Moderna Therapeutics  
Cambridge, MA

Saar Gill, MD, PhD  
University of Pennsylvania  
Philadelphia, PA

Laurie Goodrich, DVM, PhD  
Colorado State University, College of Veterinary Medicine  
Fort Collins, CO

Jennifer L Gori, PhD  
Obsidian Therapeutics, Inc.  
Cambridge, MA

Viviana Gradinaru, PhD  
California Institute of Technology  
Pasadena, CA

Paola Grandi, PhD  
University of Pittsburgh  
Pittsburgh, PA
FACULTY LIST

Philip D. Gregory, DPhil  
bluebird bio  
*Cambridge, MA*

Dirk Grimm, PhD  
Heidelberg University Hospital  
*Heidelberg, Germany*

Alisha Gruntman, PhD  
University of Massachusetts Medical School  
*Worcester, MA*

Penelope Hallett, PhD  
McLean Hospital / Harvard Medical School  
*Belmont, MA*

H. Kirk Hammond, MD  
UCSD and VA San Diego  
*San Diego, CA*

Claudia Harper, DABT  
AVROBIO  
*Cambridge, MA*

Jianping Huang, MD, PhD  
University of Florida  
*Gainesville, FL*

Timothy Hunt, JD  
*Sudbury, MA*

Raed R. Ibraheim  
University of Massachusetts Medical School  
*Worcester, MA*

Petr Ilyinskii, PhD  
Selecta Biosciences  
*Watertown, MA*

J. Keith Joung, MD, PhD  
Massachusetts General Hospital  
*Charlestown, MA*

Carl H. June, MD  
University of Pennsylvania  
*Philadelphia, PA*

Jeffrey Kahn, PhD  
Johns Hopkins University  
*Baltimore, MD*

Anna Kajaste-Rudnitski, PhD  
SR-TIGET  
*Milano, Italy*

Mark Kay, PhD  
Stanford University School of Medicine  
*Stanford, CA*

Armand Keating, MD  
University of Toronto  
*Toronto, ON*  
*Canada*

Allison Keeler-Klunk, PhD  
University of Massachusetts Medical School  
*Worcester, MA*

Eric Kelsic, PhD  
Wyss Institute/ Harvard Medical School  
*Boston, MA*

Annahita Keravala, PhD  
Rocket Pharma  
*Palo Alto, CA*

Makan Khoshnejad, PhD  
The Wistar Institute  
*Philadelphia, PA*

Anastasia Khvorova, PhD  
University of Massachusetts Medical School  
*Worcester, MA*

Omar Khwaja, MD, PhD  
Roche / Voyager  
*Oberwil, Switzerland*

Scott G. Kitchen, PhD  
UCLA AIDS Institute, David Geffen School of Medicine at UCLA  
*Los Angeles, CA*
FACULTY LIST

Benjamin Kleinstiver, PhD
Massachusetts General Hospital
Boston, MA

Dwight Koeberl, MD, PhD
Duke University School of Medicine
Durham, NC

Donald Kohn, MD
University of California, Los Angeles
Los Angeles, CA

Konstantin Konstantinov, PhD
Codiak BioSciences
Cambridge, MA

Darrell Kotton, PhD
Boston University School of Medicine
Boston, MA

Delfi Krishna, PhD
GlaxoSmithKline
Collegeville, PA

Daniel Lipinski, DPhil
Medical College of Wisconsin
Milwaukee, WI

Gerald Lipshutz, MD
David Geffen School of Medicine at UCLA
Los Angeles, CA

David Liu, PhD
Harvard University and HHMI
Cambridge, MA

Punam Malik, MD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Paris Margaritis, DPhil
Center for Advanced Retinal and Ocular Therapeutics, University of Pennsylvania
Philadelphia, PA

David Markusic, PhD
Indiana University School of Medicine
Indianapolis, IN

Marcela Maus, PhD
Massachusetts General Hospital
Lexington, MA

Carol Miao, PhD
University of Washington
Seattle, WA

Cheryl McDonald, MD
National Heart Lung and Blood Institute, NIH
Bethesda, MD

Jeffrey A Medin, PhD
Medical College of Wisconsin
Milwaukee, WI

Jerry Mendell, MD
Gene Therapy Center Nationwide
Columbus, OH

Carol Miao, PhD
University of Washington
Seattle, WA

Federico Mingoazzi, PhD
Spark Therapeutics
Philadelphia, PA

Branden Moriarity, PhD
University of Minnesota
Minneapolis, MN

Nuria Morral, PhD
Indiana University School of Medicine
Indianapolis, IN

Christian Mueller, PhD
University of Massachusetts Medical School
Worcester, MA
FACULTY LIST

Andrés F. Muro, PhD
International Centre for Genetic Engineering and Biotechnology (ICGEB)
Trieste, Italy

Luigi M. Naldini, MD, PhD
San Raffaele Telethon Institute for Gene Therapy
Milan, Italy

Dao Pan, PhD
Cincinnati Children’s Medical Center
Cincinnati, OH

Angela Pannier, PhD
University of Nebraska-Lincoln
Lincoln, NE

Eirini Papapetrou, PhD
Icahn School of Medicine at Mount Sinai
New York, NY

Norbert Pardi, PhD
University of Pennsylvania
Philadelphia, PA

Marcelo Pasquini, MD
Medical College of Wisconsin
Milwaukee, WI

Kinnari Patel, PharmD
Rocket Pharmaceuticals, Ltd
New York, NY

Nicole Paulk, PhD
University of California San Francisco
San Francisco, CA

Kah-Whye Peng, PhD
Mayo Clinic
Rochester, MN

Carlos G. Perez-Garcia, PhD
Arcturus Therapeutics
San Diego, CA

Rita Perlingeiro, PhD
University of Minnesota
Minneapolis, MN

Chantal Pichon, PhD
Centre de Biophysique Moléculaire-CNRS
Orleans, France

Matthew Porteus, MD, PhD
Stanford University School of Medicine
Stanford, CA

Avery Posey, PhD
University of Pennsylvania
Philadelphia, PA

Richard Price, PhD
University of Virginia
Charlottesville, VA

Susan Prockop, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Giorgia Quadrato, MD
University of Southern California
Los Angeles, CA

Joseph E. Rabinowitz, PhD
Pfizer, Inc.
Cambridge, MA

Rajagopal Ramesh, PhD
University of Oklahoma Health Sciences Center
Oklahoma City, OK

Jayandharan Rao, PhD
Indian Institute of Technology
Kanpur, India

Maria-Grazia Roncarolo, MD
Stanford University School of Medicine
Stanford, CA
FACULTY LIST

Rayne Rouce, MD
Baylor College of Medicine
Houston, TX

Debasish Roychowdhury, MD
Nirvan Consultants, LLC
Lexington, MA

Michel Sadelain, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Matti Sallberg, DDS
Karolinska University Hospital
Huddinge
Stockholm, Sweden

Jude Samulski, PhD
UNC Gene Therapy Vector Core
Chapel Hill, NC

Barbra J. Sasu, PhD
Allogene
South San Francisco, CA

Craig Sauter, MD
MSKCC
New York, NY

Raymond Schifellers, PhD
University Medical Center Utrecht
Utrecht, Netherlands

Manfred Michael Schmidt, PhD
GeneWerk GmbH
Heidelberg, Germany

Miguel Sena-Esteves, PhD
University of Massachusetts Medical School
Worcester, MA

Sandhya Sharma
Baylor College of Medicine
Houston, TX

Shen Shen, PhD
Biogen
Cambridge, MA

Jae-Hyuck Shim, PhD
University of Massachusetts Medical School
Worcester, MA

Richard Snyder, PhD
Thermo Fisher Scientific
Alachua, FL

Katy Spink, PhD
Dark Horse Consulting
Redwood Shores, CA

Kaye Spratt, PhD
BridgeBio
Cleveland, OH

Edward Stadtmauer, MD
University of Pennsylvania
Philadelphia, PA

Catherine Stehman-Breen, MD
Obsidian Therapeutics
Cambridge, MD

Samuel H Sternberg, PhD
Columbia University
New York, NY

Duncan Stewart, MD, FRCP
Ottawa Hospital Research Institute
Ottawa, ON
Canada

Gregory Stewart, PhD
Axovant
New York, NY

Katie M. Stiles, PhD
Weill Cornell Medical College
New York, NY

Renata Stripecke, PhD
Hannover Medical School
Hanover, Germany

Millicent Sullivan, PhD
University of Delaware
Newark, DE
FACULTY LIST

Bakhos Tannous, PhD
Harvard Medical School and
Massachusetts General Hospital
Boston, MA

Purushothama Rao Tata, PhD
Duke University School of Medicine
Durham, NC

Sally Temple, PhD
Neural Stem Cell Institute
Rensselaer, NY

Gabriele Thumann, MD
University of Geneva
Geneva, Switzerland

John Tisdale, MD
NIH, NHLBI
Bethesda, MD

Bruce E. Torbett, PhD
The Scripps Research Institute
La Jolla, CA

Bruce Trapnell, MD
Cincinnati Children’s Hospital Medical Ctr.
Cincinnati, OH

Katherine Tsokas, JD
Janssen Pharmaceutical Companies
Johnson & Johnson
Spring House, PA

Johannes van der Loo, PhD
Children’s Hospital of Philadelphia
Philadelphia, PA

Luk H. Vandenberghe, PhD
Harvard, Broad Institute, Mass Eye and Ear
Boston, MA

Francesca Vitelli, PhD
Lonza, Houston Inc.
Houston, TX

Rogerio Vivaldi, MD
Sigilon Therapeutics
Cambridge, MA

Lili Wang, PhD
University of Pennsylvania
Philadelphia, PA

David Weiner, PhD
The Wistar Institute
Philadelphia, PA

Monica L. Weldon
Bridge the Gap - SYNGAP
Washington, DC

Kerry Welsh, MD, PhD
Food & Drug Administration
Silver Spring, MD

Andrew Wilber, PhD
SIU School of Medicine
Springfield, IL

David A. Wilcox, PhD
Department of Pediatrics, Medical College of Wisconsin
Milwaukee, WI

David Williams, MD
Boston Children’s Hospital
Boston, MA

James Wilson, MD, PhD
University of Pennsylvania
Philadelphia, PA

Matthew Wilson, PhD
Vanderbilt University
Nashville, TN

Scot Wolfe, PhD
University of Massachusetts Medical School
Worcester, MA

J. Fraser Wright, PhD
Stanford
Philadelphia, CA
FACULTY LIST

Xiao Xiao, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC

Feng Zhang, PhD
Massachusetts Institute of Technology
Cambridge, MA

Jiehua Zhou, PhD
Beckman Research Institute of City of Hope
Monrovia, CA

Assem G Ziady, PhD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH

John Anthony Zuris, PhD
Editas Medicine
Cambridge, MA
Congratulations to the following individuals for receiving an ASGCT Award.

**OUTSTANDING NEW INVESTIGATOR AWARDS**

Daniel Bauer, MD, PhD  
Principal Investigator and Staff Physician, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Assistant Professor in Pediatrics, Harvard Medical School

James Dahlman, PhD  
Assistant Professor, Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University

Viviana Gradinaru, PhD  
Professor of Neuroscience and Biological Engineering, California Institute of Technology

Shengdar Tsai, PhD  
Assistant Member in the Department of Hematology, St. Jude Children’s Research Hospital

*The Outstanding New Investigator are sponsored by*

**BURROUGHS WELLCOME FUND**

**OUTSTANDING ACHIEVEMENT AWARD**

Mavis Agbandje-McKenna, PhD  
Professor of Biochemistry and Molecular Biology, University of Florida College of Medicine

*The Outstanding Achievement Award is sponsored by*

**AUDENTES**  
An Astellas Company

**SONIA SKARLATOS PUBLIC SERVICE AWARD**

Peter Marks, MD, PhD  
Director of the Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration
ASGCT AWARD RECIPIENTS

EXCELLENCE IN RESEARCH AWARDS
The Excellence in Research Awards will be presented on Wednesday, May 13 during the George Stamatoyannopoulos Memorial Lecture.

The Excellence in Research Awards are sponsored by

[Logos of sponsors]

The Meritorious Abstract Travel Awards and Underrepresented Minority Travel Awards are sponsored by

[Logos of sponsors]

Funding for this program was made possible (in part) by (5 R13 TR 002411 - 02) from the National Center for Advancing Translational Sciences (NCATS). The views expressed in written program materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
## SCHEDULE AT A GLANCE

All times are listed in Eastern Daylight Time (EDT UTC -4).

### TUESDAY, MAY 12, 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>Exhibit Hall Open</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Virtual Career Fair</td>
</tr>
<tr>
<td>8:00 am – 9:45 am</td>
<td>Scientific Symposia Session I</td>
</tr>
<tr>
<td>10:15 am – 12:00 pm</td>
<td>Oral Abstract Session I</td>
</tr>
<tr>
<td>12:00 pm – 1:30 pm</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>12:00 pm – 1:30 pm</td>
<td>Tools and Technologies Forum I</td>
</tr>
<tr>
<td>1:30 pm – 3:15 pm</td>
<td>Education Session I</td>
</tr>
<tr>
<td>3:30 pm – 4:45 pm</td>
<td>Tools and Technologies Forum II</td>
</tr>
<tr>
<td>3:30 pm – 4:45 pm</td>
<td>Oral Abstract Session II</td>
</tr>
</tbody>
</table>

### WEDNESDAY, MAY 13, 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>Exhibit Hall Open</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Virtual Career Fair</td>
</tr>
<tr>
<td>8:00 am – 9:45 am</td>
<td>Scientific Symposia Session II</td>
</tr>
<tr>
<td>8:00 am – 9:45 am</td>
<td>Education Session II</td>
</tr>
<tr>
<td>10:15 am – 12:00 pm</td>
<td>George Stamatoyannopoulos Memorial Lecture &amp; Presentation of the Excellence in Research Awards</td>
</tr>
<tr>
<td>12:00 pm – 1:30 pm</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>12:00 pm – 1:30 pm</td>
<td>Tools and Technologies Forum III</td>
</tr>
<tr>
<td>12:00 pm – 1:30 pm</td>
<td>Industry Sponsored Symposia - Sponsored by Cytiva, formerly known as GE Healthcare Life Sciences, Sarepta Therapeutics, Pall Biotech</td>
</tr>
<tr>
<td>1:30 pm – 3:00 pm</td>
<td>Outstanding New Investigator Symposium</td>
</tr>
<tr>
<td>3:30 pm – 4:45 pm</td>
<td>Tools and Technologies Forum IV</td>
</tr>
<tr>
<td>3:30 pm – 4:45 pm</td>
<td>Oral Abstract Session III</td>
</tr>
</tbody>
</table>

*Eastern Time Zone (EDT UTC -4)*
## SCHEDULE AT A GLANCE

All times are listed in Eastern Daylight Time (EDT UTC -4).

<table>
<thead>
<tr>
<th>THURSDAY, MAY 14, 2020</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Open 24 Hours Online</td>
<td>Exhibit Hall Open</td>
</tr>
<tr>
<td></td>
<td><em>Exhibitors Available 8:00 am - 6:30 pm</em></td>
</tr>
<tr>
<td>Open 24 Hours Online</td>
<td>Virtual Career Fair</td>
</tr>
<tr>
<td>8:00 am – 9:45 am</td>
<td>Scientific Symposia Session IV</td>
</tr>
<tr>
<td>10:15 am – 12:00 am</td>
<td>Outstanding Achievement Award Lecture &amp; Sonia Skarlatos Public Service Award Presentation <em>Sponsored by <a href="https://www.audentes.com">AUDENTES</a></em></td>
</tr>
<tr>
<td>12:00 pm – 1:30 pm</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>12:00 pm – 1:30 pm</td>
<td>Tools and Technologies Forum V</td>
</tr>
<tr>
<td>12:00 pm – 1:30 pm</td>
<td>Industry Sponsored Symposia - <em>Sponsored by Terumo BCT, FUJIFILM Diosynth Biotechnologies, PTC Therapeutics, GenScript USA Inc.</em></td>
</tr>
<tr>
<td>1:30 pm – 3:15 pm</td>
<td>Presidential Symposium &amp; Presentation of the Top Abstracts <em>Sponsored by <a href="https://www.oxfordbiomedicalresearch.com">Oxford Biomedical Research</a></em></td>
</tr>
<tr>
<td>3:45 pm – 5:30 pm</td>
<td>Oral Abstract Session IV</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRIDAY, MAY 15, 2020</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Open 24 Hours Online</td>
<td>Exhibit Hall Open</td>
</tr>
<tr>
<td></td>
<td><em>Exhibitors Available 8:00 am - 12:00 pm</em></td>
</tr>
<tr>
<td>Open 24 Hours Online</td>
<td>Virtual Career Fair</td>
</tr>
<tr>
<td>7:30 am - 8:00 am</td>
<td>ASGCT Business Meeting</td>
</tr>
<tr>
<td>8:00 am – 9:45 am</td>
<td>Scientific Symposia Session V</td>
</tr>
<tr>
<td>9:45 am – 10:15 am</td>
<td>Break</td>
</tr>
<tr>
<td>10:15 am - 12:00 pm</td>
<td>Oral Abstract Session V</td>
</tr>
<tr>
<td>12:00 pm</td>
<td>Annual Meeting Concludes</td>
</tr>
</tbody>
</table>

*Eastern Time Zone (EDT UTC -4)*
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

**SCIENTIFIC SYMPOSIUM 100**
8:00 AM - 9:45 AM
*Room: Ballroom B*

Developing New Therapies for Children with Metabolic Disorders - Organized by the Gene & Cell Therapy of Genetic and Metabolic Diseases Committee

**CO-CHAIRS:** Paris Margaritis, DPhil and Dao Pan, PhD

**SPEAKERS**

8:00 AM – 8:26 AM
Petr Ilyinskii, PhD. Selecta Biosciences, Watertown, MA
*ImmtOR Immune Tolerance*

8:26 AM – 8:52 AM
Lili Wang, PhD. University of Pennsylvania, Philadelphia, PA
*mRNA Therapy and Gene Editing for OTC Deficiency*

8:52 AM – 9:18 AM
Andrés F. Muro, PhD. International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy
*Promoterless Gene Editing in Crigler-Najjar*

9:18 AM – 9:45 AM
Gerald Lipshutz, MD. David Geffen School of Medicine at UCLA, Los Angeles, CA
*mRNA Therapy in Arginase Deficiency*

**SCIENTIFIC SYMPOSIUM 101**
8:00 AM - 9:45 AM
*Room: Ballroom A*

Advances in Allogeneic and Off-the-Shelf Hematopoietic Cell Therapies - Organized by the Hematologic and Immunologic Gene and Cell Therapy Committee

**CO-CHAIRS:** David Markusic, PhD and Jayandharan Rao, PhD

**SPEAKERS**

8:00 AM – 8:26 AM
Barbra J. Sasu, PhD. Allogene, South San Francisco, CA
*Allogeneic CAR T Cells for the Treatment of Cancer*
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

8:26 AM – 8:52 AM
Agnieszka Czechowicz, MD, PhD. Stanford University School of Medicine, Stanford, CA
Improving HSCT Transplantation by Novel Conditioning - How it Applies to Allogeneic HSCT

8:52 AM – 9:18 AM
Branden Moriarity, PhD. University of Minnesota, Minneapolis, MN
Engineering NK Cells and Monocytes for Research and Therapies

9:18 AM – 9:45AM
Gay M. Crooks, MD. University of California Los Angeles, Los Angeles, CA
From Pluripotent Stem Cells to Engineered T Cells

SCIENTIFIC SYMPOSIUM 102
8:00 AM – 9:45 AM
Room: 302
Growing Gene and Cell Therapy (GGACT): An NCATS-funded Collaborative Effort to Support Development of Academic Clinical Trials for Rare Diseases
CO-CHAIRS: Jose Cancelas, PhD and Donald Kohn, MD

SPEAKERS
8:00 AM – 8:25 AM
David A. Wilcox, PhD. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; Children’s Research Institute, Children’s Hospital of Wisconsin, Milwaukee, WI

8:25 AM – 8:50 AM
Bruce Trapnell, MD. Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Pulmonary Transplantation of Autologous CD34+ Cell Derived Macrophages for Hereditary Pulmonary Alveolar Proteinosis

8:50 AM – 9:15 AM
Jianping Huang, MD, PhD. University of Florida, Gainesville, FL
Clinical Development of CART Cell Therapy Targeting CD70 in Glioblastoma
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

9:15 AM – 9:45 AM
David Wald, PhD, MD. Case Western Reserve University, Cleveland, OH
NK Cell Therapy for AML

SCIENTIFIC SYMPOSIUM 103

8:00 AM - 9:45 AM
Room: Ballroom C

New Developments in Particles, Transfer Methods and Vectors for Gene Delivery - Organized by the Physical Delivery, Therapeutics & Vector Development Committee

CO-CHAIRS: Carol Miao, PhD and Matthew Wilson, PhD

SPEAKERS

8:00 AM – 8:26 AM
Jennifer Adair, PhD. Fred Hutchinson Cancer Research Center, Seattle, WA
Nanoformulations to Deliver CRISPR Gene Editing

8:26 AM – 8:52 AM
Gabriele Thumann, MD. University of Geneva, Geneva, Switzerland
Gene Transfer to the Eye Using Transposons

8:52 AM – 9:18 AM
Mariola Fotin-Mleczek, PhD. CureVac AG, Tubingen, Germany
RNA Delivery as a Vaccine

9:18 AM – 9:45 AM
Richard Price, PhD. University of Virginia, Charlottesville, VA
To the Blood-Brain Barrier and Beyond: MRI-Guided Gene Delivery with Focused Ultrasound
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

### SCIENTIFIC SYMPOSIUM 104

8:00 AM - 9:45 AM  
Room: 312  

Pharmacovigilance and Long-Term Follow-Up of Gene Therapies in the Post-Approval World - Organized by the Regulatory Affairs Committee  

**CO-CHAIRS:** Marcela Maus, PhD and Kaye Spratt, PhD  

**SPEAKERS**  
8:00 AM – 8:20 AM  
Kerry Welsh, MD, PhD. Food and Drug Administration, Silver Spring, MD  
**Collection and Use of Long-Term Follow-Up/Pharmacovigilance Data in the Post-Market Setting**  
8:20 AM – 8:40 AM  
Kenneth Cornetta, MD. Indiana University, Indianapolis, IN  
**Long-Term Results of Replication-Competent Vector Testing**  
8:40 AM – 9:00 AM  
Marcelo Pasquini, MD. Medical College of Wisconsin, Milwaukee, WI  
**CIBMTR’s Registry Collection of LTFU Data for CAR T-Cell Therapies**  
9:00 AM – 9:20 AM  
Anne-Virginie Eggimann, MSc. bluebird bio, Cambridge, MA  
**Challenges Associated With Long-Term Follow-Up of Gene Therapies**  
9:20-9:45 AM  
Panel Discussion

### SCIENTIFIC SYMPOSIUM 105

8:00 AM - 9:45 AM  
Room: 304 & 306  

Successes in Gene Therapy for Musculoskeletal Disease - Organized by the Musculo-Skeletal Gene & Cell Therapy Committee  

**CO-CHAIRS:** Claudia Harper, DABT and Rita Perlingeiro, PhD  

**SPEAKERS**  
8:00 AM – 8:26 AM  
Xiao Xiao, PhD. University of North Carolina at Chapel Hill, Chapel Hill, NC  
**DMD Mechanisms and Therapy Development**
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

8:26 AM – 8:52 AM
Jeffrey Chamberlain, PhD. University of Washington School of Medicine, Seattle, WA
Development and Delivery of Microdystrophins

8:52 AM – 9:18 AM
Jerry R. Mendell, MD. Gene Therapy Center Nationwide, Columbus, OH
Clinical Development of Gene Therapy Vector Applications for the Muscular Dystrophies

9:18 AM – 9:45 AM
Laurie Goodrich, DVM, PhD. Colorado State University College of Veterinary Medicine, Fort Collins, CO
AAV Gene Deliver for Bone Disease and Stem Cell Therapy

SCIENTIFIC SYMPOSIUM 106

8:00 AM - 9:45 AM
Room: Auditorium

The Golden Age of Gene Therapy: Past, Present and Future Perspectives
CO-CHAIRS: Jean Bennett, MD, PhD and Malcolm Brenner, PhD

SPEAKERS

8:00 AM – 8:26 AM
Jude Samulski, PhD. UNC Gene Therapy Vector Core, Chapel Hill, NC
Adeno-associated Virus Evolution, from “Almost A Virus” to “An Amazing Vector”

8:26 AM – 8:52 AM
Michel Sadelain, MD, PhD. Memorial Sloan Kettering Cancer Center, New York, NY
Cancer Immunotherapy Revolution and Where It Is Going

8:52 AM – 9:18 AM
Marina Cavazzana, MD, PhD. Assistance Publique-Hôpitaux de Paris, Paris, France
Clinical Breakthroughs in HSC-based Gene Therapy

9:18 AM – 9:45 AM
David Liu, PhD. Harvard University and HHMI, Cambridge, MA
Base Editing and Prime Editing: Genome Editing without Double-strand Breaks
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

SCIENTIFIC SYMPOSIUM 107
8:00 AM - 9:45 AM
Room: 302

Advances in Therapeutic RNAi - Organized by the Oligonucleotide and RNAi Therapeutics Committee

CO-CHAIRS: Christian Mueller, PhD and Shen Shen, PhD

SPEAKERS
8:00 AM – 8:26 AM
   Anastasia Khvorova, PhD. University of Massachusetts Medical School, Worcester, MA
   siRNAs That Cross the Blood Brain Barrier

8:26 AM – 8:52 AM
   Christian Mueller, PhD. University of Massachusetts Medical School, Worcester, MA, Sanofi Genzyme, Framingham, MA
   Suppression of Mutant SOD1 in Amyotrophic Lateral Sclerosis with an Intrathecally Administered AAVmiR

8:52 AM – 9:18 AM
   Jae-Hyuck Shim, PhD. University of Massachusetts Medical School, Worcester, MA
   Bone-targeting AAV-mediated Gene Silencing for Osteoporosis Therapy

9:18 AM – 9:45 AM
   Omar Khwaja, MD, PhD. Voyager, Oberwil, Switzerland
   Development of AAV-based RNAi Therapeutics for Huntington Disease

BREAK
9:45 AM - 10:15 AM
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 110
10:15 AM - 12:00 PM
Room: Auditorium

Gene Therapy for the Special Senses
Chair: Paul Gamlin, PhD

10:15 AM – 10:30 AM
1: Retinal Gene Therapy in X-Linked Retinitis Pigmentosa Caused by Mutations in RPGR: Results at 6 Months in a First in Human Clinical Trial
Jasmina Cehajic-Kapetanovic, University of Oxford, Oxford, United Kingdom

10:30 AM – 10:45 AM
2: Therapeutic Efficacy of ARCUS Meganuclease Gene Editing - Arrest of Rod Degeneration and Restoration of Rod Function in a Transgenic Pig Model of Autosomal Dominant Retinitis Pigmentosa
Maureen McCall, University of Louisville, Louisville, KY, United States

10:45 AM – 11:00 AM
3: Gene Therapy in a Novel Large Animal Model of Stargardt Disease
Ivana Trapani, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy

11:00 AM – 11:15 AM
4: Preclinical Testing of AAV9-PHP.B for Transgene Expression in the Non-Human Primate Cochlea
Maryna Ivanchenko, Harvard Medical School, Boston, MA, United States

DISCOVER THE BENEFITS OF ASGCT MEMBERSHIP

- Subscription to Molecular Therapy journals
- Annual Meeting Discounts
- Opportunities for Committee Involvement
- Grants, Awards & More

Join the largest and most inclusive gene and cell therapy community
Learn more at asgct.org/membership
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:15 AM – 11:30 AM
5: Dual AAV Delivery of Otoferlin Durably Rescues Hearing in Congenitally Deaf Preclinical Models
Jonathon Whitton, Decibel Therapeutics, Boston, MA, United States

11:30 AM – 11:45 AM
6: Optimizing the Safety of Dual AAV-Based Treatments for MYO7A Usher Syndrome (USH1B) in Myo7a⁻/⁻ Mice
Kaitlyn Calabro, University of Florida, Gainesville, FL, United States

11:45 AM – 12:00 PM
7: Multi-Center Blinded Preclinical Efficacy Study Shows Significant Differences in Promoter Performance for Gene Replacement Therapy of SMARD1/CMT2S
Kathrin Meyer, Nationwide Children's Hospital, Columbus, OH, United States

ORAL ABSTRACT SESSION 111

10:15 AM - 12:00 PM
Room: Ballroom A

Genome Editing: Preclinical & Rare Disease
Chair: Scot Wolfe, PhD

10:15 AM – 10:30 AM
8: Clonal Tracking Uncovers Barriers and Validates New Strategies to Enhance Gene Editing in Human Hematopoietic Stem Cells
Aurelien Jacob, San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy

10:30 AM – 10:45 AM
9: Therapeutic Base Editing of Human Hematopoietic Stem Cells
Jing Zeng, Boston Children's Hospital, Boston, MA, United States

10:45 AM – 11:00 AM
10: Expansion with E478 Significantly Increases the Rate of CRISPR-Mediated Homology Directed Repair (HDR) and Improves Engraftment of Human Hematopoietic Stem Cells
Kevin Goncalves, Magenta Therapeutics, Cambridge, MA, United States

11:00 AM – 11:15 AM
11: Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration
Adrian Oliver, Duke University, Durham, NC, United States
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:15 AM – 11:30 AM
12: Regulated Allele Specific Gene Editing for Huntington’s Disease
Alex Mas Monteys, University of Pennsylvania/CHOP, Philadelphia, PA, United States

11:30 AM – 11:45 AM
13: Engraftment and Persistence of HDR-Edited Hematopoietic Stem and Progenitor Cells in Nonhuman Primates
Christopher Peterson, Fred Hutchinson Cancer Research Center, Seattle, WA, United States

11:45 AM – 12:00 PM
14: Highly Efficient Base Correction of Adult Dystrophic Mice Using iABE-NG
Renzhi Han, The Ohio State University, Columbus, OH, United States

ORAL ABSTRACT SESSION 112
10:15 AM - 11:45 AM
Room: Ballroom B

Cancer - Targeted Gene and Cell Therapy
Chair: Michael Milone, PhD

10:15 AM – 10:30 AM
15: Defining the Role of Spatial and Molecular Adaption of Glioblastoma to Personalized Neural Stem Cell Therapy Using Integrated In Vivo and Ex Vivo Models
Andrew Satterlee, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

10:30 AM – 10:45 AM
16: Transforming Challenges into Opportunities: The T Cell Exhaustion Signature Can Guide the Identification of Patient-Derived, Tumor-Reactive TCRs and Promote TCR Gene Editing for AML
Francesco Manfredi, VIta-Salute San Raffaele University, Milan, Italy

10:45 AM – 11:00 AM
17: Tumor-Selective Gene Circuits Enable Highly Specific Localized Cancer Immunotherapy
Russell Gordley, Senti Biosciences, South San Francisco, CA, United States
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:00 AM – 11:15 AM
18: MyD88/CD40 (MC) Enhances Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Proliferation, Cytokine Release and Anti-Tumor Efficacy Against BCMA* Tumors
J. Henri Bayle, Bellicum Pharmaceuticals, Houston, TX, United States

11:15 AM - 11:30 AM
21: Tumor-Tropic Liposome-Mediated Therapeutic Delivery of mRNA for T Cell Malignancies
Shoji Saito, Shinshu University School of Medicine, Matsumoto, Japan

11:30 AM – 11:45 AM
20: Nanoparticles for Targeted Theranostic Gene Delivery to Hepatocellular Carcinoma
Hannah Vaughan, Johns Hopkins, BALTIMORE, MD, United States

ORAL ABSTRACT SESSION 113
10:15 AM - 12:00 PM
Room: Ballroom C

Advances in AAV Vector Engineering
Chair: Jun Xie, PhD

10:15 AM – 10:30 AM
22: Evolution and Investigation of Engineered AAV Capsids Exhibiting Enhanced Transduction of the Central Nervous System with or without Murine Strain Specificity
Sripriya Ravindra Kumar, California Institute of Technology, Pasadena, CA, United States

Congratulations to ASGCT's Newly Elected Directors and Officers

VICE PRESIDENT
Hans-Peter Kiem, MD, PhD

TREASURER
Paloma Giangrande, PhD

AT-LARGE DIRECTORS
Marcela Maus, MD, PhD • Federico Mingozzi, PhD • Anastasia Khvorova, PhD
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

10:30 AM – 10:45 AM
23: Engineering and Evaluation of Novel AAV Serotypes for Gene Delivery to the Central Nervous System
David Ojala, Sangamo Therapeutics, Richmond, CA, United States

10:45 AM – 11:00 AM
24: Cross-Species Evolution of Synthetic AAV Strains for Clinical Translation
Trevor Gonzalez, Duke University School of Medicine, Durham, NC, United States

11:00 AM – 11:15 AM
25: A Highly Efficient Dual AAV Technology for Therapeutic (epi) Genome Editing Applications
Lisa Riedmayr, Ludwig-Maximilians-University Munich, Munich, Germany

11:15 AM – 11:30 AM
26: A Novel AAV9 Variant Exhibiting Strong Preference for Neuronal Transduction in Mice and Non-Human Primates Following Systemic Administration
Samuel Huang, Oregon Health & Science University, Portland, OR, United States

11:30 AM – 11:45 AM
27: Sequencing of Barcoded AAV Libraries Enables Reprogramming of AAV Capsids with Respect to Liver Tropism
Eric Zinn, Grousbeck Gene Therapy Center, Mass Eye and Ear, Harvard Medical School & The Broad Institute of Harvard and MIT, Boston, MA, United States

11:45 AM – 12:00 PM
28: Deamidation of Adeno-Associated Virus Capsid Impacts Transduction Activity in AAV9
Rosemary Meggersee, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 114
10:30 AM - 12:00 PM
Room: 302

CAR T-Cell Therapies I
Chair: Jen Adair, PhD

10:30 AM – 10:45 AM
30: CT-0508 is an Anti-HER2 Chimeric Antigen Receptor (CAR) Macrophage that Promotes a Pro-Inflammatory Solid Tumor Microenvironment and Eliminates Cancer Cells via Phagocytosis
Michael Klichinsky, Carisma Therapeutics, Philadelphia, PA, United States

10:45 AM – 11:00 AM
31: Mechanisms of Adoptive T Cell Micropharmacies
Christopher Bourne, Weill Cornell Medicine, New York, NY, United States

11:00 AM – 11:15 AM
32: CART T-Cells Targeting the EDB Splice Variant of Fibronectin Have Potent Anti-Tumor and Anti-Vasculature Activity in Preclinical Solid Tumor Models
Jessica Wagner, St. Jude Children’s Research Hospital, Memphis, TN, United States

11:15 AM – 11:30 AM
33: Pooled Knock-In Targeting for Genome Engineering of Cellular Immunotherapies
Theodore Roth, UCSF, San Francisco, CA, United States

JOIN THE MOLECULAR THERAPY FAMILY
SUBMIT YOUR NEXT PAPER!

- Increase the visibility of your work
- Take advantage of ASGCT membership-discounted publication and open access fees
- Publish along with other high-quality, cutting-edge studies

asgct.org/submitMT
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:30 AM – 11:45 AM
  34: G-CSF Mobilized Apheresis as an Alternative Source of CAR T Cells
      Katherine Cummins, The University of Pennsylvania, Perelman School of
      Medicine, Philadelphia, PA, United States

11:45 AM – 12:00 PM
  35: Enhanced tgTCR T Cell Product Attributes Through Process
      Improvement of CRISPR/Cas9 Engineering
      Aaron Prodeus, Intellia Therapeutics, Cambridge, MA, United States

ORAL ABSTRACT SESSION 115

10:15 AM - 12:00 PM
Room: 304 & 306

Oligonucleotide Therapies for Genetic Diseases
Chair: Anastasia Khvorova, PhD

10:15 AM – 10:30 AM
  36: A Novel Oligonucleotide-Based RNA Base Editing Therapeutic
      Approach for the Treatment of Hurler Syndrome
      Pengfei Yuan, EdiGene, Inc., Beijing, China

10:30 AM – 10:45 AM
  37: Targeting DNA Damage Response Genes with Oligonucleotides for
      Therapeutic Modulation of Somatic Instability at Disease Gene Repeats
      Brian Bettencourt, Triplet Therapeutics, Cambridge, MA, United States

10:45 AM – 11:00 AM
  38: SINEUPs: A New Antisense, Long Non-Coding RNA-Based Platform
      to Increase Endogenous Protein Levels for Therapy
      Stefano Espinoza, Istituto Italiano di Tecnologia, Genova, Italy

11:00 AM – 11:15 AM
  39: Restoration of Full-Length Dystrophin Expression in the Dup2
      Mouse Induced by Systemic Delivery of a Peptide-Conjugated
      Morpholino Oligomer
      Liubov Gushchina, Abigail Wexner Research Institute at Nationwide
      Children's Hospital, Columbus, OH, United States

11:15 AM – 11:30 AM
  40: A Novel Lentiviral Vector for Gene Therapy of
      β-Hemoglobinopathies: Co-Expression of a Potent Anti-Sickling
      Transgene and a microRNA Downregulating BCL11A
      Mégane Brusson, Imagine Institute, INSERM UMR1163, Paris, France
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:30 AM – 11:45 AM
  41: Engineering Backsplicing Introns for Robust Expression of Synthetic Circular RNAs from AAV Vectors
    Rita M. Reganck, Duke University, Carrboro, NC, United States

11:45 AM – 12:00 PM
  42: Delivery of mRNA and CRISPR in CNS with a Novel Polymer Nanoparticle
    Kunwoo Lee, GenEdit, South San Francisco, CA, United States

ORAL ABSTRACT SESSION 116

10:15 AM - 12:00 PM
Room: 309

Immune Responses Against AAV Vectors

Chair: Roberto Calcedo, PhD

10:15 AM – 10:30 AM
  43: IL-1R/MyD88-Dependent CD8+ T Cell Responses to Hepatic AAV Gene Transfer
    Sandeep Kumar, Indiana University, Indianapolis, IN, United States

10:30 AM – 10:45 AM
  44: A Vector Independent Method of Neutralizing Antibody Evasion Potently Protects AAV for Efficient Gene Delivery
    Charles Askew, University of North Carolina, Chapel Hill, Chapel Hill, NC, United States

10:45 AM – 11:00 AM
  45: Effect of CpG Depletion on Anti-Capsid CD8+T Cell Priming to AAV Gene Therapy
    Thais Bertolini, Indiana University School of Medicine, Indianapolis, IN, United States

11:00 AM – 11:15 AM
  46: Transgene-Specific T Cell Immunomodulation is Achieved in Mice by a Subretinal Co-Injection of the AAV Gene Transfer Vector with Peptides from the Transgene
    Sylvain Fisson, Genethon, Evry, France

11:15 AM – 11:30 AM
  47: Systemic Immunity Baseline Alterations in X Linked Retinoschisis: Do They Confound to AAV8-RS1 Gene Therapy Outcomes?
    Alaknanda Mishra, UC Davis, Davis, CA, United States
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:30 AM – 11:45 AM
48: Elastin-Like Polypeptide Mediated AAV Delivery Improved Transduction Efficiency and Reduced Immune Response
Kai Wang, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

11:45 AM – 12:00 PM
49: A Systematic Analysis of the Immunologic Effects of Intrathecal AAV9 Mediated Gene Transfer Targeting the Nervous System in Giant Axonal Neuropathy
Diana Bharucha-Goebel, NIH & Children’s National Hospital, Bethesda, MD, United States

ORAL ABSTRACT SESSION 117

10:15 AM - 12:00 PM
Room: 310

Assay Development

Chair: Linda Couto, PhD

10:15 AM – 10:30 AM
50: Development of a Flexible In Situ Sequencing Method with Single-Cell Resolution
Jana Rajova, Lund University, Lund, Sweden

10:30 AM – 10:45 AM
51: Using Nanopore Sequencing for Quality Control Analysis of Viral Vectors for use as Gene Therapies
Carolyn Yrigollen, Children’s Hospital of Philadelphia, Philadelphia, PA, United States

10:45 AM – 11:00 AM
52: Establishment of a Validated Assay for Clinical Vector Integration Site Analysis: S-EPTS/LM-PCR
Irene Gil-Farina, GeneWerk GmbH, Heidelberg, Germany

11:00 AM – 11:15 AM
53: Development of a Peptide Immunoaffinity LC-MS/MS Assay for Frataxin Transgene Protein Measurements after AAV9-FXN Treatment of the MCK Mouse Model of Friedreich Ataxia
Vahid Farrokhi, Pfizer Inc, Cambridge, MA, United States
PROGRAM SCHEDULE  
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:15 AM – 11:30 AM  
54: Development and Optimization of a New, Harmonized Droplet Digital PCR (ddPCR) Method for Pharmacokinetic (PK) Monitoring of Axicabtagene Ciloleucel (Axi-Cel) and Association with Outcomes in ZUMA-1  
Vicki Plaks, Kite, a Gilead Company, Santa Monica, CA, United States

11:30 AM – 11:45 AM  
55: Implementation of an Automated VCN Platform to Assess Integration of Lentiviral Vectors in a High-Throughput Capacity  
Maple Gioia, bluebird bio, Cambridge, MA, United States

11:45 AM – 12:00 PM  
56: Development of a Single-Cell Western Assay for Anti-Sickling Beta Globin Drug Products for Sickle Cell Disease  
Paige Coles, bluebird bio, Cambridge, MA, United States

ORAL ABSTRACT SESSION 118

10:15 AM - 12:00 PM  
Room: 311

Vector and Cell Engineering, Production or Manufacturing I

Chair: Robert Kotin, PhD

10:15 AM – 10:30 AM  
57: Akt Inhibition Enhances Memory, Proliferation and Cytotoxicity in CD19 CAR T Cells  
Vedika Mehra, UCL, London, United Kingdom

10:30 AM – 10:45 AM  
58: A New Primary Human Muscle Stem Cell Product, PHSats  
Janine Kieshauer, Experimental and Clinical Research Center, Berlin, Germany

10:45 AM – 11:00 AM  
59: Novel Strategies to Enhance CAR-T Cell Production and Improve Quality During Manufacturing  
Gauri Lamture, FDA, White Oak, MD, United States

11:00 AM – 11:15 AM  
60: A Universal High Density Cell Respirator (HDCR) Bioreactor for Intensified Production of Gene Therapy Vectors  
Colin Cook, Beckman Research Institute of the City of Hope, Duarte, CA, United States
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:15 AM – 11:30 AM
  61: Acoustic Affinity Cell Selection: A Non-Paramagnetic Scalable Technology for T Cell Selection From Unprocessed Apheresis Products
      Jack Saloio, MilliporeSigma, Wilbraham, MA, United States

11:30 AM – 11:45 AM
  62: The Lisocabtagene Maraleucel (liso-cel) Manufacturing Process is Designed for Consistency, Purity, and Robustness Across B-Cell Malignancies
      Jeffrey Teoh, Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, United States

11:45 AM – 12:00 PM
  63: Using Numberical Modelling (CFD) to Design and Improve a 3D Printed Atomizer for the Transfection of Cells with Virus
      Justin O'Sullivan, APC Ltd, Dublin, Ireland

ORAL ABSTRACT SESSION 119

10:15 AM - 12:00 PM
Room: 312

CAR T-Cells Targeting Solid Tumors
Chair: Paola Grandi, PhD

10:15 AM – 10:30 AM
  64: Combining De-Glycosylating Agents with CAR T Cells for Targeting Solid Tumors and Improving Therapeutic Index
      Beatrice Greco, San Raffaele Hospital Scientific Institute, Milan, Italy

10:30 AM – 10:45 AM
  65: Overcoming the Breast Tumor Microenvironment by Targeting MDSCs through CAR-T Cell Therapy
      Saisha Nalawade PhD., Baylor College of Medicine, Houston, TX, United States

10:45 AM – 11:00 AM
  66: Induction of Potent Systemic and Tissue Resident Immune Responses by ExoVACCTM: A Novel Exosome-Based Vaccine Platform
      Nikki Ross, Codiak BioSciences, Cambridge, MA, United States
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:00 AM – 11:15 AM
  67: Glypican-3-Specific CAR NKT Cells Armored with IL-15 Mediate Potent Anti-Tumor Response Against Hepatocellular Carcinoma
  Rahamthulla Shaik, Baylor College of Medicine, Houston, TX, United States

11:15 AM – 11:30 AM
  68: Preclinical Study of Oral Cancer Vaccine Using Recombinant Bifidobacterium Expressing WT1 Protein in Murine Bladder Cancer Model and Non-Human Primate
  Koichi Kitagawa, Kobe University Graduate School of Science, Technology and Innovation, Kobe, Japan

11:30 AM – 11:45 AM
  69: T Cells Redirected to the Pan-Cancer Target GRP78 Have Potent Antitumor Activity in Preclinical Models
  Nikhil Hebbar, St. Jude Children's Research Hospital, Memphis, TN, United States

11:45 AM – 12:00 PM
  70: Faster, Higher, Stronger: Optimizing Fuel Selection to Improve CAR-T Cell Metabolic Fitness in Solid Tumors
  Roderick O'Connor, University of Pennsylvania, Philadelphia, PA, United States

BREAK
12:00 PM - 1:30 PM
Lunch Break

TOOLS AND TECHNOLOGIES FORUM

12:00 PM - 1:30 PM
Room: 210

Tools and Technologies Forum I

SPEAKERS:

12:00 PM - 12:15 PM
  Guangnan Meng. PerkinElmer, Waltham, MA
  AAV Purity Analysis Modernized for a New Decade

12:15 PM - 12:30 PM
  Hongshan Li, PhD. ForteBio, Freemont, CA
  AAV Quantification by Octet Using BLI Technology
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

12:30 PM - 12:45 PM
Rene Gantier. Repligen, Waltham, MA
Technology-Ready Processes for Gene Therapy Manufacturing 2.0

12:45 PM - 1:00 PM
Philippe Garabedian. MYRIADE, Paris, France
Characterize and Count Nanoparticles in a Single Drop and in Real Time

1:00 PM - 1:15 PM
Henry George. MilliporeSigma, Saint Louis, MO
VirusExpress™ Lentiviral Production Platform

1:15 PM - 1:30 PM
Peter Guterstam, PhD, Cytiva, Uppsala, Sweden
Fibro Chromatography to Revamp Productivity in Downstream AAV Processing

EDUCATION SESSION 120

1:30 PM - 3:15 PM
Room: 304 & 306

Synthetic Biology Meets Immunology: DNA and RNA Tools

CHAIR: David Weiner, PhD

SPEAKERS

1:30 PM – 2:05 PM
David Weiner, PhD. The Wistar Institute, Philadelphia, PA
DNA Vaccines and Synthetic DNA Encoded Bifunctional Antibodies
BITES

2:05 PM – 2:40 PM
Norbert Pardi, PhD. University of Pennsylvania, Philadelphia, PA
mRNA Vaccines - A Novel Vaccine Generation

2:40 PM – 3:15 PM
Eric Kelsic, PhD. Dyno Therapeutics, Cambridge, MA
AAV Gene Therapy and Capsid Engineering
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

EDUCATION SESSION 121
1:30 PM - 3:15 PM
Room: 312

“Off the Shelf” Cell Therapies
CO-CHAIRS: Catherine Bollard, MD and Rayne Rouce, MD

SPEAKERS
1:30 PM – 2:05 PM
Susan Prockop, MD. Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY
Viral Specific T Cells - From Donor Derived to Off-the-Shelf Products

2:05 PM – 2:40 PM
Rayne Rouce, MD. Baylor College of Medicine, Houston, TX
NK Cells or iNKT Cells as a Platform for Off the Shelf Therapies

2:40 PM – 3:15 PM
Blake Aftab, PhD. Atara Biotherapeutics, Inc., Thousand Oaks, CA
Review of Clinical Stage Allogeneic T-Cell Therapies

EDUCATION SESSION 122
1:30 PM - 3:15 PM
Room: Auditorium

Adeno-associated Virus (AAV) Vectors - From Basic Biology to Vector Application

CO-CHAIRS: Hildegard Büning, PhD and Graeme Fielder, PhD

SPEAKERS
1:30 PM – 2:05 PM
Nicole K. Paulk, PhD. University of California San Francisco, San Francisco, CA
AAV Basics

2:05 PM – 2:40 PM
Eduard Ayuso, DVM, PhD. INSERM, University of Nantes, Nantes, France
Manufacturing AAV

2:40 PM – 3:15 PM
James Wilson, MD, PhD. University of Pennsylvania, Philadelphia, PA
Safety and AAV
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

EDUCATION SESSION 123

1:30 PM - 2:40 PM  
Room: 311

Bioinformatics: Artificial Intelligence (AI) takes Gene Therapy to the Next Level

CO-CHAIRS: Paloma Giangrande, PhD and Thomas J. Cradick, PhD.

SPEAKERS

1:30 PM – 2:05 PM  
Ryan Boudreau, PhD. University of Iowa, Iowa City, IA  
Bioinformatics & Gene Therapy

2:05 PM – 2:40 PM  
Andrew Giessel, PhD. Moderna Therapeutics, Cambridge, MA  
Data Science and AI in mRNA Drug Development

EDUCATION SESSION 124

1:30 PM - 2:40 PM  
Room: 302

Building Robust Animal Models for Preclinical Testing Gene and Immune Therapies for Humans

CO-CHAIRS: Avery Posey, PhD and Renata Stripecke, PhD

SPEAKERS

1:30 PM – 2:05 PM  
Michael Brehm, PhD. University of Massachusetts Medical School, Worcester, MA  
Human Immune Reconstitution in Mice for Modeling Diabetes

2:05 PM – 2:40 PM  
Scott G. Kitchen, PhD. UCLA AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA  
Engineering CAR T-Cells and Cell-Based Vaccines against HIV in Mice and NHPs
PROGRAM SCHEDULE  
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

EDUCATION SESSION 125  
1:30 PM - 3:15 PM  
Room: Ballroom B

Engineered T-Cell Therapies for Malignancies

CHAIR: Craig Sauter, MD

SPEAKERS

1:30 PM – 2:05 PM  
Saar Gill, MD, PhD. University of Pennsylvania, Philadelphia, PA  
New CAR Targets - AML Targets and Solid Tumor Targets

2:05 PM – 2:40 PM  
Nabil Ahmed, MD. Baylor College of Medicine, Houston, TX  
CAR T-cells to Overcome CD19 Escape in Acute B-lineage Leukemia

2:40 PM – 3:15 PM  
Sandra P. D'Angelo, MD. Memorial Sloan Kettering Cancer Center, New York, NY  
TCRs for Solid Organ Malignancies

EDUCATION SESSION 126  
1:30 PM - 3:15 PM  
Room: Ballroom A

Gene Editing with CRISPR/Cas9, Discovery to Application

CO-CHAIR: John Tisdale, MD

SPEAKERS

1:30 PM – 2:05 PM  
Raed Ibraheim, University of Massachusetts Medical School, Worcester, MA  
All-in-one Nme2Cas9 AAV Platforms for Segmental Deletions and Precise HDR-Based Editing

2:05 PM – 2:40 PM  
Nadav Ahituv, PhD. University of California San Francisco, San Francisco, CA  
CRISPR-mediated Activation of a Promoter or Enhancer to Rescue Obesity Caused by Haploinsufficiency
**PROGRAM SCHEDULE**  
**TUESDAY, MAY 12**

All times are listed in Eastern Daylight Time (EDT UTC -4).

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 2:40 PM – 3:15 PM | Scot Wolfe, PhD. University of Massachusetts Medical School, Worcester, MA  
Structure-Guided Chemical Modification of Guide RNAs to Facilitate In Vivo Genome Editing by Cas9 |

**EDUCATION SESSION 127**

1:30 PM - 3:15 PM  
*Room: Ballroom C*

**Updates on Immunogenicity Against AAV and Cas9**

**SPEAKERS**

1:30 PM – 2:05 PM  
Federico Mingozzi, PhD. Spark Therapeutics, Philadelphia, PA  
Adaptive Immunity to AAV

2:05 PM – 2:40 PM  
Anna Kajaste-Rudnitski, PhD. SR-TIGET, Milano, Italy  
Vector-host Interactions and Innate Immunity in Hematopoietic Stem Cell Gene Engineering

2:40 PM – 3:15 PM  
Matthew Porteus, MD, PhD. Stanford University School of Medicine, Stanford, CA  
Immunity to CrisprCAS

**BREAK**

3:15 PM - 3:45 PM

**TOOLS AND TECHNOLOGIES FORUM**

3:30 PM - 4:45 PM  
*Room: 210*

Tools and Technologies Forum II

**SPEAKERS:**

3:30 PM - 3:45 PM  
Tim Schroeder. Repligen, Waltham, MA  
Jana Langhoff. Tecan, Mannedorf, Switzerland  
Automated High Throughput Viral Vector Purification to Streamline Downstream Process Development in Gene Therapy
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

3:45 PM - 4:00 PM
Helen Gu. GenScript ProBio, Piscataway, NJ
Accelerate Gene and Cell Therapy Product Development

4:00 PM - 4:15 PM
Dr. Marco Schmeer. PlasmidFactory GmbH & Co. KG, Bielefeld, Germany
Minicircle DNA – New Tool for Cell Therapy

4:15 PM - 4:30 PM
Dana Holzinger, PhD. PROGEN Biotechnik GmbH, Heidelberg, Germany
AAV Antibodies: An Overview of Qualified Applications

4:30 PM - 4:45 PM
Dr. Wei Wang. GeneWerk GmbH, Heidelberg, Germany
Vector Safety in Gene and Immune Gene Therapies

ORAL ABSTRACT SESSION 130

3:45 PM - 5:30 PM
Room: Auditorium

New Gene Editing Technologies and Approaches
Chair: Shondra Pruett-Miller, PhD

3:45 PM – 4:00 PM
71: Programmable C-to-G Transversions in Human Cells with Engineered CRISPR Base Editors
Ibrahim Kurt, Massachusetts General Hospital, Charlestown, MA, United States

4:00 PM – 4:15 PM
72: Unconstrained Genome Targeting with Engineered Near-PAMless CRISPR-Cas Variants
Kathleen Christie, Massachusetts General Hospital, Boston, MA, United States

4:15 PM – 4:30 PM
73: Efficient Multiplex Base Editing at Single Target Sites with a Dual-Deaminase Base Editor
Julian Grünewald, MGH, Charlestown, MA, United States
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:30 PM – 4:45 PM
74: Rational Selection of CRISPR/Cas9 gRNAs to Maximize Homology-Directed Genome Editing
Kristina Tatiossian, University of Southern California, Los Angeles, CA, United States

4:45 PM – 5:00 PM
75: dCas13-Mediated Therapeutic RNA Base Editing for In Vivo Gene Therapy
Jiaming Wang, University of Massachusetts Medical School, Worcester, MA, United States

5:00 PM – 5:15 PM
76: CRISPR/Cas9-Mediated Gene Editing Corrects Disease-Causing Mutation in Crigler-Najjar Syndrome Mice
Giulia Bortolussi, ICGEB, Trieste, Italy

5:15 PM – 5:30 PM
77: Development of a CRISPR/Cas9 System for Mitochondrial Diseases
Michelle Ho, City of Hope, Duarte, CA, United States

ORAL ABSTRACT SESSION 131

3:45 PM - 5:30 PM
Room: Ballroom A

CAR T and Other Engineered T Cells Targeting Hematological Malignancies
Chair: Conrad Russell Cruz, MD, PhD

3:45 PM – 4:00 PM
78: Exploiting CRISPR-Genome Editing and WT1-Specific T Cell Receptors to Redirect T Lymphocytes Against Acute Myeloid Leukemia
Eliana Ruggiero, San Raffaele Scientific Institute, Milan, Italy

4:00 PM – 4:15 PM
79: Co-Targeting CD38 with a Chimeric Costimulatory Receptor Enhances Adoptive T Cell Therapy for Hematological Malignancies
Afroditi Katsarou, Amsterdam UMC, Location VUMc, Amsterdam, Netherlands

4:15 PM – 4:30 PM
80: Generation of Human Memory Stem T Cells Specific for Tumor Antigens and Resistant to Inhibitory Signals by Genome Editing
Beatrice Cianciotti, San Raffaele Scientific Institute, Milan, Italy
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:30 PM – 4:45 PM
81: Pre-selected CAR $T_{N/SCM}$ Outperform CAR $T_{BULK}$ in Driving Tumor Eradication in the Absence of Cytokine Release Syndrome and Neurotoxicity
Claudia Mezzanotte, IRCSS San Raffaele Scientific Institute, Milan, Italy

4:45 PM – 5:00 PM
82: Therapeutic Efficacy of CAR-T Cells Targeting gp350 in a Humanized Mouse Model of Epstein Barr Virus-Induced Lymphoproliferation and Prospects for Clinical Trials
Renata Stripecke, Hannover Medical School, Hannover, Germany

5:00 PM – 5:15 PM
83: DNMT3A-Dependent Epigenetic Programs Constrain CAR T Cell Survival and Effector Function
Brooke Prinzing, St Jude Children’s Research Hospital, Memphis, TN, United States

5:15 PM – 5:30 PM
84: Insufficient Activation Limits the Efficacy of CAR T Cell Therapy in Chronic Lymphocytic Leukemia
McKensie Collins, University of Pennsylvania, Philadelphia, PA, United States

ORAL ABSTRACT SESSION 132

3:45 PM - 5:30 PM
Room: Ballroom B

AAV Vector Biology: New Insights

Chair: Jay Chiorini, PhD

3:45 PM – 4:00PM
85: The Membrane-Associated Accessory Protein (MAAP) is Essential for Rapid Extracellular Secretion of Adeno-Associated Viruses
Zachary C. Elmore, Duke University School of Medicine, Durham, NC, United States

4:00 PM – 4:15 PM
86: Dependency of AAV Entry on GPR108 Maps to Motif on VP1u That is Transferable Across AAV Serotypes
Nerea Zabaleta, Grousbeck Gene Therapy Center, Mass Eye and Ear, Harvard Medical School & The Broad Institute of Harvard and MIT, Boston, MA, United States
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:15 PM – 4:30 PM
87: USP36, A Nucleolar Enriched Deubiquitinating Enzyme, Promotes AAV Vector Production by Optimally Stabilizing AAP Levels
Swapna Kollu, Oregon Health & Science University, Portland, OR, United States

4:30 PM – 4:45 PM
88: Improved Genome Packaging Efficiency of AAV Vectors Using Rep Hybrids
Mario Mietzsch, University of Florida, Gainesville, FL, United States

4:45 PM – 5:00 PM
89: The Primate Selective Transduction of rAAV-LK03 Vectors is Unrelated to Variation in Double-Stranded Viral Genome Formation in the Nucleus Between Species
Adriana Gonzalez Sandoval, Stanford University, Stanford, CA, United States

5:00 PM – 5:15 PM
90: AAPs Harbor Degrons, a Protein Self-Degradation Motif, Important for Regulating Stability of AAP in the Process of AAV Capsid Assembly
Anusha Sairavi, Oregon Health & Science University, Portland, OR, United States

5:15 PM – 5:30 PM
91: Cardiac Toxicity of AAV9 Vector Upon Heart-Specific Expression of an Immunogenic Non-Self Transgene
Andrew Park, AstraZeneca, Gaithersburg, MD, United States

ORAL ABSTRACT SESSION 133
3:45 PM - 5:15 PM
Room: Ballroom C

AAV Gene Delivery for CNS Disorders
Chair: Rita Batista, PhD

3:45 PM – 4:00 PM
92: A New Approach for Designing a Feedback-Enabled AAV Genome Improves Therapeutic Outcomes of MiniMeCP2 Gene Transfer in Mice Modeling Rett Syndrome (RTT)
Sarah Sinnett, UTSW, Dallas, TX, United States
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:00 PM – 4:15 PM
98: AAV9/hCDKL5 Delivery to Cerebrospinal Fluid of Juvenile CDKL5-Deficient Mice Improves Learning and Memory and Motor Function in Adult Mice
Maggie Wright, Ultragenyx Pharmaceutical, Novato, CA, United States

4:15 PM - 4:30 PM
94: Gene Correction in Peripheral Organs May Contribute to the Treatment of Central Nervous System Diseases
Anoushka Lotun, University of Massachusetts Medical School, Worcester, MA, United States

4:30 PM – 4:45 PM
95: Evaluating the Efficacy and Safety of Cerebrospinal Fluid-Delivered Gene Therapy for Krabbe Disease in Murine and Canine Models
Juliette Hordeaux, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States

4:45 PM – 5:00 PM
96: Developing a CDKL5 Gene-Therapy Vector for a Mouse Model of CDKL5-Deficiency Disorder
Ralf Schmid, University of Pennsylvania, Philadelphia, PA, United States

5:00 PM – 5:15 PM
97: Intrathecal Delivery of Human Bicistronic Hexosaminidase Vector (TGTX-101) to Correct Sandhoff Disease in a Murine Model: A Dosage Study
Alex Ryckman, Queen’s University, Kingston, ON, Canada

ORAL ABSTRACT SESSION 134

3:45 PM - 5:00 PM
Room: 302

Oligonucleotide Therapies for Acquired Diseases
Chair: Annemieke Aartsma-Rus, PhD

3:45 PM – 4:00 PM
99: rAAV-Mediated Hepatocyte-Specific Expression of miR-375 Protects Against the Acetaminophen-Induced Acute Liver Failure in Mice
Yi Wang, Sichuan University, Chengdu, China
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:00 PM – 4:15 PM
100: Therapeutic saRNAstargeting CEBPA in Myeloid Cells. A Potential Immunomodulatoryswitch for Anticancer Therapy
Vikash Reebye, Imperial College London, London, United Kingdom

4:15 PM – 4:30 PM
101: Targeted Systemic Delivery of Small Nucleic Acids to Metastatic and Brain-Localized Triple-Negative Breast Cancer by HER3-Homing Nano-Capsids
Felix Alonso-Valenteen, Cedars-Sinai Medical Center, Los Angeles, CA, United States

4:30 PM – 4:45 PM
104: A Novel Approach to Potentially Treat Influenza: Selective Induction of Apoptosis in Infected Cells by Hijacking the Virus Machinery
Serhat Gumrukcu, Seraph Research Institute, Los Angeles, CA, United States

4:45 PM – 5:00 PM
105: Systemic Senolysis in Naturally Aged Mice Using a Fusogenix FAST-LNP Gene Therapy Approach
John Lewis, University of Alberta, Edmonton, AB, Canada

ORAL ABSTRACT SESSION 135
3:45 PM – 5:30 PM
Room: 304 & 306
HSPC Gene Therapies for Blood and Immune Disorders
Chair: Cyndi Dunbar, MD

3:45 PM – 4:00 PM
106: Durable Therapeutic Restoration of Immunity in the Scid-X1 Canine Model via In-Vivo Delivery of Cocal Pseudotyped Lentivirus Vector Carrying II2R-Γc
Yogendra Rajawat, Fred Hutchinson Cancer Research Center, Seattle, WA, United States
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:00 PM – 4:15 PM
107: Efficient, Specific and Universal Therapeutic Gene Editing of ELANEFor Severe Congenital Neutropenia in Human Hematopoietic Stem Cells
Shuquan Rao, Division of Hematology/Oncology, Boston Children’s Hospital, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Broad Institute, Harvard Medical School, Boston, MA, United States

4:15 PM – 4:30 PM
108: A Genomic Editing-Based Therapeutic Approach for RAG2 Deficiency
Mara Pavel-Dinu, Stanford University, Stanford, CA, United States

4:30 PM – 4:45 PM
109: A Phase 1/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Initial Results from the First Treated Patient
Donald Kohn, University of California, Los Angeles, Los Angeles, CA, United States

4:45 PM – 5:00 PM
110: Updated Results of a European Gene Therapy Trial in Fanconi Anemia Patients, Subtype A
Juan Bueren, CIEMAT/CIBERER/Fund. Jiménez Díaz, Madrid, Spain

5:00 PM – 5:15 PM
111: Long-Term Follow-Up Study after Lentiviral Hematopoietic Stem/Progenitor Cell Gene Therapy for Wiskott-Aldrich Syndrome
Alessandra Magnani, Necker-Enfants Malades Hospital, Paris, France

5:15 PM – 5:30 PM
112: Results from a Phase I/II Clinical Trial for X Linked Chronic Granulomatous Disease (CGD): Possible Impact of Inflammation on Gene Therapy Efficacy
Emmanuelle Six, Imagine Institute, Paris, France
### ORAL ABSTRACT SESSION 136

**3:45 PM - 5:30 PM**  
**Room: 309**  
**Antiviral Immunotherapy**  
**Chair:** Masataka Suzuki, PhD

3:45 PM – 4:00 PM  
113: *In Situ Analysis of Follicular Targeting Antiviral CD4-MBL CAR/CXCR5 T Cells in SIV Infected Rhesus Macaques*  
Hadia Abdelaal, University of Minnesota, Saint Paul, MN, United States

4:00 PM – 4:15 PM  
114: *Targeting HIV Using Anti-HIV duoCAR-T Cell Therapy*  
Kim Anthony-Gonda, Lentigen, a Miltenyi Biotec Company, Gaithersburg, MD, United States

4:15 PM – 4:30 PM  
115: *Genome Editing the Immunoglobulin Locus with Single-Domain Antibodies to Create HIV-Specific B Cells*  
Geoffrey Rogers, University of Southern California, Los Angeles, CA, United States

4:30 PM – 4:45 PM  
116: *Lentiviral-Mediated Expression of Monoclonal Antibodies in the Lung to Protect Against Influenza*  
Yue Du, University of Oxford, Oxford, United Kingdom

4:45 PM – 5:00 PM  
117: *Multi-Virus Specific T Cells Dominate and Persist in the Patient Immune Repertoire Post Allogeneic Hematopoietic Stem Cell Transplant*  
Sarah Davies, NHLBI, Bethesda, MD, United States

5:00 PM – 5:15 PM  
118: *Protection Against Crimean-Congo Hemorrhagic Fever Virus in a Cynomolgus Macaque Disease Model by Genetic Vaccination*  
Matti Sallberg, Karolinska Institutet, Stockholm, Sweden

5:15 PM – 5:30 PM  
119: *Superior Hematopoietic Stem Cell based CAR-T Cell Therapy for HIV Infection*  
Anjie Zhen, UCLA, Los Angeles, CA, United States
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 137
3:45 PM - 5:30 PM
Room: 310

Hematopoietic Cell Therapies
Chair: Eirini Papapetrou, MD, PhD

3:45 PM – 4:00 PM
John Wagner, University of Minnesota, Minneapolis, MN, United States

4:00 PM – 4:15 PM
121: Exchange of Alveolar Macrophages Restores Pulmonary Immunity by Niche Specific Adaption of Ex Vivo Generated Macrophages
Kathrin Haake, Medical School Hannover, Hannover, Germany

4:15 PM – 4:30 PM
122: Engineered B Cells Undergo Antigen Induced Activation to Allow Memory Retention, Class Switch Recombination and Clonal Selection in Mice
Alessio Nahmad, Tel Aviv University, Tel Aviv, Israel

4:30 PM – 4:45 PM
123: MGTA-145, in Combination with Plerixafor, Rapidly Mobilizes Large Numbers of HSCs in Humans That Can Be Gene Edited with CRISPR/Cas9 and Mediate Superior Engraftment to Standard-of-Care
Kevin Goncalves, Magenta Therapeutics, Cambridge, MA, United States

4:45 PM – 5:00 PM
124: "Cerberus" T Cells: A Single Glucocorticoid-Resistant T Cell Product to Simultaneously Target Multiple Pathogens in Immunocompromised Patients
Anastasia Papadopoulou, George Papanicolaou Hospital, Thessaloniki, Greece

5:00 PM – 5:15 PM
125: Restored Macrophage Function Ameliorates Disease Pathophysiology in a Mouse Model for Very Early Onset Inflammatory Bowel Disease (VEO-IBD)
Mania Ackermann, Hannover Medical School, Hannover, Germany
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

5:15 PM – 5:30 PM
126: Natural Killer Cells Generated from Human Induced Pluripotent Stem Cells Under Defined Conditions, Engineered for Immunotherapy of Solid Tumors
Kyle Lupo, Purdue University, West Lafayette, IN, United States

ORAL ABSTRACT SESSION 138

3:45 PM - 5:00 PM
Room: 311

Vector and Cell Engineering, Production or Manufacturing II

Chair: Matthias Hebben, PhD

3:45 PM – 4:00 PM
127: Enhanced Lentiviral Vector Transduction of CD34+ Hematopoietic Stem and Progenitor Cells by Targeting Anti-Viral Restriction Factors
Diego Leon-Rico, UCL GOS Institute of Child Health, London, United Kingdom

4:00 PM – 4:15 PM
128: Establishing cGMP Manufacturing of CRISPR/Cas9-Edited Human CAR T Cells
Xiuyan Wang, Memorial Sloan Kettering Cancer Center, New York, NY, United States

4:15 PM – 4:30 PM
132: Clinical Production of Ex-Vivo Gene Corrected Hematopoietic Stem and Progenitor Cells Using a cGMP-Compliant Semi-Closed Manufacturing Process
Premanjali Lahiri, Stanford University, Palo Alto, CA, United States

4:30 PM – 4:45 PM
130: Validation of cGMP-Generation of Genetically Engineered T Cells on the CliniMACS Prodigy™
Heather Daley, Dana-Farber Cancer Institute, Boston, MA, United States

4:45 PM – 5:00 PM
131: The Influence of Cytokines and Seeding-Density in a Scalable Feeder-Free System for Natural Killer Cell Expansion
Chris Johnson, Bio-Techne, Woburn, MA, United States
ORAL ABSTRACT SESSION 139

3:45 PM - 5:30 PM
Room: 312

AAV Vectors Preclinical and Proof-of-Concept Studies in Optimizing the Toolbox

Chair: Phillip Tai, PhD

3:45 PM – 4:00 PM
134: A Novel Lung Tropic AAV Vector Restores Surfactant Homeostasis and Improves Survival in a Mouse Model of Inherited Surfactant B Deficiency
Martin Kang, Ottawa Hospital Research Institute, Ottawa, ON, Canada

4:00 PM – 4:15 PM
135: Quantitative PET/CT Based Pharmacokinetic Study of AAV9 Administered to the Cerebrospinal Fluid of Non-Human Primates
Mikhail Papisov, Massachusetts General Hospital, Boston, MA, United States

4:15 PM – 4:30 PM
136: Building a Toolbox of Compact Enhancers for Cell Type-Specific Gene Expression from AAVs in the Primate Brain
John Mich, Allen Institute for Brain Science, Seattle, WA, United States

4:30 PM – 4:45 PM
137: Rapalog-Mediated Regulation of an AAV miRNA Targeting Huntingtin in a HD Transgenic Mouse Model
Rachael Miller, University of Massachusetts Medical School, Worcester, MA, United States

4:45 PM – 5:00 PM
138: A Discovery Platform that Screens Thousands of Gene Therapy Candidates in a Single Animal
Martin Borch Jensen, Gordian Biotechnology, San Francisco, CA, United States

5:00 PM – 5:15 PM
139: Combined Transgene and Intron-Derived miRNA Therapy for the Treatment of SCA1
Megan Keiser, The Children's Hospital of Philadelphia, Philadelphia, PA, United States
PROGRAM SCHEDULE
TUESDAY, MAY 12

All times are listed in Eastern Daylight Time (EDT UTC -4).

5:15 PM – 5:30 PM
140: A Highly-Evolved Novel AAV Gene Therapy Directly Addresses Fabry Disease Pathology In Vivo by Cell Autonomous Expression in the Heart and Other Target Organs
David Kirn, 4D Molecular Therapeutics, Emeryville, CA, United States

EXHIBIT HALL
Open 24 hours online

POSTER SESSION I
Open 24 hours on May 12

5:30 PM - 6:30 PM
Scheduled presenters requested to be available for live Q&A
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

EDUCATION SESSION 200
8:00 AM - 9:45 AM
Room: 302

Ins and Outs of Lentiviral Vectors: From Technology to Applications

CO-CHAIRS: Juliana Alvarez, MD and Punam Malik, MD

SPEAKERS
8:00 AM – 8:26 AM
Luigi Naldini, MD, PhD. San Raffaele Telethon Institute for Gene Therapy, Milan, Italy
Evolution and Application of Lentiviral Vectors to Correct Hematopoiesis

8:26 – 8:52 AM
Manfred Schmidt, PhD. GeneWerk GmbH, Heidelberg, Germany
Lentiviral Vectors - Safety and Integration Site Studies

8:52 AM – 9:18 AM
Bruce E. Torbett, PhD. The Scripps Research Institute, La Jolla, CA
Deciphering Cellular Pathways to Improve Lentiviral Vector Transduction

9:18 AM – 9:45 AM
Christian Buchholz, PhD. Paul-Ehrlich-Institut, Langen, Germany
Retargeting Lentiviral Vectors for In Vivo Applications

EDUCATION SESSION 201
8:00 AM - 9:20 AM
Room: 311

Career Development in Academia and Industry

CHAIR: Nuria Morral, PhD

SPEAKERS
8:00 AM – 8:20 AM
Andrew Wilber, PhD. SIU School of Medicine, Springfield, IL
Building a Gene Therapy Career in Academics

8:20 AM – 8:40 AM
Jennifer L. Gori, PhD. Obsidian Therapeutics, Inc., Cambridge, MA
Ensuring Long Term Career Success in the Gene and Cell Therapy Industry
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

8:40 AM – 9:00 AM
Jeffrey A. Medin, PhD. Medical College of Wisconsin, Milwaukee, WI
One PhD's Pathway

9:00 AM – 9:20 AM
Dirk Grimm, PhD. Heidelberg University Hospital, Heidelberg, Germany
Developing a Leadership Career in Gene Therapy

EDUCATION SESSION 202

8:00 AM - 9:45 AM
Room: 312
Strategies for Preparing Synthetic Vectors for Clinical Application
CHAIR: Chantal Pichon, PhD
SPEAKERS
8:00 AM – 8:35 AM
Raymond Schiffelers, PhD. University Medical Center Utrecht, Utrecht, Netherlands
Using Exosomes for Targeted RNA Delivery

8:35 AM – 9:10 AM
Assem G. Ziady, PhD. Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Targeting DNA Nanoparticles for CF Gene Delivery

9:10 AM – 9:45 AM
Millicent Sullivan, PhD. University of Delaware, Newark, DE
Design of Non-viral Vectors for Clinical Applications

SCIENTIFIC SYMPOSIUM 210

8:00 AM - 9:20 AM
Room: Ballroom B
Cell-based Therapies for Eye and Nervous System Disorders: Translation from Research to Early Clinical Stages - Organized by the Neurologic & Ophthalmic Gene & Cell Therapy Committee
CO-CHAIRS: Paul Gamlin, PhD
SPEAKERS
8:00 AM – 8:26 AM
Sally Temple, PhD. Neural Stem Cell Institute, Rensselaer, NY
Overview of the Field - RPE Cell Therapy
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

8:26 AM – 8:52 AM
   Penelope Hallett. McLean Hospital / Harvard Medical School, Belmont, MA
   Neurologic Clinical: Autologous iPSC based Cell Therapy for Parkinson’s Disease

8:52 AM – 9:18 AM
   Kapil Bharti. National Eye Institute, National Institutes of Health, Bethesda, MD
   Initiating a Phase I Clinical Trial for an Autologous IPS Cell Therapy for Macular Degeneration: From Bench-to-Bedside

SCIENTIFIC SYMPOSIUM 211

8:00 AM - 9:45 AM
Room: Ballroom A

Globalization Roadmap for Cell and Gene Therapies - Organized by the Commercialization Committee

CO-CHAIR: Debasish Roychowdhury, MD and Katy Spink, PhD

SPEAKERS

8:00 AM – 8:15 AM
   Delfi Krishna, PhD. GlaxoSmithKline, Collegeville, PA
   Assessing the Potential for Return on Investment of Cell and Gene Therapy Assets Across Global Markets

8:15 AM – 8:30 AM
   John Doyle, PhD. Pfizer, New York, NY
   Global Access/Pricing/Commercial Operations
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

8:30 AM – 8:45 AM
   Katherine Tsokas, JD. Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, PA
   Global Regulatory Challenges and the Opportunities in Developing Cell and Gene Therapy Products

8:45 AM – 9:00 AM
   Rogerio Vivaldi, MD, MBA. Sigilon Therapeutics, Cambridge, MA
   Patient Identification/Global Clinical Trial Design

9:00 AM – 9:45 AM
   Panel Discussion

SCIENTIFIC SYMPOSIUM 212
8:00 AM - 9:45 AM
   Room: Auditorium

   Social, Ethical, and Scientific Perspectives on Germline Gene Editing - Organized by the Ethics and Government Relations Committees

   CO-CHAIRS: Lauriel Earley, PhD and Timothy Hunt, JD

   SPEAKERS

   8:00 AM – 8:05 AM
      Timothy Hunt, JD. Sudbury, MA
      Introduction and Summary of the ASGCT Policy Summit on Germline Gene Editing

   8:05 AM – 8:25 AM
      Monica L. Weldon. Bridge the Gap - SYNGAP, Washington, DC
      Germline Gene Editing: A Parent & Patient Advocate Perspective

   8:25 AM – 8:45 AM
      Victor J. Dzau, MD. National Academy of Medicine, Washington, DC
      Germline Gene Editing: A Responsible Path Forward

   8:45 AM – 9:05 AM
      J. Keith Joung, MD, PhD. Massachusetts General Hospital, Charlestown, MA
      Germline Gene Editing: The Scientific Case for a Moratorium

   9:05 AM - 9:25 AM
      Jeffrey Kahn, PhD. Johns Hopkins University, Baltimore, MD
      Germline Gene Editing: A Bioethical Perspective

   9:25 - 9:45 AM
      Panel Discussion
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

**SCIENTIFIC SYMPOSIUM 213**

8:00 AM - 9:45 AM
*Room: Ballroom C*

Targeting the Lung: Vectors and Stem Cells - Organized by the Respiratory & GI Tract Gene & Cell Therapy Committee

**CO-CHAIRS:** Katherine Excoffon, PhD and Allison Keeler-Klunk, PhD

**SPEAKERS**

8:00 AM – 8:26 AM  
Purushothama Rao Tata, MS, PhD. Duke University School of Medicine, Durham, NC 
*Lung Stem Cell-Trophic AAV Evolution for Targeted Regenerative Medicine*

8:26 AM – 8:52 AM  
Viviana Gradinaru, PhD. California Institute of Technology, Pasadena, CA  
*Systemic AAVs and Tissue Clearing for Targeting and Mapping Distinct Cell Types*

8:52 AM – 9:18 AM  
Matthew Porteus, MD, PhD. Stanford University School of Medicine, Stanford, CA  
*Gene Editing in Airway Stem Cells for CF*

9:18 AM – 9:45 AM  
Carlos G. Perez-Garcia, PhD. Arcturus Therapeutics, San Diego, CA  
*LUNAR-CF, An Aerosolized mRNA Therapy for CF Lung Disease*

**BREAK**

9:45 AM - 10:15 AM

**EXHIBIT HALL**

*Open 24 hours online*

**PLENARY SESSION**

10:15 AM - 12:00 PM
*Room: Auditorium*

George Stamatoyannopoulos Memorial Lecture & Presentation of the Excellence in Research Awards

*Sponsored by [REGENXBIO]*
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

BREAK
12:00 PM - 1:30 PM

LUNCH SESSION
12:00 PM -1:30 PM
Transitioning from Academia to Industry
  Morgan Maeder, PhD - Third Rock Ventures  
  Laura Sepp-Lorenzino, PhD - Intellia Therapeutics  
  Nick Restifo, MD - Lyell Immunopharma

Sponsored by

TOOLS AND TECHNOLOGIES FORUM
12:00 PM - 1:30 PM
Room: 210

Tools and Technologies Forum III

SPEAKERS:

12:00 PM - 12:15 PM
  Jeffrey Hung, PhD. ViGene Biosciences, Rockville, MD  
  Scalable Upstream and Downstream Production for AAV, Lentivirus and Retrovirus

12:15 PM - 12:30 PM
  Phil Morton. Albumedix Ltd., Nottingham, United Kingdom  
  Increasing Performance of Your Cells from Harvest to Administration – Addressing Logistical Challenges with an Optimized Cryopreservation Solution

12:30 PM - 12:45 PM
  James Brown, PhD. Aldevron, Fargo, ND

12:45 PM - 1:00 PM
  Johnny Truong. Benchling, San Francisco, CA  
  How Benchling Brings Life to Cell and Gene Therapy R&D

1:00 PM - 1:15 PM
  Cedrick Rousseaux. Yposkesi, Corbeil-Essonnes, France  
  High Performing platform for the production of large-scale lentiviral vector in suspension

1:15 PM - 1:30 PM
  Mathieu Porte, Polyplus-transfection, Illkirch, France  
  Next-Generation Transfection Reagent for Large Scale Manufacturing
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

INDUSTRY SPONSORED SYMPOSIUM
12:00 PM - 1:30 PM
Room: Ballroom A

Production of AAV Viral Vectors

Sponsored by

PRESENTER: Dr. Mats Lundgren, Cytiva, formerly GE Healthcare Life Sciences

INDUSTRY SPONSORED SYMPOSIUM
12:00 PM - 1:30 PM
Room: Ballroom B

Development of Gene Transfer Therapies: Rational Design and Application to Duchenne Muscular Dystrophy and the LGMDs

Sponsored by

12:00 PM - 12:30 PM
Rationale for Design of Sarepta’s Gene Therapy Platform and Implications for Theoretical Effect
Louise Rodino-Klapac, PhD, Sarepta Therapeutics

12:30 PM - 1:00 PM
Translational Development of Sarepta’s Gene Therapy Platform
Eric Pozsgai, PhD, Sarepta Therapeutics

1:00 PM - 1:30 PM
SRP-9001 Micro-dystrophin Clinical Updates
Louise Rodino-Klapac, PhD

CAREER DEVELOPMENT AWARDS

Providing $300,000 in 2020 to ASGCT Members Developing Their Careers

Applications open June 1–August 1
asgct.org/CareerAwards
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

INDUSTRY SPONSORED SYMPOSIUM
12:00 PM - 1:30 PM

Room: Ballroom C

Current and Future Trends for Scalable Manufacturing of Viral Vectors for Cell and Gene Therapy

Sponsored by Pall Biotech

12:00 PM - 12:05 PM
Introduction and Session Chair
Dr. Clive Glover, Director of Cell & Gene Therapy, Pall Biotech

12:05 PM - 12:30 PM
Implementation of iCELLis® Technology for the Manufacture of Lentivirus and AAV
Dr. Giuliana Vallanti, Development and Quality Control Director and Qualified Person, MolMed

12:30 PM - 12:55 PM
Single-Use Platform for Scalable Purification of a VSV-G Lentiviral Vector
Dr. Mark Schofield, Senior R&D Manager, Pall Biotech

12:55 PM - 1:20 PM
Speeding to the Clinic. From Contract Process Development to PODs
Jeremy Rautenbach, Global Product Manager for Integrated Solutions, Pall Biotech
Peter Makowenskyj, Director - Sales Engineering, G-CON Manufacturing

1:20 PM - 1:30 PM
Discussion and Summary
Dr. Clive Glover

PLENARY SESSION
1:30 PM - 3:00 PM

Room: Auditorium

Outstanding New Investigator Symposium

Sponsored by Burroughs Wellcome Fund

BREAK
3:00 PM - 3:45 PM
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

TOOLS AND TECHNOLOGIES FORUM
3:30 PM - 4:45 PM
Room: 210

Tools and Technologies Forum IV

SPEAKERS:

3:30 PM - 3:45 PM
Steve Pincus, PhD. FUJIFILM Diosynth Biotechnologies, Morrisville, NC
A look at FUJIFILM Diosynth Development of an Advanced Gene Therapy Platform

3:45 PM – 4:00 PM
Alla Zilberman, PhD. Cygnus Technologies, Southport, NC
Analytics for bioprocess-related impurities in viral vector manufacturing

4:00 PM - 4:15 PM
Renee Tobias. Halo Labs, Burlingame, CA
Automated, Low-Volume Subvisible AAV Aggregate Analysis with the HORIZON System

4:15 PM - 4:30 PM
Kevin Lance, PhD. Unchained Labs, Pleasanton, CA
Unraveling the Uncoating, Capsid Stability, and Aggregation of AAV with High-Throughput Screening on Uncle

4:30 PM – 4:45 PM
Jayanthi Grebin. CPC - Colder Products Company, St. Paul, MN
Single-Use Connectors to Close Systems

ORAL ABSTRACT SESSION 250
3:45 PM - 5:30 PM
Room: Auditorium

CAR T-Cell Therapies II
Chair: Saad Kenderian, MB, ChB

3:45 PM – 4:00 PM
482: CD19-Positive Brain Pericytes as Targets of Immunotherapy-Associated Neurotoxicity
Denis Migliorini, University of Geneva, Geneva, Switzerland
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:00 PM – 4:15 PM
483: Cellular Delivery of Oncolytic Adenoviruses Utilizing Mesenchymal Stromal Cells (MSCs) in Combination with CAR-T Cell Therapy
Katie McKenna, Baylor College of Medicine, Houston, TX, United States

4:15 PM – 4:30 PM
484: Enhancing Tumor Directed T Cells with a Costimulatory CAR
Mara Cardenas, Baylor College of Medicine, Houston, TX, United States

4:30 PM – 4:45 PM
485: Multiplexed Cytidine Deamination Enables Generation of Fratricide-Resistant ‘Universal T v T’ Chimeric Antigen Receptor Cell Therapy
Christos Georgiadis, UCL, GOS Institute of Child Health, London, United Kingdom

4:45 PM – 5:00 PM
486: A Phase 1 Clinical Trial Using Armored GPC3-Car T Cells for Children with Relapsed/Refractory Liver Tumors
David Steffin, Baylor College of Medicine, Houston, TX, United States

5:00 PM – 5:15 PM
487: Automatic Neutralization of IL6 Storm and Blockade of IL1 Signaling During CART Therapy to Reduce Cytokine Toxicity and Minimize Neurotoxicity
Biliang Hu, Celledit, Worcester, MA, United States

5:15 PM – 5:30 PM
488: Iberdomide Increases the Potency of the Anti-BCMA CART Cell Product Orvacabtagene Autoleucel (orva-cel)
Neha Soni, Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, United States
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 251
3:45 PM - 5:15 PM
Room: Ballroom A

Preclinical Large Animal Studies for Neurologic Diseases
Chair: Heather Gray-Edwards, DVM, PhD

3:45 PM – 4:00 PM
489: Combination Hematopoietic Stem Cell Transplantation and Intravenous AAV Gene Therapy Corrects Neurologic Phenotype in Canine Krabbe Disease
Allison Bradbury, University of Pennsylvania, Philadelphia, PA, United States

4:00 PM – 4:15 PM
490: Method to Prevent AAV-Induced Dorsal Root Ganglia Toxicity & Axonopathy in Nonhuman Primates, and Insights into the Pathophysiology
Juliette Hordeaux, University of Pennsylvania, Philadelphia, PA, United States

4:15 PM – 4:30 PM
491: One-Time Intrathecal Administration of AAV5-miATXN3 in Non-Human Primates
Melvin Evers, uniQure, Amsterdam, Netherlands

4:30 PM – 4:45 PM
495: Effect of Administration Route and AAV Serotype for Treatment of Feline GM1 Gangliosidosis
Amanda Gross, Auburn University, Auburn, AL, United States

4:45 PM – 5:00 PM
493: Intravenous AAV Gene Therapy Improves Lifespan and Clinical Metrics in Feline Sandhoff Disease
Anne Maguire, Auburn University, Auburn, AL, United States

5:00 PM – 5:15 PM
494: Translating Gene Therapy for Spinocerebellar Ataxia Type 1: Unforeseen Consequences in Higher Mammals
Megan Keiser, The Children’s Hospital of Philadelphia, Philadelphia, PA, United States
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 252

3:45 PM - 5:30 PM
Room: Ballroom B

Musculo-skeletal Diseases I

Chair: Rita Perlingeiro, PhD

3:45 PM – 4:00 PM

496: Progress Toward Translating AAV.CRISPR-Cas13 Therapy for FSHD
Afrooz Rashnonejad, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States

4:00 PM – 4:15 PM

497: CRISPR-Mediated Gene Correction in a Severe Humanized Mouse Model of Duchenne Muscular Dystrophy
Karen Bulaklak, Duke University, Durham, NC, United States

4:15 PM – 4:30 PM

498: A New Laminin a2-Based Gene Therapy for Congenital Muscular Dystrophy 1A
Davin Packer, Nationwide Children’s Hospital, Columbus, OH, United States

4:30 PM – 4:45PM

499: AAV.CAPN3 Systemic Gene Therapy Improves the Phenotype in the Calpain3-Null Mouse Model for LGMD2A
Zarife Sahenk, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States

4:45 PM – 5:00 PM

500: SGT-001 Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
J Gonzalez, Solid Biosciences, Cambridge, MA, United States

5:00 PM – 5:15 PM

501: AAV PGC1-Alpha Gene Therapy Improves the Cardiac Function in a Mouse Model of Duchenne Muscular Dystrophy
Nalinda Wasala, University of Missouri, Columbia, MO, United States

5:15 PM – 5:30 PM

502: Assessment of Immunomodulatory Regimens that Allow Systemic Redosing of an AAV-CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy
Courtney Young, MyoGene Bio, Los Angeles, CA, United States
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 253
4:00 PM - 5:30 PM
Room: Ballroom C

AAV Vectors - Clinical Studies II
Chair: Carsten Bonnemann, MD

4:00 PM – 4:15 PM
504: ADVM-022 Intravitreal Gene Therapy for Neovascular AMD - Results from the Phase 1 OPTIC Study
Szilard Kiss, Weill Cornell University, New York, NY, United States

4:15 PM – 4:30 PM
505: AAV8 Gene Therapy as a Potential Treatment in Adults with Late-Onset OTC Deficiency: Results from a Phase 1/2 Clinical Trial
Wen-Hann Tan, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States

4:30 PM – 4:45 PM
506: Optogenetics in the Clinic: PIONEER, a Phase 1/2a Gene Therapy Program for Non-Syndromic Retinitis Pigmentosa
Joseph Martel, University of Pittsburgh, Pittsburgh, PA, United States

4:45 PM – 5:00 PM
507: Improving the Quantification of rSIV.F/HN Vectors for Cystic Fibrosis Gene Therapy Using Droplet Digital PCR
Toby Gamlen, University of Oxford, Oxford, United Kingdom

5:00 PM – 5:15 PM
508: Engineering Viral Protein Ratios to Impact AAV Potency
Andrade Hendricks, Voyager Therapeutics, Cambridge, MA, United States

5:15 PM – 5:30 PM
509: Phase 1 Study of Gene Therapy in Late-Onset Pompe Disease: Analyses of Safety and Secondary Endpoints
Dwight Koeberl, Duke University School of Medicine, Durham, NC, United States
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 254
3:45 PM - 5:30 PM
Room: 302

Controlling AAV Gene Expression: Shifting Paradigms

Chair: Frederico Mingozzi, PhD

3:45 PM – 4:00 PM

510: A Reversible RNA On-Switch That Controls Expression of Aav-Delivered Transgenes In Vivo
Guocai Zhong, Shenzhen Bay Laboratory (SZBL), Shenzhen, China

4:00 PM – 4:15 PM

511: AAV Capsid-Promoter Interactions Determine CNS Cell Selective Gene Expression In Vivo
Sara Powell, Asklepios Biopharmaceutical, Inc., Durham, NC, United States

4:15 PM – 4:30 PM

512: The Genomic Architecture of a Genotoxic Recombinant AAV Integration in a Murine Hepatocellular Carcinoma
Randy Chandler, National Institutes of Health, Bethesda, MD, United States

4:30 PM – 4:45 PM

513: PESCA: A Scalable Platform for Regulatory Element Engineering of Viral Gene Therapy Vectors
Sinisa Hrvatin, Harvard Medical School, Boston, MA, United States

4:45 PM – 5:00 PM

514: Tailored AAV-Based Transgene Expression in the Inner Ear with Cell Type-Specific Promoters
Adam Palermo, Decibel Therapeutics, Boston, MA, United States

5:00 PM – 5:15 PM

515: Structure-Guided Rational Design of Adeno-Associated Viral Capsids with Expanded Sizes
Xiaozhe Ding, California Institute of Technology, Pasadena, CA, United States

5:15 PM – 5:30 PM

516: Engineering CpG-Free ITR for AAV Gene Therapy
Xiufang Pan, University of Missouri, Columbia, MO, United States
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 255

3:45 PM - 5:30 PM
Room: 304 & 306

Evaluating Genome Editing Activity and Precision

Chair: Shengdar Tsai, PhD

3:45 PM – 4:00 PM
517: Large-Scale CRISPR-Cas Genome-Wide Activity Profiling in Human Primary T-Cells Reveals Genetic and Epigenetic Determinants of Genome-Wide Nuclease Activity
Cicera Lazzarotto, St Jude Children’s Research Hospital, Memphis, TN, United States

4:00 PM – 4:15 PM
518: Evaluation of the Long-term Effects of AAV-Meganuclease Genome Editing of PCSK9 in Macaque Liver
Lili Wang, University of Pennsylvania, Philadelphia, PA, United States

4:15 PM – 4:30 PM
519: Unintended Consequences of CRISPR/Cas9-Mediated Genome Editing for Treating Sickle Cell Disease
So Hyun Park, Rice University, Houston, TX, United States

4:30 PM – 4:45 PM
520: Muscle-Specific Editing in a Therapeutic Target of Duchenne Muscular Dystrophy Using Cas9 and miRNA-Repressible Anti-CRISPR Proteins
Jooyoung Lee, University of Massachusetts Medical School, Worcester, MA, United States

4:45 PM – 5:00 PM
521: Base Editing of Splice Sites Mediates High Efficiency Multiplex Disruption and Modulation of Genes in Primary Human T Cells and NK Cells
Mitchell Kluesner, University of Minnesota, Minneapolis, MN, United States

5:00 PM – 5:15 PM
522: High-Throughput Screen to Optimize gRNA Pairs for CRISPR-Cas9-Mediated Exon Deletion
Veronica Gough, Duke University, Durham, NC, United States
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

5:15 PM – 5:30 PM
   523: A Dual AAV Vector System to Visualize Prime Editing in Mammalian Cells
   Jonathan Lang, Children's Hospital of Philadelphia, Philadelphia, PA, United States

ORAL ABSTRACT SESSION 256

3:45 PM - 5:30 PM
Room: 309
Clinical Gene Therapies for Inborn Errors of Metabolism
Chair: Charles Venditti, MD, PhD

3:45 PM – 4:00 PM
   Kevin Flanigan, Nationwide Children's Hospital, Columbus, OH, United States

4:00 PM – 4:15 PM
   525: Preliminary Outcomes of Haematopoietic Stem Cell Gene Therapy in a Patient with Mucopolysaccharidosis IIIA
   Brian Bigger, University of Manchester, Manchester, United Kingdom

4:15 PM – 4:30 PM
   526: Transpher B, an Open-Label, Multicenter, Single-Dose, Dose-Escalation, Phase 1/2 Clinical Trial of Gene Transfer of ABO-101 in Sanfilippo Syndrome Type B (Mucopolysaccharidosis IIIB)
   Maria de Castro, Hospital Clinico Universitario de Santiago, Santiago De Compostela, Spain

4:30 PM – 4:45 PM
   527: Hematopoietic Stem Cell Gene Therapy for Cystinosis: Initial Results from a Phase I/II Clinical Trial
   Stephanie Cherqui, University of California, San Diego, La Jolla, CA, United States
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:45 PM – 5:00 PM
   **528: Pathophysiological Mechanisms of Bone Defects and Impact of Ex Vivo Hematopoietic Stem Cell Gene Therapy in Mucopolysaccharidosis Type I Hurler**
   Ludovica Santi, San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy

5:00 PM – 5:15 PM
   **529: Gb3 Substrate in Endothelial Cells of Renal Peritubular Capillaries Was Reduced in a Previously Untreated Classic Fabry Male Patient Treated with AVR-RD-01 Investigational Lentiviral Gene Therapy**
   Birgitte Volck, AVROBIO, Inc., Cambridge, MA, United States

5:15 PM – 5:30 PM
   **530: Late Phases of Hematopoietic Reconstitution in Metachromatic Leukodystrophy Gene Therapy Patients Are Characterized by Lineage Commitment of Individual HSC Clones**
   Andrea Calabria, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy

---

**ORAL ABSTRACT SESSION 257**

3:45 PM - 5:15 PM
*Room: 310*

**Applications of Physical, Chemical and Exosomal Delivery**

*Chair:* David Dean, PhD

3:45 PM – 4:00 PM
   **531: Induction of Long-Term Tolerance to a Specific Antigen Using Anti-CD3 Lipid Nanoparticles Following Gene Therapy**
   Chun-Yu Chen, Seattle Children's Hospital Research Institute, Seattle, WA, United States

4:00 PM – 4:15 PM
   **532: Fusion Gene-Based Therapy for Prevention and Treatment of Obesity and Obesity-Associated Metabolic Diseases**
   Yueze Yang, University of Georgia, Athens, GA, United States

4:15 PM – 4:30 PM
   **533: A Single Dose of Fast Half-Life CD117 Antibody Drug Conjugate Enables Hematopoietic Stem Cell Based Gene Therapy in Nonhuman Primates**
   Naoya Uchida, NIH, Bethesda, MD, United States
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:30 PM – 4:45 PM
534: Developing Nonviral Gene Therapies for Inherited Blinding Disorders Using CRISPR/Cas9 Genomic Editing and Human Pluripotent Stem Cells
Amr Abdeen, University of Wisconsin-Madison, Madison, WI, United States

4:45 PM – 5:00 PM
535: Building a Versatile and Clinically Translatable Platform for DNA-Based Antibody Therapeutics
Kevin Hollevoet, KU Leuven - University of Leuven, Leuven, Belgium

5:00 PM – 5:15 PM
537: Optimization of Lipid Nanoparticle Formulation Leads to Functional mRNA Delivery in Rat Lungs and New Opportunities for Gene Editing and Delivery
Kristina Friis, AstraZeneca, Gothenburg, Sweden

ORAL ABSTRACT SESSION 258
3:45 PM - 5:00 PM
Room: 311

Vector and Cell Engineering, Production or Manufacturing III

Chairs: Isabelle Riviere, PhD

3:45 PM – 4:00 PM
538: Generation of Immune Resistant, Stem Cell Targeting Lentivirus for Cystic Fibrosis Airway Gene Therapy
Juliette Delhove, University of Adelaide, Adelaide, Australia

4:00 PM – 4:15 PM
539: HeLa 3.0: CRISPR Knockout of Genes Modulating Titer in Established rAAV-Producing Cell Lines
Nicholas Richards, Ultragenyx Gene Therapy, Cambridge, MA, United States

4:15 PM – 4:30 PM
540: A Complete “Self-Repressing” Adenovirus System Enables Efficient Manufacture of Adeno-Associated Viral Vectors without Contamination by Adenovirus or Small Drugs
Weiheng Su, University of Oxford, Oxford, United Kingdom

4:30 PM – 4:45 PM
541: Massively Parallel Deep Diversification of AAV Capsid Proteins by Machine Learning
Sam Sinai, Dyno Therapeutics, Cambridge, MA, United States
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:45 PM – 5:00 PM
543: Characterization of Phenotypic and Genotypic Stability of rAAV Producing HeLa Cell Lines
Alix Eastham, Ultragenyx Gene Therapy, Cambridge, MA, United States

ORAL ABSTRACT SESSION 259

3:45 PM - 5:15 PM
Room: 312

HSPC Gene Therapies for Hemoglobin Disorders
Chair: Megan Hoban, PhD

3:45 PM – 4:00 PM
545: Durable Robust Fetal Globin Induction in Rhesus Monkeys Following BCL11A Erythroid Enhancer Edited Autologous Hematopoietic Stem Cell Transplant
Selami Demirci, NIH, Bethesda, MD, United States

4:00 PM – 4:15 PM
546: In Vivo HSC Gene Therapy for Hemoglobinopathies: A Proof of Concept Evaluation in Rhesus Macaques
Chang Li, University of Washington, Seattle, WA, United States

4:15 PM – 4:30 PM
547: Base Editing of Gamma Globin Gene Promoters Generates Durable Expression of Fetal Hemoglobin for the Treatment of Sickle Cell Disease
Adrian Rybak, Beam Therapeutics, Cambridge, MA, United States

4:30 PM – 4:45 PM
548: Gene Correction Using CRISPR/Cas9: IND-Enabling Studies to Support a Clinical Trial of a CRISPR/Homology-Directed Repair Treatment for Sickle Cell Disease
Mark DeWitt, University of California, Los Angeles, Los Angeles, CA, United States

4:45 PM – 5:00 PM
549: Editing the LRF Repressor Binding Site in the γ-Globin Promoters Induces Therapeutically Relevant Fetal Hemoglobin Levels for the Treatment of β-Hemoglobinopathies
Giacomo Frati, Imagine Institute, Paris, France
PROGRAM SCHEDULE
WEDNESDAY, MAY 13

All times are listed in Eastern Daylight Time (EDT UTC -4).

5:00 PM – 5:15 PM
551: Editing Hematopoietic Stem Cells at the FOXP3 Locus: A Gene Editing Approach to Treat IPEX Patients
Swati Singh, Seattle Children's Research Institute, Seattle, WA, United States

EXHIBIT HALL
Open 24 hours online

POSTER SESSION II
Open 24 hours on May 13

5:30 PM - 6:30 PM
Scheduled presenters requested to be available for live Q&A
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

**SCIENTIFIC SYMPOSIUM 300**
Organized by the American Society for Transplantation and Cellular Therapy
8:00 AM - 9:45 AM
Room: Ballroom A

Engineering Immunity: CARS for Non-B Cell Malignancies - Organized by the American Society for Transplantation and Cellular Therapy

*SPEAKERS:*

8:00AM – 8:26 AM
Yvonne Y. Chen, PhD. University of California Los Angeles, Los Angeles, CA
*Engineering Next-Generation T Cells for Cancer Immunotherapy*

8:26 AM – 8:52 AM
Aude Chapuis, PhD. Fred Hutchinson Cancer Research Center, Seattle, Washington

8:52 AM – 9:18 AM
Waseem Qasim, PhD. UC London, London UK
*Extending Genome Edited CAR T Cells to Non-B cell Haematological Malignancies*

9:18 AM – 9:45 AM
John DiPersio, MD, PhD. Washington University, St. Louis, MO
*CART for T Cell Malignancies*

**SCIENTIFIC SYMPOSIUM 301**
8:00 AM - 9:20 AM
Room: 304 & 306

Advancing Therapeutic Exosomes for the Treatment of Disease - Organized by the Nanoagents & Synthetic Formulations Committee

*CO-CHAIRS:* Angela Pannier, PhD and Rajagopal Ramesh, PhD

*SPEAKERS*

8:00 AM – 8:26 AM
Xandra Breakefield, PhD. Massachusetts General Hospital / Harvard Medical School, Charlestown, MA
*Equipping Extracellular Vesicles with Functional Reporters*

8:26 AM – 8:52 AM
Konstantin Konstantinov, PhD. Codiak BioSciences, Cambridge, MA
*Towards Industrialization of the GMP Manufacture of Exosome-Based Biotherapeutics*
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

8:52 AM – 9:18 AM
   Susanne Gabrielson, PhD. Karolinska Institute, Stockholm, Sweden
   Exosomes for Cancer Therapy

SCIENTIFIC SYMPOSIUM 302
8:26 AM - 9:45 AM
Room: Ballroom C

Clearing the Path to an IND: How We Succeeded - Organized by the Translational Science Committee

CO-CHAIRS: Nicole Paulk, PhD and Johannes van Der Loo, PhD

SPEAKERS
8:26 AM – 8:52 AM
   Miguel Sena-Esteves, PhD. University of Massachusetts Medical School, Worcester, MA
   A DIY Approach to Bringing Academic AAV Gene Therapy Programs to First-in-Human Clinical Trials

8:52 AM – 9:18 AM
   Francesca Vitelli, PhD. Lonza, Inc., Houston, TX
   CDMO’s Perspectives on Process Development for Viral Vectors

9:18 AM – 9:45 AM
   Barry Byrne, MD, PhD. University of Florida College of Medicine, Gainesville, FL
   IND Submission: Differences in Academia vs. Industry

SCIENTIFIC SYMPOSIUM 303
8:00 AM - 9:45 AM
Room: Auditorium

Latest Advances in Cancer Gene and Cellular Therapies - Organized by the Cancer Gene & Cell Therapy Committee

CHAIR: Paola Grandi, PhD

SPEAKERS
8:00 AM – 8:26 AM
   Edward Stadtmauer, MD. University of Pennsylvania, Philadelphia, PA
   CRISPR-engineered T Cells in Patients with Refractory Cancer
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

8:26 AM – 8:52 AM
  Armand Keating, MD. University of Toronto, Toronto, ON, Canada
  NK Cell Therapy with Off the Shelf” Natural Killer Cells

8:52 AM – 9:18 AM
  John Bell, PhD. Ottawa Hospital Research Institute, Ottawa, ON, Canada
  Cancer Vaccines and Neo Antigens

9:18 AM 9:45 AM
  Kah-Whye Peng, PhD. Mayo Clinic, Rochester, MN
  Solid Tumor Oncolytic Viruses

SCIENTIFIC SYMPOSIUM 304

8:00 AM - 9:45 AM
Room: Ballroom B

Vector Development, Clinical Implementation, and Corporate Connections - Organized by the Viral Gene Transfer Vectors Committee

CHAIR: Daniel M. Lipinski, DPhil

SPEAKERS

8:00 AM – 8:26 AM
  Ben E. Deverman, PhD. Broad Institute of MIT and Harvard, Cambridge, MA
  Engineering AAV Capsids for the Delivery of Gene Therapies to the CNS

8:26 AM – 8:52 AM
  Joseph E. Rabinowitz, PhD. Pfizer, Inc., Cambridge, MA
  Industry Perspectives of AAV Vectors

ASGCT PATIENT EDUCATION PROGRAM

Scientific, Reliable Information for the Public

- Gene & Cell Therapy Basics
- Advancements for specific diseases
- Clinical trials education and finder

New website coming July 2020

asgct.org/education
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

8:52 AM – 9:18 AM
Maria-Grazia Roncarolo, MD. Stanford University School of Medicine, Stanford, CA
Academic Perspectives of Lentiviral Vectors

9:18 AM – 9:45 AM
Philip D. Gregory, DPhil. bluebird bio, Cambridge, MA
Industry Perspectives of Lentiviral Vectors

NIH SESSION 310

8:00 AM - 9:45 AM
Room: 311
IND-Enabling NIH Resources to Advance Clinical and Translational Gene Therapy

CHAIR: Terence Flotte, MD

SPEAKERS

8:00 AM – 8:10 AM
Cheryl McDonald, MD. National Heart Lung and Blood Institute, NIH, Bethesda, MD
Introduction and Overview of NIH Resource Programs

8:10 AM – 8:40 AM
David A. Wilcox, PhD. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; Children’s Research Institute, Children’s Hospital of Wisconsin, Milwaukee, WI
Platelet-Targeted Gene Therapy for Hemophilia A

8:40 AM – 9:10 AM
Barry J. Byrne, MD, PhD. University of Florida College of Medicine, Gainesville, FL
Pathway for Investigator Initiated Studies to IND and Beyond

9:10 AM – 9:40 AM
Dwight Koeberl, MD, PhD. Duke University School of Medicine, Durham, NC
Recombinant AAV Gene Therapy for Pompe Disease

9:40 AM – 9:45 AM
Terence Flotte, MD. University of Massachusetts Medical School, Worcester, MA
Summary
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

EXHIBIT HALL

Open 24 hours online

BREAK

9:45 AM - 10:15 AM

PLENARY SESSION

10:15 AM - 12:00 PM
Room: Auditorium

Outstanding Achievement Award Lecture & Presentation & Sonia Skarlatos
Public Service Award

Sponsored by AUDENTES

BREAK

12:00 PM - 1:30 PM
Lunch Break

LUNCH SESSION

12:00 PM - 1:30 PM
Navigating Career Paths for Trainees

Emmanuel Adu-Gyamfi, PhD - FDA
Kelly Moynihan, PhD - Third Rock Ventures
Xiuyan Wang, PhD - Memorial Sloan Kettering Cancer Center
Terry Flotte, MD - University of Massachusetts Medical School

Sponsored by rocket pharma

LUNCH SESSION

12:00 PM - 1:30 PM
Characterizing and Minimizing Genome Editing Off-Target Effects

CRISPR

Ayal Hendel, PhD - Bar Ilan University
TJ Cradick, PhD - CRISPR Therapeutics
Benjamin P. Kleinstiver, PhD - Massachusetts General Hospital and Harvard Medical School
Luca Pinello, PhD - Harvard Medical School

Sponsored by rocket pharma
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

TOOLS AND TECHNOLOGIES FORUM
12:00 PM - 1:30 PM
Room: 210

Tools and Technologies Forum V

SPEAKERS:

12:00 PM - 12:15 PM
Amanda Fentiman. STEMCELL Technologies, Vancouver, Canada
Optimized, Serum-Free, In Vitro Culture Conditions for CRISPR-
Mediated Gene Editing of CD34+ Cells

12:15 PM - 12:30 PM
Emilie Viey, PhD. Ovizio Imaging Systems, Brussels, Belgium
Ivie Aifuwa, PhD. Bristol-Myers Squibb, Seattle, WA
Automated, Closed Loop, In-Line and Label-Free Monitoring of CAR-T
Cells in a Production Process

12:30 PM - 12:45 PM
Seth Levy. Thermo Fisher Scientific, Alachua, FL
Documentation of Clonality as Part of the CMC Process in Viral Vector
Production

12:45 PM - 1:00 PM
Rachel Legmann, PhD. Pall Biotech, Westborough, MA
AAV9 Viral Vector Large Scale Bioreactor Production: From Bench Top
to Manufacturing

1:00 PM - 1:15 PM
Rob Durham, PhD. Gyros Protein Technologies, Uppsala, Sweden
Innovative Immunoassays: Boosting Workflow Efficiency and Data
Quality in Bioprocessing and Immunogenicity

1:15 PM - 1:30 PM
Jian Chen, PhD. Celetrix Electroporation, Manassas, VA
Revisiting and Revamping Electroporation Concepts and Practices
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

**INDUSTRY SPONSORED SYMPOSIUM**
12:00 PM - 1:30 PM
Room: Ballroom A

*Doing More with Less: Perspectives on Automating Manufacturing of Cell and Gene Therapy Products*

*Sponsored by* TERUMO BCT

*PRESENTERS:* Gerhard Bauer, Professor, Director, UC Davis GMP Facility; Johnathon D. Anderson, PhD, Assistant Professor, UC Davis Institute for Regenerative Cures

**INDUSTRY SPONSORED SYMPOSIUM**
12:00 PM - 1:30 PM
Room: Ballroom B

*Viral Safety: The Alpha and the Omega - Key considerations for developing and manufacturing safe products in a safe working environment when working with Advanced Viral Vectors*

*Sponsored by* FUJIFILM Diosynth Biotechnologies

*Moderator:* Steven Pincus, Head of Science and Innovation, FUJIFILM Diosynth Biotechnologies

*Panelists:* Akunna Iheanacho, PhD, Director of Research and Development, Texcell North America; Michael Mercaldi, Director of Purification Process Development, Homology Medicines; Daniel Strauss, Principal Scientist, Asahi Kasei Bioprocess America

**INDUSTRY SPONSORED SYMPOSIUM**
12:00 PM - 1:30 PM
Room: Ballroom C

*From Bench to Bedside: Uncovering the Potential of Gene Therapy*

*Sponsored by* PTC Therapeutics measured by momentis

12:00 PM - 12:05 PM
*Welcome and Introduction*
Mark Pykett, Chair
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

12:05 PM - 12:40 PM
  Overview of PTC Therapeutics’ Gene Therapy Programs
  Mark Pykett, Chief Scientific Officer, PTC Therapeutics

12:40 PM - 1:10 PM
  Gene Therapy for Neurological Disease: Clinical Outcomes in AADC Deficiency
  Timothy Feyma, Co-Director, Complex Movement Disorder Clinic, Gillette Children's Specialty Healthcare

1:10 PM - 1:25 PM
  Interactive Q&A
  Moderated by Chair

1:25-1:30
  Adjourn

INDUSTRY SPONSORED SYMPOSIUM

12:00 PM - 1:30 PM
Room: 304/306

Sponsored by GenScript

12:00 PM - 12:30 PM
  Characterization of AAV Provector Targeted Delivery through Scar Optimization
  Susan Butler, Rice University

12:30 PM - 1:00 PM
  AAV-Mediated CRISPR/Cas9 Delivery
  Bence Gyorgy, Institute of Molecular and Clinical Ophthalmology

1:00 PM - 1:30 PM
  Precise, Non-Viral, CAR-T Engineering with CRISPR sgRNA and ssDNA
  Dr. Lumeng Ye, GenScript USA

PRESIDENTIAL SYMPOSIUM

1:30 PM - 3:15 PM
Room: Auditorium

Presidential Symposium & Presentation of the Top Abstracts

Sponsored by Oxford Biomedical
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

BREAK
3:15 PM - 3:45 PM

ORAL ABSTRACT SESSION 350
3:45 PM - 5:30 PM
Room: Auditorium

Viral Vector Development: RNA Virus Vectors
Chair: Carol Miao, PhD

3:45 PM – 4:00 PM
909: Human CD3 as a Target Receptor for Simultaneous Activation and Cell-Specific Transduction by Lentiviral Vectors
Annika Frank, Paul-Ehrlich-Institut, Langen, Germany

4:00 PM – 4:15 PM
910: Lentiviral Gene Therapy for p47phox Deficient Chronic Granulomatous Disease: One Step Closer to the Clinic
Andrea Schejtman, UCL Great Ormond Street Institute of Child Health, London, United Kingdom

4:15 PM – 4:30 PM
911: Investigating the Stability of Lentiviral Vector Targeted Liver Cells During Post-Natal Growth for In Vivo Gene Therapy Applications
Alessio Cantore, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy

4:30 PM – 4:45 PM
912: Development of Cas9 Protein Delivery Non-Integrating Lentiviral Vectors for Gene Correction in Sickle Cell Disease
Naoya Uchida, NIH, Bethesda, MD, United States

4:45 PM – 5:00 PM
913: Cell Type Specific Co-Factors are Required for IFITM3 Antiviral Activity in Human Hematopoietic Stem and Progenitor Cells
Giulia Unali, San Raffaele Scientific Institute, TIGET, Milan, Italy

5:00 PM – 5:15 PM
914: Safety Evaluation of Intracerebral Injection of Lentiviral ABCD1 for X-ALD Gene Therapy
Yunyun Liu, UESTC, Chengdu, China

5:15 PM – 5:30 PM
915: Profiling of Encapsidated Producer Cell RNA in Lentiviral Vectors
Matteo Franco, GeneWerk GmbH, Heidelberg, Germany
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 351
3:45 PM - 5:30 PM
Room: Ballroom A

AAV Vector Development: Towards Translation

Chair: Luk Vandenberghe, PhD

3:45 PM – 4:00 PM
916: A Novel Approach for Rapid and Transient Depletion of Pre-Existing Neutralizing Antibodies Against AAV Vectors
Zachary Elmore, Duke University, Durham, NC, United States

4:00 PM – 4:15 PM
917: In Situ Detection of Adeno-Associated Virus Genomes with DNA SABER-FISH
Sean Wang, Harvard Medical School, Boston, MA, United States

4:15 PM – 4:30 PM
918: Long-Read Characterization of Adeno-Associated Virus Packaged DNA by Direct Nanopore Sequencing Reveals Genome Fusions and Recombination between Genomes and Producer Plasmids
Marco Radukic, Bielefeld University, Bielefeld, Germany

4:30 PM – 4:45 PM
919: Non-Stringent Requirement in AAV D-Element Leads to Erroneous Encapsulation of Non-Vector Sequences
Junping Zhang, Temple University, Philadelphia, PA, United States

4:45 PM – 5:00 PM
920: In-Depth Parallel Profiling of Tissue and Cell-Type Tropism of AAV Variants by Single-Cell RNA Sequencing
Michael Altermatt, California Institute of Technology, Pasadena, CA, United States

5:00 PM – 5:15 PM
921: Novel AAV Vector for Delivery of Transgenes to the Photoreceptors and RPE via Intravitreal Injection Enables Rescue of Multiple Models of Retinal Disease
Rajendra Kumar-Singh, Tufts University, Boston, MA, United States
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

5:15 PM – 5:30 PM

922: Brain Transduction Profiles of Novel Human-Derived Clade B and C Variants in Mice and Non-Human Primates
Phillip Tai, University of Massachusetts Medical School, Worcester, MA, United States

ORAL ABSTRACT SESSION 352

4:00 PM - 5:15 PM
Room: Ballroom B
Musculo-skeletal Diseases II
Chair: Scott Q. Harper, PhD

4:00 PM – 4:15 PM

924: A Universal Gene Correction Approach for FKRP Mutant Patient-Specific iPS Cells: Potential for Autologous Cell Therapy
Neha Dhoke, University Of Minnesota, Minneapolis, MN, United States

4:15 PM – 4:30 PM

925: Effective Pseudo-Exon Skipping of a COL6A1 Intronic Mutation in Cultured Muscle Interstitial Fibroblasts from a Novel Humanized Mouse Model
Véronique Bolduc, NINDS/NIH, Bethesda, MD, United States

4:30 PM – 4:45 PM

926: Hematopoietic Stem Cell Gene Therapy Corrects Neuromuscular Manifestations in Preclinical Study of Pompe Mice
Niek van Til, AVROBIO Inc, Cambridge, MA, United States

4:45 PM – 5:00 PM

929: Combined CNS and Systemic Directed Gene Therapy in a Mouse Model of Pompe Disease with Advanced Disease at Treatment
Juliette Hordeaux, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States

5:00 PM – 5:15 PM

Glen Grandea, Immusoft, Seattle, WA, United States
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 353
3:45 PM - 5:30 PM
Room: Ballroom C

New Techniques in Gene Therapy for Neurological Disorders

Chair: Dan Wang, PhD

3:45 PM – 4:00 PM
930: Monosynaptic Tracing Induced by a Novel AAV Show Appropriate Circuit Integration of Human Dopamine Neurons (in a Rat Model of Parkinson’s Disease)
Malin Akerblom, Lund University, Lund, Sweden

4:00 PM – 4:15 PM
931: Selective Intein Degradation for Safe AAV Mediated Large Gene Delivery
Patrizia Tornabene, TIGEM, Pozzuoli, Italy

4:15 PM – 4:30 PM
932: Allele-Specific AAV-Based Silencing of Mutant Ataxin-3 Alleviates Neuropathology and Motor Deficits in Spinocerebellar Ataxia Type 3
Rui Nobre, Center for Neuroscience and Cell Biology, Coimbra, Portugal

4:30 PM – 4:45 PM
933: CRISPR/Cas9-Mediated Excision of ALS-Causing Hexanucleotide Repeat Expansion in C9ORF72
Katharina Meijboom, UMASS Medical School, Worcester, MA, United States

4:45 PM – 5:00 PM
934: Gene Editing of the Ube3a Antisense-Transcript in an Angelman Syndrome Mouse Model
Ralf Schmid, University of Pennsylvania, Philadelphia, PA, United States

5:00 PM – 5:15 PM
935: Treatment of a Mouse Model of ALS by CRISPR Base Editing
Colin Lim, University of Illinois at Urbana-Champaign, Urbana, IL, United States

5:15 PM – 5:30 PM
936: Direct Vagus Nerve Injection of AAV9 as a Treatment Approach for Autonomic Dysfunction in Giant Axonal Neuropathy
Rachel Bailey, University of Texas Southwestern Medical Center, Dallas, TX, United States
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 354
3:45 PM - 5:30 PM
Room: 302

Gene Therapies for Hemophilia and Immune Disorders
Chair: Lindsey George, MD

3:45 PM – 4:00 PM
937: Modeling, Optimization and Comparative Efficacy of HSC- and T-cell Based Editing Strategies for Treating Hyper IgM Syndrome
Valentina Vavassori, SR-Tiget, Milan, Italy

4:00 PM – 4:15 PM
938: Production of Genetically Engineered T and NK Cells is Maintained in Humans by Common Long Term Lymphoid Progenitors 15 Years after Loss of Transplanted Hematopoietic Stem Cells
Natalia Izotova, University College of London, London, United Kingdom

4:15 PM – 4:30 PM
939: CRISPR/Cas9 Targeted MAGT1 Gene Addition into XMEN Patient Hematopoietic Stem Cells and Peripheral Blood T Cells
Julie Brault, NIH, Bethesda, MD, United States

4:30 PM – 4:45 PM
940: AAV Integration Analysis after Long Term Follow Up in Hemophilia a Dogs Reveals the Genetic Consequences of AAV-Mediated Gene Correction
John Everett, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, United States

4:45 PM – 5:00 PM
941: First-In-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A: Safety and FVIII Activity Results
John Sheehan, University of Wisconsin–Madison, Madison, WI, United States

5:00 PM – 5:15 PM
942: Engineered Antigen-Expressing CAAR-T Cells Targeting Autoreactive B Cells to ADAMTS13 in the Context of Thrombotic Thrombocytopenic Purpura
Kalpana Parvathaneni, Perelman School of Medicine, Philadelphia, PA, United States
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

5:15 PM – 5:30 PM

943: AAV Mediated Expression of Activated Factor V (FVa) for Hemophilia
Junjiang Sun, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

ORAL ABSTRACT SESSION 355

3:45 PM - 5:30 PM
Room: 304 & 306

AAV Vectors Preclinical and Proof-of-Concept Studies in Systemic Diseases
Chair: Miguel Sena-Esteves, PhD

3:45 PM – 4:00 PM

944: PR001 Gene Therapy Increased GCase Activity and Ameliorated GBA1-Associated Disease Phenotypes
Patty Sheehan, Prevail Therapeutics, New York, NY, United States

4:00 PM – 4:15 PM

945: Developing AAV-Mediated Clinically Translatable Gene Therapy for Maple Syrup Urine Disease (MSUD) Caused by BCKDHA Mutations in a Bovine Model
Jiaming Wang, University of Massachusetts Medical School, Worcester, MA, United States

4:15 PM – 4:30 PM

946: A Novel NAGA Variant Designed to be Non-Immunogenic in Humans and Provide Broad Cross-Correction in Fabry Disease
Jolanda Liefhebber, uniQure Biopharma B.V., Amsterdam, Netherlands

4:30 PM – 4:45 PM

947: AAV Gene Immunotherapy Reverses MS-Like Disease Against Multiple Epitopes and in Genetically Diverse Mice
Brad Hoffman, University of Florida College of Medicine, Gainesville, FL, United States

4:45 PM – 5:00 PM

948: Preclinical Gene Replacement Therapy with a New scAAV9/SUMF1 Viral Vector for the Treatment of Multiple Sulfatase Deficiency
Maximiliano Presa, The Jackson Laboratory, Bar Harbor, ME, United States
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

5:00 PM – 5:15 PM
   949: Efficacy and Safety of CSF-Delivered AVXS-401 in Mice and Non-Human Primates for the Treatment of Friedreich's Ataxia
   Martin Fugere, AveXis Research and Development, San Diego, CA, United States

5:15 PM – 5:30 PM
   950: Bicistronic AAV Gene Therapy for Tay-Sachs Disease
   Toloo Taghian, University of Massachusetts Medical School, Worcester, MA, United States

ORAL ABSTRACT SESSION 356

3:45 PM - 5:30 PM
Room: 309

Tolerance and Vaccine Approaches

Chair: Allison Keeler-Klunk, PhD

3:45 PM - 4:00 PM
   951: Creating AAV Specific CAR T-Cells and CAR Regulatory T- Cells to Model and Mitigate AAV Immune Responses
   Motahareh Arjomandnejad, University of Massachusetts Medical School, Worcester, MA, United States

4:00 PM – 4:15 PM
   952: Combination of Rapamycin and Anti-IL-15 to Preserve Transgene Expression and Allow for Re-Administration in Hepatic AAV Gene Transfer
   John Butterfield, University of Florida College of Medicine, Gainesville, FL, United States

4:15 PM – 4:30 PM
   953: Robust Antigen-Specific Immune Tolerance Can be Achieved Through Platelet-Targeted Gene Therapy Even in a Primed Model via Peripheral Clonal Deletion and Treg Cell Induction
   Qizhen Shi, Medical College of Wisconsin, Blood Research Institute, Children’s Research Institute, Milwaukee, WI, United States

4:30 PM – 4:45 PM
   954: Immunization with a Synthetic DNA Vaccine Encoding the OspA Antigen of Borrelia burgdorferi Provides Durable Immunity Against Lyme Disease
   Trevor Smith, Inovio, San Diego, CA, United States
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:45 PM – 5:00 PM
955: Phase I-IIA Study of GLS-5300 Vaccine for Mers-Cov: Preliminary Results Demonstrate B and T Cell Immune Response Elicited in Lower-Dose 2- and 3-Vaccination Intradermally Administered Regimens
Christine Roberts, GeneOne Life Science, Seoul, Korea, Republic of

5:00 PM – 5:15 PM
956: Profiling the CD8 Response Following Liver Directed AAV Gene Therapy
Geoffrey Keeler, University of Florida, Gainesville, FL, United States

5:15 PM – 5:30 PM
957: Engineering of an Enhanced DNA-Based Immunotherapeutic Against Neisseria gonorrhoeae
Elizabeth Parzych, The Wistar Institute, Philadelphia, PA, United States

ORAL ABSTRACT SESSION 357
3:45 PM - 5:30 PM
Room: 310

Genome Editing in Inborn Errors of Metabolism
Chair: Dwight Koeberl, MD, PhD

3:45 PM – 4:00 PM
958: AAV-Mediated Homology-Independent Targeted Integration in Newborn Hepatocytes Corrects Mucopolysaccharidosis Type VI
Manel Llado Santaeularia, Fondazione Telethon, Roma, Italy

4:00 PM – 4:15 PM
959: Selective Expansion of Gene-Targeted Hepatocytes In Vivo Leads to Therapeutic Levels of Transgene Expression
Anne Vonada, Oregon Health and Science University, Portland, OR, United States

4:15 PM – 4:30 PM
960: In vivo Genome Editing at the Albumin Locus Corrects Two New Mouse Models of Methylmalonic Acidemia (MMA) Caused by Methylmalonyl-CoA Mutase Deficiency (Mmut)
Jessica Schneller, National Institutes of Health, Bethesda, MD, United States
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:30 PM – 4:45 PM
961: Genomic Instability and Tumorigenesis are Long-Term Effects of Therapeutic CRISPR/Cas9 Genome Editing in Hereditary Tyrosinemia Type I
Nika Furey, Duke University, Durham, NC, United States

4:45 PM – 5:00 PM
962: Crispr/Cas9-Mediated Genome Editing Z-Allele Mutation in Hepatocytes of Alpha-1 Antitrypsin Pizz Ferrets Using Adenovirus-Associated Virus
Xiaoming Liu, The University of Iowa, Iowa City, IA, United States

5:00 PM – 5:15 PM
963: Treatment of Juvenile Mice with Methylmalonic Acidemia (MMA) by Targeted Integration of MMUT into Albumin Using a Promoterless AAV Vector
Leah Venturoni, NIH, Bethesda, MD, United States

5:15 PM – 5:30 PM
964: Ex Vivo Editing of Human Hematopoietic Stem Cells for Erythroid-Specific Expression of Therapeutic Proteins
Giulia Pavani, Genethon, Evry, France

ORAL ABSTRACT SESSION 358

3:45 PM - 5:30 PM
Room: 311

Vector and Cell Engineering, Production or Manufacturing IV
Chair: Maritza Mcintyre, PhD

3:45 PM – 4:00 PM
965: Genome-Wide CRISPR Screen in HEK293 Identifies Putative Cellular Restriction Factors for AAV Manufacturing
Anna Maurer, Grousbeck Gene Therapy Center, Mass Eye and Ear, Harvard Medical School & The Broad Institute of Harvard and MIT, Boston, MA, United States

4:00 PM – 4:15 PM
966: CRISPR-Based High-Throughput Screening Reveals Host Factor SKA2 and ITPRIP Promoting AAV Manufacturing
Hyuncheol Lee, University of California, Berkeley, Berkeley, CA, United States
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:15 PM – 4:30 PM
967: CRISPR Screening Identifies Gene Knockouts That Improve Lentiviral Vector Titers in HEK293 Cells
Brian Iaffaldano, FDA, White Oak, MD, United States

4:30 PM – 4:45 PM
968: Novel Strategy for Generating rAAV Vectors Using Pseudorabies Virus
Oana Maier, University of Pennsylvania, Philadelphia, PA, United States

4:45 PM – 5:00 PM
969: Exploring Optimal REP Gene Expression Levels for the Generation of a Stable AAV Packaging Cell Line
Lovro Jalšić, National Research Council Canada, Montréal, QC, Canada

5:00 PM – 5:15 PM
970: rAAV for Tumor Therapy Using Transcriptional and Translational Control of Suicide Gene Expression Purified by a Newly Developed Affinity Chromatography Based on the PKD Domains of AAVR
Kathrin Teschner, Bielefeld University, Bielefeld, Germany

5:15 PM – 5:30 PM
971: Lac Repressor Inducible Control of AAV Capsid Protein Ratios and Decoupling VP1, VP2 from VP3 in the Sf9 insect cell/Baculovirus Expression Vector (BEV) Platform
Jeffrey Slack, Voyager Therapeutics, Cambridge, MA, United States

ORAL ABSTRACT SESSION 359

3:45 PM - 5:30 PM
Room: 312

Pharmacology/Toxicology Studies

Chair: Abraham Scaria, PhD

3:45 PM – 4:00 PM
972: Gene Transduction, Hematopoietic Stem Cells (HSCs) Engraftment, and Red Blood Cell (RBC) Physiology in Sickle Cell Disease (SCD) Gene Therapy
Francis Pierciet Jr., bluebird bio, Inc., Cambridge, MA, United States

4:00 PM – 4:15 PM
973: InGeTox - A Modular Vector Safety Prediction System
Marco Zahn, GeneWerk GmbH, Heidelberg, Germany
PROGRAM SCHEDULE
THURSDAY, MAY 14

All times are listed in Eastern Daylight Time (EDT UTC -4).

4:15 PM – 4:30 PM
974: A Single Administration of AAV5-hFIX in Newborn, Juvenile and Adult Mice Leads to Stable hFIX Expression up to 18 Months after Dosing
Lisa Spronck, UniQure Biopharma B.V., Amsterdam, Netherlands

4:30 PM – 4:45 PM
975: In Vitro Transformation Assays for Non-Clinical Safety Assessment of CRISPR/Cas9 Genome-Edited Cells
Myriam Lemmens, Novartis, Basel, Switzerland

4:45 PM – 5:00 PM
976: Preclinical Assessment of an In Vivo Lentiviral Vector Cure for Hereditary Tyrosinemia Type 1
Robert Kaiser, Children’s Hospital Minnesota, Minneapolis, MN, United States

5:00 PM – 5:15 PM
977: Physiologically-Based Pharmacokinetic Modeling for Adeno-Associated Virus Gene Therapy
Nicholas van der Munnik, Biogen Inc., Cambridge, MA, United States

5:15 PM – 5:30 PM
978: XT-150 Human IL-10v Plasmid DNA: Results from 6-month GLP Safety Study and Efficacy After Intra-Articular Administration to Companion Dogs with OA
Raymond Chavez, Xalud Therapeutics, Inc., Berkeley, CA, United States

EXHIBIT HALL
Open 24 hours online

POSTER SESSION III
Open 24 hours on May 14

5:30 PM - 6:30 PM
Scheduled presenters requested to be available for live Q&A
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

ASGCT BUSINESS MEETING
7:30 AM - 8:00 AM
Room: 312
Business Meeting

ORAL ABSTRACT SESSION 399
8:00 AM - 9:45 AM
Room: 310
Clinical Trials Spotlight Symposium

Chairs: Aravind Asokan, PhD, and Jennifer Adair, PhD

8:00 AM - 8:15 AM
617. Safety and Tolerability of PF-06939926 in Ambulatory Boys with Duchenne Muscular Dystrophy: A Phase 1b Multicenter, Open-Label, Dose Ascending Study
Michael Binks, Pfizer Inc, Cambridge, MA, United States

8:15 AM – 8:30 AM
1298: Resolution of Sickle Cell Disease (SCD) Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 HGB-206 Group C Study
John Tisdale, NHLBI, National Institutes of Health, Bethesda, MD, United States

8:30 AM – 8:45 AM
1299: First-In-Human Gene Therapy for Tay-Sachs Disease: Report of Two Infants Treated on an Expanded Access Clinical Trial of rAAVrh8-HexA/HexB (AXO-AAV-GM2)
Terence Flotte, University of Massachusetts Medical School, Worcester, MA, United States

8:45 AM – 9:00 AM
1300: Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (ADA-SCID): Two Year Follow-Up Results
Donald Kohn, University of California, Los Angeles, Los Angeles, CA, United States
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

9:00 AM – 9:15 AM
1301: Natural Killer T Cells Expressing a GD2-CAR and IL-15 for Children with Neuroblastoma - A First-In-Human Phase 1 Trial
Andras Heczey, Baylor College of Medicine, Houston, TX, United States

9:15 AM – 9:30 AM
1302: A Phase 2 Trial of MGTA-456 Cell Therapy Demonstrates Rapid and Durable Long-Term Improvement in Disease-Specific Outcomes in Inherited Metabolic Disease (IMD) Patients
John Wagner, University of Minnesota, Minneapolis, MN, United States

9:30 AM – 9:45 AM
1303: CoupledCAR™ Technology for Treating Thyroid and Colorectal Cancer
Lei Xiao, Innovative Cellular Therapeutics, Shanghai, China

SCIENTIFIC SYMPOSIUM 400
8:26 AM - 9:45 AM
Room: 311
Challenges and Future Directions in Cardiovascular Gene and Cell Therapy - Organized by the Cardiovascular Gene & Cell Therapy Committee

CHAIR: Costanza Emanueli, FAHA

SPEAKERS
8:26 AM – 8:52 AM
Luk H. Vandenberghe, PhD. Harvard, Broad Institute, Mass Eye and Ear, Boston, MA
Rational Design of AAV for Tissue Tropism and Pharmacological Control

8:52 AM – 9:18 AM
H. Kirk Hammond, MD. UCSD and VA San Diego, San Diego, CA
Urocortin 2 Gene Transfer: Effects on Age-Related Heart Failure with Preserved EF and Diabetes

9:18 AM – 9:45 AM
Duncan Stewart, MD, FRCPC. Ottawa Hospital Research Institute, Ottawa, ON, Canada
Angiogenic Cell Therapy for Pulmonary Arterial Hypertension: Go with the Flow!
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

**SCIENTIFIC SYMPOSIUM 401**

8:00 AM - 9:45 AM

*Room: Ballroom A*

**Accessing Virus Vectors for Non-clinical and Clinical Gene Therapy Studies - Organized by the Bio-Industry Committee**

*CO-CHAIRS: Kinnari Patel, MBA and Richard Snyder, PhD*

**SPEAKERS**

8:00 AM – 8:20 AM

J. Fraser Wright, PhD. Stanford, Philadelphia, PA

*For-Profit and Non-Profit Cooperative Approaches*

8:20 AM – 8:40 AM

PJ Brooks, PhD. NIH National Center for Advancing Translational Sciences, Bethesda, MD

*NH Government Initiatives*

8:40 AM – 9:00 AM

Catherine Stehman-Breen, MD. Obsidian Therapeutics, Cambridge, MA

*Contract Manufacturing, Consulting and Internal Corporate Efforts*

9:00 - 9:45 AM

Panel Discussion

**SCIENTIFIC SYMPOSIUM 402**

8:00 AM - 9:45 AM

*Room: 312*

**Challenges and Possible Solutions in Infectious Diseases - Organized by the Infectious Diseases and Vaccines Committee**

*CO-CHAIRS: Hildegund Ertl, MD and Matti Sallberg, DDS*

**SPEAKERS**

8:00 AM – 8:26 AM

Hildegund CJ. Ertl, MD. Wistar Institute, University of Pennsylvania, Philadelphia, PA

*Introductory Talk On What We Worry About in the Future and What We Need To Do.*
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

8:26 AM - 8:52 AM
Scott G. Kitchen, PhD. UCLA AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA
Adoptive Peripheral T Cell Versus Hematopoietic Stem Cell (HSC)-based HIV-specific CART Cell Therapy Approaches In Vivo

8:52 AM – 9:18 AM
Antonio Bertoletti, MD. Duke-Nus Medical School, Singapore
Challenges of CAR- and TCR-T Cell-based Therapy for Chronic Hepatitis B

9:18 AM – 9:45 AM
Ronald C. Desrosiers, PhD. University of Miami Miller School of Medicine, Miami, FL
Long-term AAV-mediated Delivery of Potent Broadly-Neutralizing Antibodies for the Treatment and Prevention of AIDS Virus Infection

SCIENTIFIC SYMPOSIUM 403

8:00 AM - 9:45 AM
Room: Ballroom C

Gene and Cell Therapeutic Strategies to Treat Disorders of the CNS – An International Perspective - Organized by the International Committee

CO-CHAIR: Anne Galy, PhD

SPEAKERS

8:00 AM - 8:35 AM
Nathalie Cartier-Lacave, PhD. INSERM, Paris, France
AAV-Based Strategies to Treat CNS Disorders: Focus on Alzheimer's Disease

8:35 AM - 9:10 AM
Gregory Stewart, PhD. Axovant, New York, NY
AXO-Lenti-PD: A Trans-Atlantic Collaboration on Gene Therapy for Parkinson's Disease

9:10 AM - 9:45 AM
Maria Bernardo, MD, PhD. San Raffaele Telethon Institute, Milan, Italy
HSC-Based Strategies to Treat CNS Disorders: Focus on Hurler/MPS1H
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

SCIENTIFIC SYMPOSIUM 404
8:00 AM - 9:45 AM
Room: Ballroom B

Gene Editing: Emerging New Technologies and Unbiased Assessment of On and Off Target Genome Alteration - Organized by the Genome Editing Committee

CHAIR: T.J. Cradick, PhD

SPEAKERS
8:00 AM – 8:26 AM
Samuel H. Sternberg, PhD. Columbia University, New York, NY
Transposon-encoded CRISPR-Cas Systems Direct RNA-guided DNA Integration

8:26 AM – 8:52 AM
Nicole Gaudelli, PhD. Beam Therapeutics, Cambridge, MA
ABE8: Superior Adenine Base Editors with Expanded Targeting Range and Therapeutic Applications

8:52 AM – 9:18 AM
Toni Cathomen, PhD. Medical Center - University of Freiburg, Freiburg, Germany
Large-scale Genomic Alterations upon Gene Editing

9:18 AM – 9:45 AM
John Anthony Zuris, PhD. Editas Medicine, Cambridge, MA
Highly Efficient Multi-Gene Knockout and Transgene Knock-in Using CRISPR-Cas12a in Induced Pluripotent Stem Cells for the Generation of Engineered Cell Immunotherapies

SCIENTIFIC SYMPOSIUM 405
8:00 AM - 9:45 AM
Room: 304 & 306

Stem Cell-derived Organoids - Organized by the Stem Cell Committee

CO-CHAIRS: Eirini Papapetrou, PhD and Bakhos Tannous, PhD

SPEAKERS
8:00 AM – 8:26 AM
Bakhos Tannous, PhD. Massachusetts General Hospital, Boston, MA
Patient-Derived Glioma Models: From Patients to Dish to Animals
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

8:26 AM – 8:52 AM
Giorgia Quadrato, PhD. University of Southern California, Los Angeles, CA
Modeling Human Brain Development and Disease at Single Cell
Resolution with Organoids

8:52 AM – 9:18 AM
Ya-Wen Chen, PhD. University of Southern California, Los Angeles, CA
Generation of a Three-Dimensional Lung Organoid From Human
Pluripotent Stem Cells and Its Applications

9:18 AM – 9:45 AM
Ryuji Morizane, MD, PhD. Massachusetts General Hospital, Boston, MA
Kidney Organoids for Disease Modeling

SCIENTIFIC SYMPOSIUM 406
8:00 AM - 9:20 AM
Room: Auditorium
The Long-term View: Extended follow up of Patients in Pivotal Gene
Therapy Trials

SPEAKERS
8:00AM – 8:26 AM
Jerry Mendell, MD. Gene Therapy Center Nationwide, Columbus, OH
Onasemnogene Abeparvovec-xioi (ZOLGENSMA) in SMA 1 Patients

8:26 AM – 8:52 AM
Alessandro Aiuti, MD, PhD. IRCCS San Raffaele Scientific Institute for Gene
Therapy, Milan, Italy
Long-term Outcomes of Strimvelis (Ex Vivo Gene Therapy for ADA-
SCID)

8:52 AM – 9:18 AM
Richard A. Colvin, MD, PhD. bluebird bio, Cambridge, MA
Long-term Outcomes for the Treatment of Patients with Transfusion-
dependent β-thalassemia with Betibeglogene Autotemcel
(LentiGlobin) Gene Therapy
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

PLENARY SESSION 410
8:00 AM - 9:30 AM
Room: 309

2019 Career Development Award Recipients

SPEAKERS

Diana Bharucha-Goebel, MD. NIH & Children’s National Health System, Bethesda, MD
A Systematic Clinical Analysis of the Immunologic Effects of Intrathecal AAV9 Mediated Gene Transfer Targeting the Central Nervous System

Benjamin Kleinstiver, PhD. Massachusetts General Hospital, Boston, MA
Enhancing the Efficacy and Safety of Cell Engineering with Novel CRISPR Enzymes

Nicole K. Paulk, PhD. University of California San Francisco, San Francisco, CA
Characterizing the Proteomic Landscape of rAAV Vectors for Human Liver Gene Therapies

Sandhya Sharma. Baylor College of Medicine, Houston, TX
Generation of Memory Cell Enriched, Broad Repertoire Antigen Specific T Cells for EBV Positive Malignancies

Katie M. Stiles. Weill Cornell Medical College, New York, NY
Modification of the AAV Expression Cassette to Enhance Transgene Translation

Jiehua Zhou, Ph.D.. Beckman Research Institute of City of Hope, Monrovia, CA
Exploring Functional RNAs: Gene Therapy & Beyond

BREAK
9:45 AM - 10:15 AM
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 420
10:15 AM - 12:00 PM
Room: Auditorium

AAV Vectors - Clinical Studies I
Chair: Steven Gray, PhD

10:15 AM – 10:30 AM
1305: RGX-314 Ocular Gene Therapy: Overview of Phase I/Ila Ongoing Trial for Neovascular Age-Related Macular Degeneration (nAMD) and Future Directions
Olivier Danos, REGENXBIO, Rockville, MD, United States

10:30 AM – 10:45 AM
1306: AAV8-Mediated Liver-Directed Gene Therapy as a Potential Therapeutic Option in Adults with Glycogen Storage Disease Type Ia (GSDIa): Results from a Phase 1/2 Clinical Trial
David Weinstein, University of Connecticut, Farmington, CT, United States

10:45 AM – 11:00 AM
1307: First China International Gene Therapy Study in Leber’s Hereditary Optic Neuropathy
Alvin Luk, Neurophth Therapeutics Inc, Wuhan, China

11:00 AM – 11:15 AM
1308: A Systematic Review of Clinical Safety and Efficacy of AAV Gene Therapies
Dmitry Kuzmin, 4BIO Capital, London, United Kingdom

11:15 AM – 11:30 AM
1309: Clearance of Vector DNA from Bodily Fluids in Patients with Severe or Moderate-Severe Hemophilia B Following Systemic Administration of AAV5-hFIX and AAV5-hFIX Padua
Eileen Sawyer, UniQure Biopharma B.V., Lexington, MA, United States

11:30 AM – 11:45 AM
1310: Improved Motor Function in Children with AADC Deficiency Treated with Eladocagene Exuparvovec (PTC-AADC): Interim Findings from a Phase 2 Trial
Paul Wuh-Liang Hwu, National Taiwan University Hospital, Taipei, Taiwan
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:45 AM – 12:00 PM
1311: Improved Delivery in a New Clinical Trial of AAV2-BDNF Gene Therapy for Alzheimer’s Disease
Michael Castle, University of California, San Diego, La Jolla, CA, United States

ORAL ABSTRACT SESSION 421

10:15 AM - 12:00 PM
Room: Ballroom A
AAV Vectors Preclinical and Proof-of-Concept Studies in CNS Disorders
Chair: Allison Bradbury, PhD

10:15 AM – 10:30 AM
1312: PR006, an AAV Gene Therapy Vector Expressing Progranulin, Improved FTD-GRN Phenotypes In Vitro and In Vivo
Laura Heckman, Prevail Therapeutics, New York, NY, United States

10:30 AM – 10:45 AM
1313: Gene Therapy for the Progressive Visual Pathology in Late Infantile Neuronal Ceroid Lipofuscinosis Patients Receiving Enzyme Replacement Therapy
Luis Tecedor, Childrens Hospital of Philadelphia, Philadelphia, PA, United States

10:45 AM – 11:00 AM
1314: A Transient Burst of Transgene Expression Promotes Regeneration of Mature Vestibular Hair Cells
Joseph Burns, Decibel Therapeutics, Boston, MA, United States

11:00 AM – 11:15 AM
1315: In Vivo Postnatal Base Editing Restores Sensory Transduction and Transiently Rescues Hearing in a Mouse Model of Recessive Deafness
Wei-Hsi (Ariel) Yeh, Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA, United States

11:15 AM – 11:30 AM
1316: Investigational AAV Gene Therapy LYS-GM101 for GM1-Gangliosidosis
Ralph Laufer, Lysogene, Neuilly sur Seine, France
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:30 AM – 11:45 AM
  1317: Preclinical Results in Rodents Strongly Support Clinical Evaluation of scAAV9/MFSD8 as a Potential Gene Therapy for CLN7 Patients
  Xin Chen, UTSW Medical Center, Dallas, TX, United States

11:45 AM – 12:00 PM
  1318: Gene Therapy for Tuberous Sclerosis Complex Type 2 in a Mouse Model by Delivery of AAV9 Encoding a Condensed Form of Tuberin
  Shilpa Prabhakar, Massachusetts General Hospital, Charlestown, MA, United States

ORAL ABSTRACT SESSION 422

10:15 AM - 11:30 AM
Room: Ballroom B
Gene Regulation and Delivery Technologies
Chair: Benjamin Kleinstiver, PhD

10:15 AM – 10:30 AM
  1319: In Situ Gene Editing of HSPCs by TAGE, a New Biologics Class of Targeted Cas Ribonucleoproteins
  Rina Mepani, Spotlight Therapeutics Inc., Hayward, CA, United States

10:30 AM – 10:45 AM
  1320: Crispr Cas9 Mediated Gene Knockout of KLKB1 to Treat Hereditary Angioedema
  Jessica Seitzer, Intellia Therapeutics Inc., Cambridge, MA, United States

10:45 AM – 11:00 AM
  1321: Engineering the DNA-Binding Specificity of CTCF to Restore Enhancer-Mediated Gene Expression in Human Cells
  Rebecca Cottman, Massachusetts General Hospital, Charlestown, MA, United States

11:00 AM – 11:15 AM
  1322: In Vivo HSC Gene Therapy with Base Editors Allows for Efficient Reactivation of Fetal Gamma-Globin in Beta-YAC Mice
  Chang Li, University of Washington, Seattle, WA, United States

11:15 AM – 11:30 AM
  1324: AAV-CRISPR Gene Editing is Negated by Pre-Existing Immunity to Cas9
  Ang Li, Rice University, Houston, TX, United States
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 423
10:15 AM - 11:45 AM
Room: Ballroom C

Physical, Chemical and Exosomal Gene Delivery

Chair: Matthew Wilson, MD, PhD

10:15 AM – 10:30 AM
1326: Assessment of Clinical Feasibility of Image-Guided Liver Specific Hydrodynamic Gene Transfer in Non-Human Primates
Kenya Kamimura, Niigata University, Niigata, Japan

10:30 AM – 10:45 AM
1327: A Novel Serum-Insensitive Fusogenic Polyvalent Cationic Lipid for In Vivo mRNA Delivery
Franklin Kostas, Novellus, Inc., Cambridge, MA, United States

10:45 AM – 11:00 AM
1328: Safe and Effective Delivery of Nucleic Acids Using LNPs Formulated with Fusion-Associated Small Transmembrane Proteins
Arun Raturi, Entos Pharmaceuticals, Edmonton, AB, Canada

11:00 AM – 11:15 AM
1329: LOX Biphasic Gene Electrotransfer Enhances Extruded Collagen Graft Integration Subcutaneously in a Small Animal Model
Anna Bulysheva, Old Dominion University, Norfolk, VA, United States

11:15 AM – 11:30 AM
1332: A Versatile Platform for Precision Exosome Engineering
Kevin Dooley, Codiak BioSciences, Cambridge, MA, United States

11:30 AM – 11:45 AM
1331: Engineering Exosomes with Altered Cellular Tropism for Targeted Payload Delivery In Vivo
Monique Kauke, Codiak BioSciences, Cambridge, MA, United States
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

ORAL ABSTRACT SESSION 424
10:15 AM - 12:00 PM
Room: 302
Cardiovascular and Pulmonary Diseases
Chair: Uta Griesenbach, PhD

10:15 AM – 10:30 AM
1333: Lineage-Tracing Glandular Stem Cell Compartments in the Ferret Lung
Xiaoming Liu, The University of Iowa, Iowa City, IA, United States

10:30 AM – 10:45 AM
1334: Insertion of the CFTR cDNA in the Endogenous Locus in Airway Stem Cells Using CRISPR/Cas9 Restores CFTR Function to Wild-Type Levels in Differentiated Epithelia
Sriram Vaidyanathan, Stanford University, Stanford, CA, United States

10:45 AM – 11:00 AM
1335: A Novel AAV Variant that Exclusively Targets the Heart via a Potential Post-Entry Mechanism
Kei Adachi, Oregon Health & Science University, Portland, OR, United States

11:00 AM – 11:15 AM
1336: Directed Evolution of AAV Targeting Lung Epithelia Using Aerosol Delivery Identifies 4D-A101, a Variant Demonstrating Robust Gene Delivery in Non-Human Primates
Melissa Kotterman, 4D Molecular Therapeutics, Emeryville, CA, United States

11:15 AM – 11:30 AM
1337: Development of Receptor-Targeted Nanocomplexes for In Vivo Delivery of CRISPR/Cas9 as a Potential Therapy for Cystic Fibrosis
Amy Walker, UCL Great Ormond Street Institute of Child Health, London, United Kingdom

11:30 AM – 11:45 AM
1338: Liver-Directed Gene Therapy for Lung Disease in Alpha1 Antitrypsin Deficiency
Marina Zieger, University of Massachusetts Medical School, Worcester, MA, United States
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:45 AM – 12:00 PM
1339: Improved Cardiac AAV Gene Transfer Efficacy in Pigs Using Temporal Mechanical Support
Kiyotake Ishikawa, Mount Sinai, New York, NY, United States

ORAL ABSTRACT SESSION 425

10:15 AM - 12:00 PM
Room: 304 & 306
Cancer Immunotherapy: Clinical Results
Chair: Monica Casucci, PhD

10:15 AM – 10:30 AM
1340: KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results from Phase 2 of ZUMA-2
Michael Wang, MD Anderson Cancer Center, Houston, TX, United States

10:30 AM – 10:45 AM
1341: Exhaustion and Activation Status in Apheresed T Cells Correlate with Response to Anti-BCMA CAR T Cell Therapy in Myeloma
Iulian Pruteanu-Malinici, Novartis, Cambridge, MA, United States

10:45 AM – 11:00 AM
1342: Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in Apheresed T-Cells
Iulian Pruteanu-Malinici, Novartis, Cambridge, MA, United States

11:00 AM – 11:15 AM
1343: Correlative Analysis from CRB-402: An Ongoing Phase 1 Clinical Study of bb21217 Anti-BCMA CAR T Cell Therapy
Olivia Finney, bluebird bio, Cambridge, MA, United States

11:15 AM – 11:30 AM
1344: A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel; Axi-Cel) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Sattva Neelapu, MD Anderson Cancer Center, Houston, TX, United States
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:30 AM – 11:45 AM
1345: Autologous CD34+-Enriched Hematopoietic Progenitor Cells Genetically Modified for Human Interferon-Alpha2 (Temferon), Rapidly Engraft and Mature in Patients with Glioblastoma Multiforme (TEM-GBM_001 Study)
Bernhard Gentner, IRCSS San Raffaele Scientific Institute, Milan, Italy

11:45 AM - 12:00 PM
1346. Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
Marie Jose Kersten, on behalf of HOVON/LLPc (Lunenburg Lymphoma Phase I/II Consortium), Lunenburg, Netherlands

ORAL ABSTRACT SESSION 426
10:15 AM - 12:00 PM
Room: 309

Gene Therapy for Inborn Errors of Metabolism: New Approaches
Chair: Cary Harding, MD

10:15 AM – 10:30 AM
1347: ImmTOR™ Tolerogenic Nanoparticles Enable Gene Therapy of Mice with Maternally-Transferred Anti-AAV Antibodies in a Mouse Model of Methylmalonic Acidemia
Petr Ilyinskii, Selecta Biosciences, Watertown, MA, United States

10:30 AM – 10:45 AM
1348: The First Viable Mouse Model of Combined Methylmalonic Acidemia and Homocystinuric, cblC Type Displays a Sustained Response to a Single Dose of AAV Gene Therapy and is Comparable to Chronic Hydroxocobalamin Administration
Stefanos Koutsoukos, National Human Genome Research Institute, Bethesda, MD, United States

10:45 AM – 11:00 AM
1349: Developing and Evaluating Second-Generation AAV Vectors for Liver-Directed Gene Therapy of Familial Hypercholesterolemia in Nonhuman Primates
Lili Wang, University of Pennsylvania, Philadelphia, PA, United States
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:00 AM – 11:15 AM
1350: Intermittent mRNA Therapy for Arginase Deficiency Results in Prevention of Dysmyelination of the Corticospinal Tract
Suhail Khoja, University of California Los Angeles, Los Angeles, CA, United States

11:15 AM – 11:30 AM
1351: AAV Gene Therapy in Mucopolysaccharidosis IVA Murine Models
Shunji Tomatsu, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, United States

11:30 AM – 11:45 AM
1352: Base Editing of an Allosteric Site within Serpina1 Yields Improved Phenotypes in Models of Alpha-1 Antitrypsin Deficiency
Vivek Chowdhary, UMass Medical School, Worcester, MA, United States

11:45 AM – 12:00 PM
1353: In Vivo Base Editing to Correct a Murine Model of Mucopolysaccharidosis Type IH
Mark Osborn, University of Minnesota, Minneapolis, MN, United States

ORAL ABSTRACT SESSION 427
10:15 AM - 12:00 PM
Room: 310

Technical Advances in Cell Therapies
Chair: Graca Almeida-Porada, MD, PhD

10:15 AM – 10:30 AM
1354: Genetically Corrected iPSC-Derived Neural Stem Cell Grafts Deliver Naglu-IGFII Fusion Protein to Affect CNS Disease in Sanfilippo B Mice
Yewande Pearse, The Lundquist Institute at Harbor-UCLA, Los Angeles, CA, United States

10:30 AM – 10:45 AM
1355: Sleeping Beauty IDUA Transposed Human Plasma Cells for Long-Term Treatment of an Immunodeficient Murine Model of Mucopolysaccharidosis Type I
Christiane Hampe, Immusoft, Seattle, WA, United States

10:45 AM – 11:00 AM
1356: Allotransplantation of Functional Retinal Ganglion Cells for Glaucoma
Julia Oswald, Schepens Eye Research Institute, Boston, MA, United States
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

11:00 AM – 11:15 AM
1357: Human Transcription Factor Library Based Cell Type Engineering
Volker Busskamp, University of Bonn, Bonn, Germany

11:15 AM – 11:30 AM
1358: Prenatal Therapy with Placental Cells Transduced with a Lentiviral Vector Encoding a Bioengineered fVIII Transgene Results in Sustained Therapeutic fVIII Levels and in Product Specific Tolerance
Martin Rodriguez, Wake Forest Institute for Regenerative Medicine, Winston Salem, NC, United States

11:30 AM – 11:45 AM
1359: Combined Gene and Cell Therapy for the Treatment of Hemophilia A within an Implantable Therapeutic Device
Alessia Cucci, Università del Piemonte Orientale, Novara, Italy

11:45 AM – 12:00 PM
1360: Privileged Cell-Material Interactions Through Engineered Synthetic Receptors
Jonathan Brunger, Vanderbilt University, Nashville, TN, United States

ORAL ABSTRACT SESSION 428
10:15 AM - 11:45 AM
Room: 311

Vector and Cell Engineering, Production or Manufacturing V

Chair: Johannes van der Loo, PhD

10:15 AM – 10:30 AM
1361: Single Molecule Real-Time Sequencing Reveals Higher Genome Heterogeneity in AAV Vectors Produced from Insect Cells Compared to Mammalian Cells
P Tai, University of Massachusetts, Medical School, Worcester, MA, United States

10:30 AM – 10:45 AM
1362: SSV-Seq 2.0, an Optimized PCR-Free Method for the High-Throughput Sequencing of Adeno Associated Viral Vector Genomes
Magalie Penaud-Budloo, University of Nantes, CHU of Nantes, INSERM UMR1089, Nantes, France
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

10:45 AM – 11:00 AM
1363: Characterizing Next-Generation Baculovirus Transduction Processes - A Quality by Design-Based Approach for AAV Manufacturing
Benjamin Blaha, uniQure, Amsterdam, Netherlands

11:00 AM – 11:15 AM
1364: Measuring the Concentration of Adeno-Associated Virus (AAV) with Multi-Angle Dynamic Light Scattering (MADLS) Using the New Zetasizer™ Ultra
Jonathan Mehtala, Malvern Panalytical, Westborough, MA, United States

11:15 AM -11:30 AM
1367: Process Analytical Technology Strategy for Lentiviral Manufacture
Marc-Olivier Baradez, Cell and Gene Therapy Catapult, London, United Kingdom

11:30 AM – 11:45 AM
1366: Stability Under Stress of AT132, an AAV-Based Gene Therapy Drug Product for Systemic Administration to Patients Affected by X-Linked Myotubular Myopathy
Emdadul Haque, Audentes Therapeutics, South San Francisco, CA, United States

ORAL ABSTRACT SESSION 429
10:15 AM - 12:00 PM
Room: 312

Cancer - Oncolytic Viruses
Chair: Evanthia Galanis, MD

10:15 AM – 10:30 AM
1368: A Measles Virus Vector Pseudotyped with CD46-Retargeted Canine Distemper Envelope Achieves Oncolysis in the Presence of Measles-Immune Human Serum
Miguel Muñoz-Alía, Mayo Clinic, Rochester, MN, United States

10:30 AM – 10:45 AM
1369: ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Anti-Tumor Immunity
Christophe Queva, Oncorus, Inc., Cambridge, MA, United States
PROGRAM SCHEDULE
FRIDAY, MAY 15

All times are listed in Eastern Daylight Time (EDT UTC -4).

10:45 AM – 11:00 AM
1370: Phase I/II Trial of Adipose Tissue Derived Mesenchymal Stem Cell Delivery of a Measles Virus Strain Engineered to Express the Sodium Iodide Symporter in Ovarian Cancer Patients
Evanthia Galanis, Mayo Clinic, Rochester, MN, United States

11:00 AM – 11:15 AM
1371: A Novel ADP-Deleted, NIS-Expressing Adenovirus: Theranostic Applications and Clinical Development
Matthew Robertson, University of Minnesota, Minneapolis, MN, United States

11:15 AM – 11:30 AM
1372: Immunostimulatory Bacterial Antigen-Armed Oncolytic Measles Virotherapy Significantly Increases the Potency of aPD1 Checkpoint Therapy to Eradicate Glioblastoma
Eleni Panagioti, Mayo Clinic, Rochester, MN, United States

11:30 AM – 11:45 AM
1373: Single-Cell Transcriptomics Analysis of a Complete Response Phenotype in Mice with Disseminated Lung Cancer after Systemic Therapy with Oncolytic Adenovirus
Svetlana Atasheva, Emory University, Atlanta, GA, United States

11:45 AM – 12:00 PM
1374: Fusogenic Oncolytic Vaccinia Virus Changes the Tumor Immune Microenvironment by Cell Fusion and Enhances Systemic Anti-Tumor Immunity
Motomu Nakatake, Tottori University, Yonago, Japan
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

ABL INC.
9800 Medical Center Drive
Rockville, MD 20850
301 8165245
emma.alterman@ablinc.com
www.ablinc.com
ABL is a CRO and CMO with over 50 years of experience partnering with clients to meet their product development goals. ABL offers cGMP virus and protein manufacturing, coupled with preclinical and clinical testing services, enabling clients to accelerate candidate vaccines, viral vectors and biotherapeutics into the clinic.

ADVANCED INSTRUMENTS
Two Technology Way
Norwood, MA 02062
781 4712159
terriep@aicompanies.com
www.aicompanies.com
Advanced Instruments is a global provider of scientific and analytical instruments for the clinical, biopharmaceutical, and food-and-beverage industries. Advanced Instruments has a diverse portfolio of products, including: freezing-point osmometers, cerebrospinal fluid cell counters, anaerobic jar systems, cryoscopes, pasteurization test systems, and testing standards and controls. For more information, visit aicompanies.com.

AGILENT TECHNOLOGIES
5301 Stevens Creek Blvd
Santa Clara, CA 95051
800 2279770
www.agilent.com
Agilent delivers complete scientific solutions, helping customers achieve superior outcomes in their labs, clinics, business and the world they seek to improve.

One Kendall Square, 1400W Suite 14102
Cambridge, MA 02139
617 8435736
mdamon@agtc.com
www.agtc.com
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases. AGTC’s lead product candidates are designed to treat inherited orphan diseases of the eye, caused by single genes mutations, that significantly affect visual function.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

Aldevron
4055 40th Ave S
Fargo, ND 58104
701 2979256
darrel.veldhouse@aldevron.com
www.aldevron.com

Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Featuring the largest and most modern GMP plasmid DNA facility in the world, thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from research grade to clinical trials to commercial applications.

ALLCELLS
1301 Harbor Bay PKWY Suite 200
Alameda, CA 94502
510 6718707
www.allcells.com

AllCells is the leading provider of high quality, economical blood and marrow derived cells. Sourced at AllCells state-of-the-art FDA, HIPAA, IRB-compliant donor collection facility, customers around the world trust AllCells products to carry out their research, development and manufacture of cell and gene therapies. AeroSafe Global™ packaging ensures product integrity from our facility to yours.

AMERICAN SOCIETY FOR TRANSPLANTATION AND CELLULAR THERAPY
330 North Wabash Avenue, Suite 2000
Chicago, IL 60611
312-321-6820
www.astct.org

The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 2,200 physicians, investigators and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of bone and marrow transplantation and related cellular therapies.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

ARCTICZYMES
987 Old Eagle School Road, Ste 709 Wayne, PA 19073
484 5343567
https://arcticzymes.com/
ArcticZymes develops and manufactures novel, GMP-ready nucleases tailor made for bioprocessing applications. Using nucleases developed for optimal performance at the various conditions of the steps of viral vector manufacturing helps to achieve purer product and higher titers, at a reduced cost. Our Salt Active Nuclease (SAN HQ), a general endonuclease useful for removing residual DNA contamination especially at high-salt conditions (400mM-600mM). M-SAN is a novel nuclease with excellent performance at physiological conditions (175mM NaCl) found in typical cell media.

ASPHALION, S.L.
Tarragona 151-157, 10th floor
Barcelona, 08014
Spain
011 34 932 385945
info@asphalion.com
www.asphalion.com
Asphalion is an International Scientific and Regulatory Affairs consultancy with offices in Barcelona, Madrid, Amsterdam, Munich and London. We offer comprehensive services for Drug Development and Regulatory Affairs to Pharma, Biotech and Medical Devices companies. Our services range from early development, throughout the registration, until marketing and post-commercialization phases of your product.

BIOAGILYTIX
2300 Englert Drive
Durham, NC 27713
919 2101174
andie.woodson@bioagilytix.com
www.bioagilytix.com
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With locations in North Carolina’s Research Triangle area, Boston, Massachusetts, and Hamburg, Germany, BioAgilytix provides global services for biomarkers, immunogenicity, PK, and cell-based assays supporting the development of biologics across a number of industries and disease states.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

BIOMARIN PHARMACEUTICAL
105 Digital Drive
Novato, CA 94949
415 8278129
jessica.anderson@bmrn.com
www.biomarin.com
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. Approved products include the first and only therapies for PKU, LEMS, MPS I, MPS VI, MPS IVA, and CLN2 disease. Clinical development programs include investigational therapies for Hemophilia A, Achondroplasia, MPS IIIB, Friedreich’s Ataxia and other rare diseases. Please visit www.biomarin.com to learn more.

BIO-RAD
225 Linus Pauling Drive
Hercules, CA 94547
510 7414486
ellie_smith@bio-rad.com
www.bio-rad.com
Depend on Bio-Rad for tools, technologies, and expertise to enable genomic and proteomic analysis. Bio-Rad provides instrumentation and reagents for droplet digital PCR, conventional and real-time PCR, amplification reagents and primers, flow cytometry, xMAP technology, cancer bio-markers, electrophoresis, blotting systems, chromatography, imaging, cell counting, cell imaging and antibodies.

BIO-TECHNE
614 McKinley Place NE
Minneapolis, MN 55413
612 3792956
jaime.jacobson@bio-technne.com
www.bio-technne.com
Bio-Techne brings together the prestigious life science research brands of R&D Systems, Novus Biologicals, Tocris Bioscience, ProteinSimple, and Advanced Cell Diagnostics to provide researchers with high-quality reagents and Instruments. We specialize in high quality antibodies, proteins, immunoassays, small molecules, RNA probes, and instruments for protein and genomic characterization.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

CATALENT BIOLOGICS | PARAGON GENE THERAPY
7555 Harmans Road
Harmans, MD 21077
410 9754050
cfloreck@paragonbioservices.com
www.paragonbioservices.com

Paragon Gene Therapy, part of Catalent Biologics, is committed to strong client partnerships, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, and oncology immunotherapies. Paragon Gene Therapy has five locations in Maryland dedicated to process development through commercial manufacturing of most scalable AAV platforms across multiple serotypes.

CELETRIX ELECTROPORATION
9385 Discovery Blvd 137
Manassas, VA 20109
646 8011881
jchen@celetrix.com
www.celetrix.com

Celetrix is the leader in electroporation with our new high efficiency electroporation technologies for delivering DNA, RNA and proteins to cells. Celetrix provides technology and support for CAR-T manufacturing by transposon mediated expression and RNP mediated gene editing for T cells, stem cells and CD34+ HSC.

CELLGENIX INC
One New Hampshire Avenue
Portsmouth, NH 3801
857 6008790
contreras@cellgenix.com
https://cellgenix.com

CellGenix is a leading global supplier of high quality raw materials for the expanding cell and gene therapy space. We develop, manufacture and market human cytokines and growth factors in preclinical and GMP quality along with GMP serum-free media for further manufacturing of ATMPs.

CELL PRESS
50 Hampshire St. 5th Floor
Cambridge, MA 02139
jgiles@cell.com
www.cell.com

Cell Press is proud to publish the Molecular Therapy family of journals, the official journals of ASGCT.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

CEVEC PHARMACEUTICALS
GMBH
Gottfried-Hagen-Straße 60-62
Cologne, Germany
011 49 221 46020823
lutz@cevec.com
www.cevec.com

CEVEC’s proprietary CAP®GT technology is a fully scalable manufacturing platform for viral vectors, offering high titer production of AAV, LV and AV vectors in serum-free suspension cultures. For large scale production, packaging and producer cell lines are available, including a stable, helper virus-free AAV production system.

THE CHILDREN’S HOSPITAL
OF PHILADELPHIA
3501 Civic Center Blvd.
Philadelphia, PA 19104
215 5901692
https://ccmt.research.chop.edu/cores.php

The CHOP Research and Clinical Vector Core provide state-of-the-art technology in lentivirus (LV) and AAV-based vectors for gene transfer in research, pre-clinical pharm-tox studies, and early-phase clinical trials. The core has extensive experience in the manufacture of LV and multiple AAV serotypes and provides research-grade, GMP-comparable, and GMP-grade viral vectors at a variety of scales.

CHARLES RIVER
251 Ballardvale Street
Wilmington, MA 01887
800 2748371
www.criver.com

With over 70 years of experience, Charles River has a unique and comprehensive portfolio to support the development and execution of cellular and gene therapy programs from basic research to discovery and safety testing through to clinical and CMC testing support. To learn more visit www.criver.com.

CYGNUS TECHNOLOGIES
4332 Southport Supply Rd SE
Southport, NC 28461
910 4549442
erinlynn2211@yahoo.com
https://www.cygnustechnologies.com/

Cygnus Technologies supplies specialized analytical products to the biopharmaceutical industry for use in process development and quality control. As recognized experts in bioprocess impurity testing for analytes such as host cell proteins, Cygnus offers a broad menu of ready-to-use ELISA kits, reagents, and analytical services, custom process-specific antibodies and assays.
Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

Cytiva is a global provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics. Previously GE Healthcare Life Sciences, Cytiva’s diverse portfolio includes well-recognized brands such as ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex and Xuri. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the delivery of transformative medicines to patients. Visit cytiva.com for more.

Cytovance® is a leading biopharmaceutical CDMO that excels in the rapid and cost-effective development and manufacture of large molecule APIs from both mammalian cell culture and microbial fermentation such as monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines and other biological products including plasmid DNA and cell-based therapeutics.

The ESGCT is a non-profit organisation for educational and scientific purposes. The aim of ESGCT is to promote fundamental and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, exchange of information and technology.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

FDA CENTER FOR BIOLOGICS EVALUATION AND RESEARCH
10903 New Hampshire Ave
Silver Spring, MD 20993
cber.employment@fda.hhs.gov
www.fda.gov/cbercareers
The Center for Biologics Evaluation & Research (CBER) within the Food & Drug Administration (FDA) regulates biological products for human use under applicable federal laws. CBER’s Office of Tissues and Advanced Therapies plans and conducts research related to the development, manufacture, and testing of cellular, tissue, and gene therapy products.

FORTEBIO
47661 Freemont Blvd.
Freemont, CA 94538
650 3221360
www.fortebio.com
ForteBio, a business unit of Molecular Devices LLC, offering products that span multiple technology vectors including analytical instrumentation and software, clone picking and imaging, and customized engineering solutions. We partner with our customers in biologics and other life sciences segments to unlock workflow bottlenecks, provide best-in-class products and first-class service.

FRESENIUS KABI
caring for life
3 Corporate Drive
Lake Zurich, IL 60047
847 5502625
ben.nelson@fresenius-kabi.com
www.chooselovo.com
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. We bring over 60 years of experience advancing the fields of cell collection and separation with expertise in closed-system processing. Our Lovo Cell Processing System is the only cell processing system that washes and concentrates white blood cells using filtration technology, specifically to serve the needs of the cellular therapies community.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

FUJIFILM
101 J Morris Commons Lane
Morrisville, NC 27526
919 3256972
liza.rivera@fujifilm.com
www.fujifilmdiosynth.com
We are a Contract Development and Manufacturing Organization supporting our partners in the biopharmaceutical industry with the development and production of their biologic/gene therapies. We manufacture gene therapies from early preclinical stage all the way to commercial production.

GENEWIZ/BROOKS
115 Corporate Blvd
South Plainfield, NJ 07080
908 2220711
www.genewiz.com
GENEWIZ provides genomics services to over 120,000 users in 4,000 institutions worldwide, enabling researchers to advance their discoveries faster than ever before. Now a Brooks Life Sciences company, GENEWIZ leads the industry with our unique and proprietary sequencing and automation technologies backed by specialized experts in next generation sequencing, GLP/CLIA regulatory-compliant services, Sanger sequencing, and synthetic DNA solutions.

GenScript
860 Centennial Avenue
Piscataway, NJ 08854
732 6097902
tracy.yin@genscript.com
https://www.genscript.com/
GenScript encompasses extensive services in gene synthesis and molecular biology, peptide synthesis, protein expression and engineering, custom antibody development and engineering as well as variety of catalog products. With the goal of “Making Research Easy”, GenScript has striven to remain a reliable research partner for scientists across the globe.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

GLOBAL GENES
28 Argonaut, Suite 150
Aliso Viejo, CA 92656
949 2487273
helpdesk@globalgenes.org
https://globalgenes.org/

Global Genes is an international nonprofit organization that connects, empowers and inspires the rare disease community, with the ultimate goal of improving the lives of the more than 400 million rare disease patients around the world and their families. If you have a rare disease, contact Global Genes at 949-248-RARE.

GYROS PROTEIN TECHNOLOGIES
30 Technology Drive, Suite 1F
Warren, NJ 07059
520 6299626
information@gyrosproteintech.com
www.gyrosproteintech.com

Gyros Protein Technologies provides enabling peptide synthesis platforms and proprietary immunoassay solutions to accelerate your discovery, development and manufacturing of safer biotherapeutics and cell & gene therapies. www.gyrosproteintech.com

HALO LABS
1828 El Camino Real, Suite 703
Burlingame, CA 94010
800 5530977
support@halolabs.com
halolabs.com

Halo Labs is all about particle analysis. Horizon, our flagship product, can count and characterize subvisible and visible particles, including protein aggregates. It utilizes a plate-based approach that enables high throughput, low volume (25 uL) particle analysis - from candidate selection all the way through quality control.

JACKSON IMMUNORESEARCH LABORATORIES, INC.
872 W Baltimore Pike
West Grove, PA 19390
800 3675296
cuserv@jacksonimmuno.com
www.jacksonimmuno.com

Specializing in affinity-purified secondary antibodies (many adsorbed against other species) conjugated with Alexa Fluor®, DyLight™, and Cyanine fluorescent dyes; R-PE; and other detection ligands. Other products include anti-IgG, Light Chain specific for Western blotting after IP, Alexa Fluor® 680 and 790 for highly sensitive Western blots. ISO 9001:2015 registered.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

Lonza
Pharma & Biotech
14905 Kirby Drive
Houston, TX 77047
346 2994101
http://pharma.lonza.com
We provide contract development and manufacturing services that enable pharma and biotech companies to bring medicines to patients in need. Our solutions are created to simplify your outsourcing experience and provide a reliable outcome, when you expect it. Together, let’s bring your next medicine to life.

LOVELACE BIOMEDICAL
2425 Ridgecrest Drive SE
Albuquerque, NM 87108
202 8195108
mcmullen@lovelacebiomedical.org
http://www.lovelacebiomedical.org/
Lovelace Biomedical is a contract research organization that helps pharmaceutical and biotechnology companies advance their complex drug development studies from the preclinical stage, and on to clinical trials. For over 70 years Lovelace has leveraged its multidisciplinary expertise in toxicology, gene therapy, medical countermeasures, and more, providing excellent preclinical research.

Malvern Panalytical
117 Flanders Road, Westborough
Westborough, MA 01581
449 9561794
michele.giordano@malvern.com
www.malvernpanalytical.com
Malvern Panalytical is a leader in analytical characterization, creating expert solutions for the challenges associated with maximizing productivity, developing better quality products and getting them to market faster. We provide superior, customer-focused solutions and services which deliver tangible economic impact through chemical, biophysical and structural analysis.
Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

Mary Ann Liebert, Inc. is the proud publisher of groundbreaking, peer-reviewed journals including Human Gene Therapy and The CRISPR Journal, providing all-inclusive coverage of the research, developments, and novel technologies that are driving today's explosion of gene therapy advances. Its flagship trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and remains the key driver in the growth of the industry, paving the way for the development of new technologies and applications, and investment and career opportunities.

MaxCyte is a global life sciences company applying proprietary cell engineering technology to deliver the advances of cell-based medicine to patients. All top 10 global biopharmaceutical companies are developing next-generation therapeutics utilizing MaxCyte’s Flow Electroporation® Technology. MaxCyte’s 70+ partnered program licenses in cell therapy include 35+ licensed for clinical use.

MilliporeSigma, a life science leader, is a business of Merck KGaA, Darmstadt, Germany. Our BioReliance® services offer support of cell and gene therapy includes cGMP Manufacturing services for viral gene therapy, biosafety testing services for cell and gene therapy products, and gene editing technologies.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

**MYRIADE**
30 rue de Campo Formio
Paris, 75013
France
011 33 184255143
contact@myriadelab.com
www.myriadelab.com
Myriade develops the VIDEODROP, an innovative nanoscale imaging technology. Videodrop makes possible to measure in a single drop the size and concentration of living nanoparticles between 30nm and 10 microns without labeling in real time. Thanks to the Videodrop, you can continuously monitor viral vector solutions of Lentiviruses & adenoviruses.

**NEW ENGLAND BIOLABS INC.**
240 County Road
Ipswich, MA 01915
978 3807334
goodwin@neb.com
www.neb.com
For 40 years New England Biolabs, Inc. has led the industry in the discovery and production of molecular biology reagents. In addition to products for genomic research, NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis.

**NHLBI GENE THERAPY RESOURCE PROGRAM**
8757 Georgia Avenue, 12th Floor
Silver Spring, MD 20910
301 6283457
gtrpccc@s-3.com
www.gtrp.org
The NHLBI Gene Therapy Resource Program (GTRP) facilitates the translation of gene therapy research into clinical interventions primarily in heart, lung, and blood diseases. Services provided by the Program include preclinical vector production, pharmacology/toxicology testing, immunology testing of preclinical material, assistance with regulatory activities, and supplemental funds for clinical trials.

**OXFORD BIOMEDICA**
Windrush Court
Oxford, OX4 6LT
United Kingdom
011 44 1865 785322
z.collins@oxb.com
www.oxb.com
Our goal is to become an integrated, self-financing gene and cell therapy business. Using our unique LentiVector® delivery platform, we have created a valuable portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

PALL

20 Walkup Dr.
Westborough, MA 01581
516 6446151
ian_sellick@pall.com
www.pall.com

Pall meets the demanding needs of customers discovering, developing and producing biologics, vaccines, cell and gene therapy products & classic pharmaceuticals. Pall is a leading provider of continuous bioprocessing, integrated automated systems and single-use solutions to pharmaceutical and biotechnology companies - from bioreactors, through downstream purification, to formulation and filling.

PerkinElmer

940 Winter Street
Waltham, MA 02451
800 7624000
www.perkinelmer.com

PerkinElmer, Inc. offers automated solutions which improve the efficiency of genomic and proteomics workflows. With our nucleic acid isolation technology, liquid handlers, library preparation kits, automated nucleic acid and protein analysis systems, and solutions for single cell genetic analysis, PerkinElmer is eliminating the challenges associated with genomic and proteomic analysis.

PPD

929 North Front Street
Wilmington, NC 28401
910 2510081
www.ppdi.com

PPD is a leading contract research organization providing comprehensive drug development, laboratory and lifecycle management services. With offices in 46 countries and approximately 23,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners optimize value in delivering life-changing therapies.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

PROGEN
Maassstr. 30
Heidelberg, 69123
Germany
011 40 6221 827814
info@progen.com
https://www.progen.com/
PROGEN is an established manufacturer & supplier of AAV Titration ELISA tests and antibodies for gene therapy research and development. In the past 20 years, the DIN EN ISO 13485 certified company has established a unique portfolio of AAV tools for basic and clinical research as well as pharmaceutical applications.

SAREPTA THERAPEUTICS
215 First Street
Cambridge, MA 02142
617 2744000
www.sarepta.com
Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development.

SKAN US, INC.
7409 ACC Blvd. Suite 200
Raleigh, NC 27617
919 3546380
www.skan.ch
SKAN, founded in 1968, is one of the pioneer companies in the field of cleanroom equipment and isolator design for the global pharmaceutical industry. Innovative products, customer-specific solutions and an efficient service organisation have led SKAN to become a global market leader and important partner for industry and research laboratories.

STEMCELL TECHNOLOGIES
1618 Station St
Vancouver, BC V6A 1B6
Canada
604 8770713
info@stemcell.com
https://www.stemcell.com/
STEMCELL Technologies is committed to providing specialized cell isolation products, standardized cell culture media, and accessory tools for your cell therapy research. Whether you’re culturing and editing CD34+ cells or activating and expanding T cells, STEMCELL supports the advancement of science around the world. To learn more, visit www.STEMCELL.com.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

TERUMO BCT
10811 W Collins Ave
Lakewood, CO 80215
303 5132989
Wenyan.leong@terumobct.com
https://www.terumobct.com/cell-therapy

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular therapy technologies, believes in the potential of blood and cells to do even more for patients than they do today. Terumo BCT’s Cell Therapy Technologies business enables researchers, developers and manufacturers to create next-generation cell and gene therapies.

TEXCELL - NORTH AMERICA, INC.
4991 New Design Road, Suite 100
Frederick, MD 21703
301 3635600
aschubert@texcell.com
http://www.texcell.com/

Texcell-North America, Inc. is a global contract research organization based in the Maryland/Virginia biotech corridor specializing in custom cell culture, virus propagation, virus concentration, viral clearance services, and viral safety testing in support of biopharmaceutical applications submitted to the FDA and other regulatory authorities.

THERMO FISHER
168 Third Avenue
Waltham, MA 02451
800 6785599
www.thermofisher.com

Thermo Fisher Scientific provides the quality products, services, and support you need to translate your gene and cell therapy from drug discovery through large-scale commercial production. We’re working alongside the scientific community to accelerate the pace of gene and cell therapy development and enabling scientists like you to transform our approach to health care.

ULTRAGENYX PHARMACEUTICAL INC.
60 Leveroni Court
Novato, CA 94804
415 4838800
www.ultragenyx.com

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with no approved therapies.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

UNCHAINED LABS
6870 Koll Center Pkwy
Pleasanton, CA 94566
925 5879800
www.unchainedlabs.com
Here’s the deal. We’re all about helping biologics researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it.

UNIVERCELLS TECHNOLOGIES, SA
Chemin de la Vieille-Cour 56/1
Nivelles, 1400
Belgium
011 32 23188348
info@univercellstech.com
www.univercellstech.com
Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective viral production from R&D to commercial scales. The company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow. Building upon years of expertise and capitalizing on technology vetted by world leaders, Univercells Technologies was incorporated in Belgium in 2020.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

5 Research Court
Rockville, MD 20850
301 8224427
www.vigenebio.com
Vigene Biosciences, Inc. is an award-winning leader in viral vector-based gene delivery for life science research, gene therapy and cell therapy applications. Established in 2012, Vigene relies on Process Development and GMP teams of accomplished virologists and technologists to deliver FDA/EMA compliant cGMP production of plasmid, lentivirus, adenovirus and AAV.

VIROCLINICS BIOSCIENCES
Marconistraat 16
Rotterdam, 3029 AK
Netherlands
011 31 88 6684787
info@viroclinics.com
www.viroclinics.com
Viroclinics Biosciences operates at a global level, being the preferred virology testing laboratory for several of the top-10 Biopharmaceutical companies. As a virology contract research organization, we serve the biopharmaceutical community with our preclinical, clinical diagnostic, research & development and clinical trial logistics services. More info: www.viroclinics.com

VIVEBIOTECH
Paseo Mikeletegi 81
San Sebastian, 20009
Spain
011 34 943 308568
info@vivebiotech.com
www.vivebiotech.com
VIVEbiotech is a GMP CDMO fully specialized in lentiviral vector bioprocess development (from very early stages) and GMP manufacturing. VIVEbiotech has experience in manufacturing lentiviral vectors for different applications such as cancer immune-cell therapy projects (CAR-Ts/TCRs…) and rare diseases, among others, having manufactured vectors to be used in Europe, US and Australia.

VIVEBIOTECH
Paseo Mikeletegi 81
San Sebastian, 20009
Spain
011 34 943 308568
info@vivebiotech.com
www.vivebiotech.com
VIVEbiotech is a GMP CDMO fully specialized in lentiviral vector bioprocess development (from very early stages) and GMP manufacturing. VIVEbiotech has experience in manufacturing lentiviral vectors for different applications such as cancer immune-cell therapy projects (CAR-Ts/TCRs…) and rare diseases, among others, having manufactured vectors to be used in Europe, US and Australia.

YECURIS ™
P.O. Box 4645
Tualatin, OR 97062
503 3524663
robertmanni@yecuris.com
https://www.yecuris.com/
Liver-humanized FRG®KO mice provide a critical toolset for gene therapy programs by allowing optimization, verification of target specificity, and evaluation of off-target effects in a human-relevant setting. When speed and accuracy are critical to your program’s success, Yecuris is there to help you bridge the gap between bench and clinic.
ANNUAL MEETING EXHIBITORS

Virtual Exhibit Hall open 24hrs online. Exhibitors available 8:00 AM - 6:30 PM Tuesday-Thursday; 8:00 AM -12:00 PM Friday, Eastern Daylight Time (EDT UTC -4).

YPOSKESI
26 Rue Henri Auguste-Desbrueres
Corbeil-Essonnes, F - 91100
France
619 9544024
plansky@yposkesi.com
www.yposkesi.com

Yposkesi is a GMP CDMO focused on the development and manufacturing of AAV and LV. We offer platform processes for AAV and LV for both adherent and suspension up to 400L with ongoing expansion to add 2000L. We also offer in-house F/F for our viral vectors.
Some see slow and steady progress.

We see a revolution.

Sarepta is a global biotechnology company on an urgent mission: engineer precision genetic medicine to reclaim futures otherwise impacted or cut short by rare diseases.

We’re ushering in a new era of drug development, with the goal of shortening the time from lab to patient, building the world’s largest gene therapy manufacturing capacity, and rethinking access and reimbursement models for revolutionary new treatments. We are in a daily race to transform genetic understanding into genetic medicine. Because every day is an opportunity to change the lives of people living with rare disease.